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INTRoDUCTIoN
T o Ta l Pa R e N T e R a l  N U T R I T I o N 
Malnutrition and depletion can lead to immune suppression and impairment of the 
body defense systems, resulting in higher infection rates and mortality. Improving the 
nutritional state, on the other hand, can restore immunologic competence and reduce 
complications in already malnourished patients. Intestinal failure means that a patient 
cannot maintain the protein-energy, fluid, electrolyte or micronutrient balances when 
consuming a normal diet. This is usually the result of extensive surgical bowel resection, 
congenital defects or motility disorders and it may necessitate the use of total parenteral 
nutrition (TPN). TPN implies that all macro- and micronutrient requirements including 
carbohydrates, lipids, amino acids, electrolytes and trace elements, are met by means 
of a sterile aqueous solution that is administered intravenously. In clinical practice, this 
therapy is frequently used temporarily in patients with short-term intestinal failure in 
the post-operative or Intensive Care setting. In patients with irreversible or long-term 
intestinal failure, TPN can be given in the home situation (home parenteral nutrition 
(HPN). Since the first patient started this type of treatment in the United States in 1967, 
HPN has established itself as an indispensable strategy for the treatment of long-term 
intestinal failure. HPN treatment in the Netherlands was initially performed in Nijmegen 
in the early 1970’s and currently (as of 2011) our HPN-population (125 patients, of whom 
8 children) comprises around 60% of all patients in The Netherlands. 
Unfortunately, HPN treatment can spark a spectrum of possible complications. Although 
metabolic disturbances resulting in liver- or kidney dysfunction and bone diseases 
frequently occur, most problems stem from the use of a vascular access device, in the 
form of a subcutaneously tunneled central venous catheter or port, and mainly comprise 
infectious complications and vascular or catheter/port occlusion due to thrombosis 
or catheter clogging. In addition, there is evidence to suggest that infections in these 
patients are at least in part the result of modulation of the function of the immune 
system by the lipid component of TPN. These lipids are given as emulsions, i.e. aqueous 
solutions containing minuscule lipid droplets that can be based on a range of lipid sources, 
ranging from soybean- to coconut-, olive- and fish oils. Depending on their biochemical 
characteristics these lipids exert distinct effects on immune cells [1].
The present thesis explores novel techniques to improve HPN care in two respects. The 
first is to decrease infectious complications by using surgically created arteriovenous 
fistulae (AVFs) as an alternative for central venous catheters (CVCs) to administer HPN. 
This issue is relevant since our centre has so far remained unique worldwide by using 
AVFs for this purpose on a regular basis. Second, an in-depth analysis of the effects of 
the various available lipid emulsions that can be used in the context of HPN on relevant 
parameters of immune function is presented.
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Va s C U l a R aC C e s s e s  a N D aC C e s s - R e l aT e D C o M P l I C aT I o N s
Since many patients with severe intestinal failure use HPN on a (nearly) day-to-day basis, 
this treatment requires a permanent and safe vascular access. Surgically created AVFs 
were the first type of intravenous access devices to be used for the administration of HPN. 
However, since the development of CVCs in the 1970s, the use of AVFs for this purpose 
became rare. Ever since, it has remained common practice worldwide to administer 
HPN via a CVC, usually in the form of a subcutaneous implantable port or an externally 
(subcutaneously) tunnelled catheter. In case of short-term TPN administration and in 
hospitalized patients, for instance in the ICU setting, nontunnelled catheters are being 
used. 
Catheter-related infections
Of the various complications related to parenteral nutrition treatment, catheter-related 
infections are the most frequent, with a serious impact on patient morbidity and mortality, 
as well as on hospital resources. Three types of catheter-related infections can be met: 
catheter-related bloodstream infections (CRBSI or “catheter sepsis”) , exit site infections 
and infections of the subcutaneous tunnel. 
CRBSI are the most common (ranging from 0.17-2.19 episodes per catheter year) and 
most serious catheter-related infections that require hospitalization, systemic antibiotic 
therapy and often necessitate removal, re-insertion, or replacement of the catheter 
[2-8]. Replacement or re-insertion of the catheter, however, damages the vein and 
increases the patient’s risk for thrombosis with subsequent loss of the vessel for future 
catheter placement. Most commonly, CRBSI are caused by gram-positive bacteria, mainly 
coagulase-negative Staphylococcus (epidermidis species) and the coagulase-positive 
species Staphylococcus aureus. In addition, infections with gram-negative bacteria or fungi 
are frequent [9]. Treatment success rates of CRBSI are strongly species-dependent, ranging 
from over 85% for coagulase-negative Staphylococcus epidermidis, to 50% for coagulase-
positive Staphylococci and Gram-negative bacteria, while fungi and polymicrobial flora 
are hardly ever cleared. Prevention of CRBSI, thus, is of key importance. HPN training 
by an experienced nurse in a dedicated training centre is crucial before HPN treatment 
can be started in a safe manner. The use of single lumen catheters and subcutaneous 
tunneling of the catheter also reduce the risk for infection [10]. Usually, a low-dose (100-
150 u/ml) heparin lock is used in order to prevent catheter related thrombosis. Recently, 
our group has shown that the use of an antibiotic lock solution (containing 2% taurolidine) 
in comparison with a low-dose heparin lock can dramatically diminish the risk for CRBSI 
[11]. 
Catheter exit site infections are characterized by the presence of erythema with or without 
pus at the catheter skin exit site. Like CRBSI, most catheter exit site infections are caused 
by Staphylococcus species. Although most exit site infections can be adequately treated 
with (local) antibiotics, the catheter has to be removed in case of persistent or returning 
infections. In addition, patients who are Staphylococcus aureus carriers, as evidenced 
by cultures from both nostrils and the perineal region, should receive local eradication 
therapy in the form of mupirocin ointment. 
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Tunneled central venous catheters have a small, circumferential cuff that is placed a 
couple of centimeters proximal to the exit site. This cuff anchors the catheter once fibrous 
tissue has enveloped it. Many cuffs are impregnated with silver nitrate that is bactericidal 
in the first thirty days. Tunnel infections manifest as cutaneous red streaks over the 
subcutaneous tract where the catheter is inserted. For a tunnel infection, antibiotic 
penetration is limited and the catheter almost invariably has to be removed. Fortunately, 
tunnel infections are rare; these comprise 2% or less of catheter-related infections [4, 12].
Catheter occlusions
The second most common vascular access-related complication is occlusion, both of the 
catheter and the vessels wherein the catheter is located. Occlusions can be thrombotic or 
non-thrombotic in origin. Several factors that cause vascular damage, including surgical 
trauma during (repeated) catheter placement and the high osmolarity of TPN formulations 
may lead to vascular thrombosis. Catheter clogging is less frequent and most usually 
caused by lipid-containing precipitates. 
Thrombus formation mostly occurs around, rather than within the catheter. Although 
thrombosis is relatively uncommon, when unrecognized and untreated, it may necessitate 
catheter removal. The position of the catheter tip has to be in a large bore vein, with a 
high blood flow rate, such as the superior or inferior caval vein. Ideally, the catheter tip 
should be positioned at the junction of the superior caval vein and the right atrium [13]. In 
case of lower flow veins, infusion of hypertonic solutions, such as PN, may sclerose these 
vessels, thereby rendering them more vulnerable for thrombosis. Other risk factors for 
thrombosis include catheter sepsis (due to microbe-induced coagulopathy), the use of 
the catheter for other purposes than TPN administration and the presence of underlying 
diseases that affect coagulation, for instance anticoagulation factor deficiencies or certain 
malignancies. Also, patients with inflammatory bowel disease, such as Crohn’s disease 
and ulcerative colitis appear to have a hypercoagulable state and thus a higher risk for 
thrombotic complications [14]. Moreover, hypercoagulability can be the results of high 
vitamin K consumption, either dietary or from TPN components, such as the multivitamin 
preparations that are usually added. Catheter thrombosis may be treated by means of 
thrombolytic agents such as urokinase [15]. In case medical treatment is unsuccessful, 
catheter removal and replacement at another site is necessary. This is highly unfavorable 
since (repeated) catheter replacement invariably leads to vascular damage and decreases 
the remaining options for future access placement. An additional disadvantage is that 
thrombosis is an important risk factor for the development of infections [16]. Thrombosis 
can be complicated by the development of symptomatic vascular obstruction, for instance 
in the form of superior or inferior vena cava syndrome or pulmonary embolism [17, 18]. 
Prevention of thrombosis in high-risk patients can be effectively achieved using (low-
dose) intravenous coumarins, such as warfarin. 
Non-thrombotic occlusions can be related to mechanical problems, including catheter 
migration or damage, precipitations related to medication-TPN incompatibilities and lipid 
depositions. Also, repletion of calcium and phosphate stores at a too high rate can result 
in calcium-phosphate precipitates [19]. 
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Initially it may be difficult to determine whether an occlusion is of thrombotic or non-
thrombotic origin. However, an occlusion due to lipid deposition, in contrast to a thrombus, 
usually develops more gradually. Hydrochloric acid or sodium hydroxide can be used to 
dissolve several mineral and medication precipitates, whereas ethanol dissolves lipid 
depositions around the catheter. In case these treatments fail and the instillation of 
urokinase is unsuccessful as well, the catheter has to be removed.
It is obvious that when long-term HPN is required, a reliable vascular access with a 
low complication profile is mandatory. From the start of our HPN program in the early 
nineteen seventies, in addition to CVCs, we have used surgically created AVFs for vascular 
access in HPN care on a regular basis. Our feeling so far has been that patients using AVFs 
for HPN administration do very well, although AVFs require some form of maintenance 
as well, usually because of the development of arteriovenous anastomotic stenoses 
that may require percutaneous angioplasty. Data from literature on the use of AVFs for 
HPN administration has, however, remained mainly anecdotal in the latest decades. A 
re-evaluation of the feasibility of AVFs for long-term HPN administration is therefore 
mandatory to establish its relevance for clinical practice. 
Pa R e N T e R a l  l I P I D s  a N D I M M U N e M o D U l aT I o N
History of parenteral lipids
Since the 1960s parenteral nutrition has been used in clinical practice on a regular basis 
with resulting changes in morbidity and mortality. Back then, Dudrick and coworkers 
showed that prolonged parenteral administration of amino acids and glucose solutions, 
combined with minerals, vitamins and micronutrients, can induce growth and body 
weight gain in children and adults [20, 21]. Based on this work, parenteral solutions in the 
United States for a long time solely consisted of amino acids and glucose. However, the 
administration of concentrated glucose solutions may cause hyperglycemia, particularly 
in severely ill patients. Hyperglycemia in turn is associated with adverse effects, such as 
immune suppression and a higher incidence of infectious complications [22]. Also, the sole 
infusion of glucose and amino acids was found to cause liver steatosis and deficiencies of 
fat soluble vitamins and essential fatty acids, i.e. fatty acids that can not be synthesized 
by the human organism and should be obtained from the diet (linoleic acid and α-linolenic 
acid). In order to prevent hyperglycemia, insulin was administered. Another strategy was 
to partially replace glucose calories by fats. In Europe, the clinical use of intravenous lipid 
emulsions already started in 1961, after Schubert and Wretlind developed a non-toxic 
lipid emulsion that was derived from soybean oil [23, 24]. This lipid emulsion became an 
important landmark in the history of nutrition therapy for patients requiring PN. 
Lipid emulsions used in clinical practice
Lipids in parentral nutrition consist of triglycerides, i.e. glycerol backbones to which three 
fatty acid chains are attached. The fatty acids can be saturated, i.e. containing no double 
bonds, mono-unsaturated (MUFAs), i.e. containing one double bond, or poly unsaturated 
(PUFAs), i.e. containing two or more double bonds. The carbon atoms are numbered from 
the terminal methyl end towards the carboxyl group of the carbon chain. Poly unsaturated 
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fatty acids are classified based on the position of the first double bond in the carbon chain. 
This classification gives rise to the n- or ω nomenclature. Parenteral lipid emulsions have 
been designed to resemble natural chylomicrons, with a triglyceride core enveloped by an 
emulsifier that is most frequently derived from egg yolk.
Long-chain triglyceride containing emulsions
The first generation of lipid emulsions included those that were rich in long-chain 
triglycerides (LCT), mainly originating from soybean, safflower but also corn and sunflower 
seed oils, such as Intralipid® (Fresenius Kabi). The LCTs have a fatty acid chain length of 
longer than 12 carbon atoms. Soybean oil (SO) contains a high ratio (7:1) of n-6 PUFAs, 
mainly linoleic acid (18:2n-6), to n-3 PUFAs, such α-linolenic acid (18:3n-3). Linoleic acid and 
α-linolenic acid are termed essential fatty acids as in humans they cannot be produced the 
novo but have to be supplied by the diet. They can solely be synthesized by plant enzymes. 
Linoleic acid is the precursor of the family of n-6 PUFAs, such as arachidonic acid (20:4n-6), 
whereas α-linolenic acid is the precursor of the n-3 PUFAs such as eicosapentanoic acid 
(EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3)(Figure 1.1). 
Figure 1.1: Synthesis of long chain n-3 and n-6 polyunsaturated fatty acids from their 
precursors. Adapted from Wanten et al., Am J Clin Nutr 2007;85;1171-84.
The first step in the metabolism of both linoleic acid and α-linolenic acid depends on 
the Δ6-desaturase enzyme. Although α-linolenic acid is the preferred substrate for the 
Δ6-desaturase enzyme, the Western diet contains 5-20 times more linoleic acid resulting 
in much higher n-6 than n-3 PUFA contents in blood and cell membranes. In the past 
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decades, concerns on the use of LCT based lipid emulsions raised. The high amount of 
n-6 PUFAs and their metabolism by cyclo-oxygenase (COX) and lipoxygenase (LOX) 
enzymes might promote the overproduction of pro-inflammatory eicosanoids such as 
the 2-series prostaglandins (PG) and thromboxanes (TXA), the 4-series leukotrienes (LT) 
and hydroxyeicosatetraenoic acids (HETEs) and increase oxidative stress (Figure 1.2). 
PGE2 for example induces fever, increased vascular permeability and vasodilation, and 
enhances pain and oedema caused by other factors such as bradykinin and histamine 
[25, 26]. TXA
2
 promotes vascular permeability, platelet aggregation, leukocyte adhesion, 
and bronchoconstriction [25, 27]. LTB
4
 activates leukocytes, resulting in generation of 
reactive oxygen species, release of proteases, neutrophil chemotaxis, and synthesis of 
lipid mediators [28]. Of note, also metabolism of AA by 15-LOX gives rise to lipoxin A
4 
which has been found to have anti-inflammatory effects.
Figure 1.2: Synthesis of eicosanoids from arachidonic acid. Reprinted with permission from 
Calder P.C., Biochemical Society Transactions, 33, 2005, 423-427.
The described pro-inflammatory effects appear to be particularly unfavorable in clinical 
situations with an already imbalanced immune response with a pro-inflammatory profile, 
such as sepsis and trauma [29, 30]. Early clinical observations in the 1980s showed an 
increased risk for bacteremia in neonates using parenteral lipids [31-33]. Also higher 
infection rates in surgical and critically ill patients receiving lipid-based TPN than in 
patients receiving lipid-free formulations are described [1, 34]. In contrast, in a large 
clinical trial in 482 patients undergoing bone marrow transplantation, bacteremia and 
fungemia rates were not related to administered lipid amounts [35]. Sedman et al. 
also failed to observe any effects of soybean oil infusion on natural killer cell activity 
of PBMCs and mitogen induced T-cell proliferation and Il-2 production in malnourished 
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patients undergoing surgery for gastric cancer [36]. In accordance with these conflicting 
clinical data, experimental studies on immune modulation by LCTs have also yielded 
inconsistent results. Some studies showed that LCTs negatively affect phagocytic function, 
leukocyte migration and the function of the reticuloendothelial system [37, 38]. Also, 
LCT administration has been described to potentiate endotoxin-induced coagulation 
activation, which might induce thrombotic complications in patients with infections 
[39]. Other studies, however, found no evidence for an effect of LCTs on wide range of 
immune cell functions, cellular signaling and membrane fluidity [40-43]. Despite these 
disparate data, concerns over the unbalanced fatty acid profiles of the first generation 
lipid emulsions led to the development of new parenteral lipid emulsions in which part 
of the n-6 component is replaced by less bioactive fatty acids, as described briefly in the 
next four paragraphs.
Medium-chain triglycerides containing emulsions
Emulsions containing medium chain triglycerides (MCTs), derived from coconut and palm 
kernel oils, have been introduced in the 1980s. The fatty acids in MCTs are saturated 
and have a carbon chain length that varies from 6 to 12 atoms. Because of special 
psychochemical properties, medium chain fatty acids have several advantages over LCTs. 
They have a low molecular weight and are more soluble, therefore, they are cleared at 
a faster rate from the plasma and induce less hyperlipidemia. They are easily oxidized 
and not stored as triglycerides. Furthermore, they are ketogenic and might therefore be 
protein sparing, they put less strain on liver function, they do not interfere with pulmonary 
hydrodynamics or gas exchange and they are not susceptible to lipid peroxidation 
since they contain no double bonds [44, 45]. Also, MCTs can be beta-oxidized in the 
mitochondria following transport that is essentially independent from carnitine making 
them a rapid source of energy supply [46, 47]. However, administration of MCTs solely is 
not well tolerated since, due to their rapid metabolism, they may induce keto-acidosis if 
administered at high rates. Also, they do not contain any essential fatty acids. Therefore, 
they are usually given as a physical mixture with LCTs; for instance in the form of 50/50% 
LCT/MCT emulsions, such as Lipofundin® (B Braun). Experimental studies suggest that 
MCTs activate isolated leukocytes and impair several of their functions. Previous studies at 
our laboratory showed that MCTs in the in vitro setting induce the production of reactive 
oxygen species, sensitize neutrophils for opsonized yeast particles induced intracellular 
calcium signalling, inhibit the migration of neutrophils and decrease their capacity to kill 
Candida albicans [48-51]. In clinical studies, however, LCT/MCT has been shown to be 
well tolerated and safe in various patients groups. Clinical results include a decreased 
incidence of intra-abdominal abscesses in malnourished patients undergoing laparotomy 
[52], decreased weight loss and less fatty acid infiltration of the liver in surgical patients 
[53], a significantly better nitrogen balance and a higher ketogenesis in pediatric patients 
with surgical stress [54]. Also, LCT/MCT when compared to pure LCT induces a higher 
increase in fat utilization and a lower use of carbohydrates, without compromising the 
respiratory system [54]. That the experimental setting is important when studying lipid 
effects became obvious when various investigators found contradicting results of LCT/
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MCTs on the immune system. Waitzberg et al., for instance, observed no ex vivo effect 
of LCT/MCT on chemotaxis, phagocytosis, bacterial death or oxidative metabolism of 
monocytes and neutrophils in 10 malnourished patients with gastric cancer[55]. Clarke 
et al. did not observe a difference between LCT/MCT and LCT on calorie supply and 
metabolic parameters in stable TPN patients [56]. As for LCTs, a clear picture of MCT-
containing emulsions has so far not been established. 
Olive oil based emulsions
Olive oil (OO) is abundantly used in the Mediterranean diet and is believed to be health-
promoting. In the late 1990s, an OO- based emulsion, ClinOleic® (Baxter) became available 
for use in TPN. In this emulsion 80% of SO has been replaced by OO, the remaining 20% 
being SO. The major fatty acid in this emulsion is oleic acid (18:1-n9) which is a n-9 
MUFA. Including OO reduces the amount of administered n-6 PUFAs and results in higher 
vitamin E levels, which seems beneficial since vitamin E prevents lipid peroxidation. Also, 
oleic acid, containing only a single double bond, is relatively resistant to peroxidation in 
comparison to n-6 PUFAs. Sala-vila et al. reviewed in vitro, animal and clinical studies using 
ClinOleic®[57]. So far, experimental studies on the immune modulating effects of OO-
based parenteral emulsions have mainly shown immune neutral effects. In vitro studies 
demonstrate that the impairment of immune function, especially of T cell proliferation 
and Il-2 production, that occurs with soybean oil-based emulsions is avoided with ClinOleic 
[58]. Our group previously showed that parenteral lipid emulsions evoke an attenuation 
of cell stimulation by a bacterial tripeptide, fMLP. Herein, OO and SO emulsions were by 
far less potent than SO-MCT and FO [59]. With respect to inhibition of proinflammatory 
cytokine production by isolated PBMCs, OO effects were significantly lower than SO and 
SO-MCT effects [60].
Mainly small clinical trials on the use of OO-based emulsions have shown that these 
are well tolerated and safe and do not affect immune function, inflammatory markers, 
oxidative stress or routine laboratory parameters [61-63]. However, when comparing 
ClinOleic® to soybean oil in critically ill patients; Mateu de Antonio et al. observed no 
differences in inflammatory markers, infections, intensive care unit stay, hospital stay and 
mortality [64]. Similar results (i.e. no difference) were observed by Garcia-de Lorenzo et al. 
who compared ClinOleic® to LCT/MCT in patients with severe burns in the intensive care 
unit [65]. Thus, OO-based emulsions overall seem immune neutral with no clear evidence 
of any clinical advantage of OO over pure LCT- or LCT/MCT emulsions. 
Structured lipids
The supposed beneficial metabolic and immunologic effects of adding MCTs to LCT 
containing emulsions, led to the development of structured lipids (SL) in the 1990s. SL 
are synthetic triglycerides in which both long chain fatty acids and medium chain fatty 
acids are randomly attached to the 1,2 or 3 position of the same glycerol backbone. So far, 
only short-term clinical investigations on the effect of SL on infectious complications and 
patient survival have been performed. These studies suggest that SL are well tolerated 
and more rapidly cleared from the plasma compared with pure LCTs or LCT/MCTs [66, 67]. 
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In addition, human and animal studies indicate that the use of SL in catabolic patients 
improves nitrogen balance and preserves the function of the reticuloendothelial system 
with less impairment of liver function than is observed for LCTs or LCT/MCTs [68, 69]. 
However, data on the immune modulating properties of SL so far remain sparse. 
Fish oil based emulsions
Fish oil (FO) is rich in the very long chain n-3 PUFAs eicosapentanoic acid (EPA) and 
docosahexaenoic acid (DHA). Very long chain triglycerides (VLCTs) consist of fatty acids 
with a carbon chain length of more than 18 carbon atoms. In contrast to OO and MCTs, 
the addition of FO to LCTs decreases the amount of n-6 PUFAs and increases the amount 
of n-3 PUFAs. As mentioned previously, EPA and DHA compete with arachidonic acid 
for incorporation into cell membranes and for metabolism to bioactive eicosanoids 
based on the fact that all of these components are metabolized by the same enzymes 
(cyclooxygenases and lipoxygenases). Metabolism of n-3 PUFAs usually results in the 
production of less pro-inflammatory eicosanoid such as the 3-series prostaglandins and 
tromboxanes, the 5-series leukotrienes and the hydroxyl-EPAs [70-72](Figure 1.3). In 
addition, a novel group of protective mediators, named E- and D-series resolvins, formed 
by COX-2 from EPA and DHA, respectively, has been identified recently. These mediators 
dampen acute leukocyte responses and facilitate the resolution of inflammation [73]. 
Besides affecting eicosanoid synthesis, experimental evidence suggests that n-3 PUFAs 
have very potent effects on the expression of a range of inflammatory genes [74, 75] which 
might be exerted through direct inhibitory actions on intracellular signaling pathways that 
lead to the activation of transcription factors such as nuclear factor κB (NK-κB) [76-79]. 
 
Figure 1.3: Anti-inflammatory actions of long-chain n-3 PUFAs. Reprinted with permission 
from Calder P.C., Biochemical Society Transactions, 33, 2005, 423-427.
Emulsions containing FO that are currently available include Omegaven® (Fresenius 
Kabi), Lipoplus® (B Braun) and SMOFLipid® (Fresenius Kabi). Omegaven® is a pure fish oil 
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emulsion, containing 100 g lipid/l, i.e. 27-59 g EPA and DHA/l emulsion. It is recommended 
to be used with other emulsions, such as those based on pure LCTs or mixed LCT/MCTs so 
that Omegaven® provides 10-20% of the infused emulsion. Lipoplus® is a mixture of 50 
(% v/v) MCT, 40 LCT and 10 FO. Lipoplus contains 9-17 g EPA plus DHA/l. SMOFLipid® is 
a mixture of 30 (% v/v) MCT, 30 LCT, 25 OO and 15 FO, containing 200 g lipid/l emulsion 
and 0-6 g EPA and DHA/100 ml. FO, when compared with vegetable oils, has been shown 
to improve survival, decrease metabolic perturbations, improve heart and lung function, 
decrease lung edema and decrease the ex vivo pro-inflammatory cytokine production in 
animal models of endotoxemia [80-84]. In humans, Mayer et al. performed a randomized 
study in 21 patients with sepsis and intolerance to enteral nutrition who received an 
n-3 FA-rich lipid emulsion (Omegaven®) or a standard n-6-rich lipid emulsion (Lipoven®; 
Fresenius Kabi) for 5 days. The administration of Omegaven® induced an increase in n-3-
free FAs in plasma and leukocyte membranes and increased the n-3/n-6 ratio. Also, ex 
vivo endotoxin induced TNF-α, interleukin 1-β, IL-6, and IL-8 production were reduced. 
However, serum cytokine levels were not different between patient groups [85]. Chen et 
al. recently performed a meta-analysis of 13 randomized controlled trials to evaluate the 
safety and efficacy of a FO enriched parenteral nutrition regimen in patients undergoing 
major abdominal surgery [86]. The FO enriched parenteral nutrition regimen had a positive 
effect on length of hospital stay, length of intensive care unit stay and postoperative 
infection rate. Also plasma EPA and DHA levels increased and LT-B
5
 production in leukocytes 
was upregulated on postoperative day 6. No significant differences were found between 
the 2 groups in postoperative mortality, incidence of postoperative cardiac complications, 
serum levels of bilirubin, triglyceride, or arachidonic acid, or the liberation of LT-B
4
. Also, 
studies in patients with sepsis are strongly suggestive for clinical benefits of n-3 PUFAs in 
parenteral lipid formulations. Grecu et al. observed significantly lower reoperation rates, 
intensive care unit and hospital stay in patients receiving FO (mixed with SO) compared to 
pure SO. Mortality rates were not different between groups [87]. It should be mentioned 
here that the latter study has only appeared in abstract form.
In patients with abdominal sepsis, Heller et al. showed lower infection rates and shorter 
length of ICU and hospital stay after FO infusion (0.05 g/kg)[88]. In addition, mortality 
rates were decreased when higher amounts (>1 g/kg) were administered. In contrast to 
the generally positive results of the previous studies, in a large randomized clinical trial 
of Friesecke et al., a clinical benefit of FO/SO/MCT infusion over SO/MCT in ICU patients 
in several outcomes, including inflammatory markers, ventilation requirements, infection 
rates, length of ICU stay and mortality could not be demonstrated [89]. The authors 
speculated that the absence of clinical effects might be explained by the initiation of the 
lipid infusion after the initial inflammatory process was already terminated, which is in 
contrast to studies in which beneficial effects were shown [90,91]. Timing and dosing 
of FO supplementation therefore seem crucial. Importantly, in the above mentioned 
studies, no deleterious immunologic effects of FO inclusion were observed and although 
contradictory findings exist, overall the data available are suggestive of clinical benefits of 
FO inclusion in parenteral regimens for surgical and critically ill patients. 
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In this thesis, we explored two therapeutic strategies to improve HPN care by reducing 
complications. First, we investigated whether HPN-related complication rates can be 
decreased by using AVFs as a vascular access device as an alternative for CVC’s, in the 
form of subcutaneously tunneled catheters and subcutaneous ports. To illustrate the 
feasibility of AVFs in this respect, in chapter 2, a case was reported of a patient who has 
been on HPN by an AVF for more than 25 years without major complications. In chapter 3, 
an in dept retrospective analysis with regard to the occurrence of blood stream infection 
and occlusion rates during CVC and AVF use in our long-term HPN population is described. 
The second part of this thesis focuses on the alternation of immune system functions 
under the influence of the currently available lipid emulsions. In chapter 4, the modulation 
of leukocyte phenotype after in vitro exposition of leukocytes to different lipid emulsions 
was described. In chapter 5, the Streptococcus Pneumoniae elimination capacity of 
neutrophils that were incubated with parenteral lipid emulsions in vitro was studied. 
Since in many of our in vitro studies MCT-containing lipid emulsions have been shown 
to be the most potent with respect to leukocyte activation and function modulation, in 
chapter 6, the involvement of a pertussis toxin sensitive G-protein coupled receptor in 
the MCT-induced neutrophil modulation was assessed. Chapter 7 describes the in vivo 
effects of the most commonly used lipid emulsions, based on LCTs and mixed LCTs/MCTs, 
on immune functions in healthy humans. Also, the occurrence of leukocyte sequestration, 
as a possible explanation for the lack of in vivo effects of lipid emulsions that by contrast 
clearly showed immune modulation in vitro, was assessed. In chapter 8, a new and short-
term infusion protocol for LCT- and VLCT (fish oil)- based emulsions was evaluated in 
healthy human volunteers with respect to leukocyte membrane fatty acid composition 
and modulation of cellular activation and  function. 
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Abstract
The quality of life of patients on home parenteral nutrition is seriously compromised 
by the frequent occurrence of technique-related complications, mainly in the form 
of venous access-related problems and metabolic derangements. In addition, many 
patients experience significant psychological problems. We present a patient who 
developed acute intestinal failure more than thirty years ago following near-total 
small bowel resection due to ischemia based on malrotation. She has remained on 
HPN ever since and the latter 25 years have passed uneventful since the use of a 
surgically created arteriovenous fistula (AVF) for venous access. With this case we 
want to point out that AVFs can be a feasible means to provide HPN. In addition, 
this shows that we as clinicians should set our goals high in our care for patients 
with severe intestinal failure, since good quality of life during HPN treatment is by no 
means impossible. 
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Total parenteral nutrition in the home setting (home parenteral nutrition(HPN)) is a life saving strategy in patients with severe intestinal failure. However, the quality of life of patients on HPN remains to be seriously 
compromised by the frequent development of technique-related complications, such 
as vascular access-related problems in the form of catheter infections, occlusion or 
thrombosis, and metabolic derangements that result in liver failure or bone disease [1]. 
Not unexpected therefore, a recent study and a review concluded that the psychological 
problems that these patients face are considerable and comparable to those seen in 
patients on renal replacement therapy [2,3]. However, despite all this the following 
case should remind us that over the long haul not all patients remain to be pursued 
by these daunting problems. It also shows that, at least in our experience, the use of 
arteriovenous fistulae (AVFs) can be a suitable means to provide overnight parenteral 
nutrition in this setting in otherwise active and ambulant patients. 
Case HIsToRY
The medical history of this female, born in 1950, was unremarkable until at the age of 26, 
in the 26th week of her second pregnancy, she acutely developed severe abdominal pain 
with the clinical signs of an acute abdomen. During laparatomy a diagnosis of intrauterine 
foetal death was made. In addition, severe small bowel and mesenteric ischemia was 
observed because of acute strangulation in the presence of a congenital intestinal 
malrotation. A near-total small bowel resection was performed and the remaining part 
of the duodenum was anastomosed to the transverse colon. Parenteral nutrition was 
initiated over a nontunnelled central venous catheter (CVC). An AVF was created surgically 
on the left forearm from bovine graft material. This fistula was used for venous access 
from September 1976 on and was punctured by her husband, and later on by the patient 
herself. Six months later she was acutely admitted to the intensive care unit because of 
a septic shock. Her clinical course was complicated by severe multi-organ failure, and 
even cardiac resuscitation during an episode of hyperpotassaemia. The cause for this 
crisis proved to be a contaminated bag of parenteral nutrition from which Streptococcus 
viridans was cultured. Her AVF occluded during this period with repeated episodes of 
hypotension. A tunnelled venous subclavian catheter was placed and a second bovine 
graft AVF created on the right forearm. Six weeks later she was readmitted to the hospital 
with fever and chills. Cultures from blood and catheter tip yielded Staphylococcus aureus. 
The CVC was removed and TPN was continued via the matured AVF. In 1981 this AVF 
became occluded following multiple punctures at the same spot, however could be 
saved following embolectomy and surgical revision. During the first ten years of HPN her 
liver functions remained completely unremarkable, while a crista biopsy suggested very 
mild osteopenia. In 1982 her second AVF became occcluded again and this time revision 
failed. A Hickman catheter was placed in the left subclavian vene and a third fistula was 
created on the right forearm with autologous material obtained from the left greater 
saphenous vene. Six weeks later, the CVC had to be removed because of a catheter sepsis 
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caused by Staphylococcus aureus. Ever since, 25 years after her operation for this third 
AVF, there have been no major events. In 1994, dual-energy X-ray absorptiometry (DEXA) 
suggested normal bone density. In 2003 she developed mild liver function disturbances 
(total bilirubin < 5 mmol/l; alkaline phosphatase 409 U/l; aspartate-amino-transferase 
71 U/l; alanine-amino-transferase 76 U/l; γ-glutamyltranspeptidase 261 U/l). Because 
ultrasonography revealed no abnormalities of the liver or bile ducts, a percutaneous 
liver biopsy was performed which showed discrete steatosis and “foamy” macrophages 
together with minor fibrosis and chronic inflammation of the portal tracts, without 
evidence for cirrhosis. These findings were considered consistent with long-term use 
of parenteral nutrition. A DEXA in 2002 revealed osteoporosis of the lumbar spine and 
osteopenia of the right femoral neck, for which treatment with bisphosphonates was 
started. Recently, there were no radiological signs of spinal fractures. She is currently 
doing very well, and recently became a grandmother. Apart from her busy family life she 
is actively involved in voluntary work. Her weight has remained at the set target of 58 
kg, at a stable height of 1.65 m. There apparently is some degree of bowel adaptation 
with absorption of enteral nutrients since we managed to decrease the frequency of her 
TPN intake to 5 times a week, using an olive-oil based formulation with added vitamins 
and trace elements. Intravenous warfarin (as anticoagulant because of her arteriovenous 
fistula) and alendronate comprise her only medications at this point. 
Recent laboratory investigations revealed a normal ESR, minerals and kidney function. 
Her liver functions remain stable, but slightly cholestatic (total serum bilirubin 10 μmol/l; 
alkaline phosphatase 331 U/l; aspartate-amino-transferase 71 U/l; alanine-amino-
transferase 68 U/l; γ-glutamyltranspeptidase 181 U/l). There is a mild normocytic anaemia, 
with a hemoglobin level of 7.0 mmol/l. Leukocyte and thrombocyte counts are within 
normal ranges. There is no evidence for vitamin or trace element deficiencies. 
DIsCUssIoN
Our centre in Nijmegen has been involved in HPN treatment since the early 1970s and 
is the larger of the two centres that provide HPN care in the Netherlands. From 1970 to 
2004 we have treated 208 adult patients out of a total of 290 patients in our country [4]. 
To our knowledge, our centre has remained unique in the world in that we, from the start 
of our HPN program on, have used surgical AVFs for venous HPN access on a regular basis. 
Back in 1983 we already reported on our experience for the first time and concluded that 
AVFs are valuable alternatives for CVCs [5]. Ever since, the information in the literature on 
the use of AVFs for this indication has remained very sparse and mostly anecdotal [6-8]. 
The largest series concerns 16 patients and comes from 1980 [9]. Our actual population 
comprises 65 patients out of whom 20 (31%) currently use an AVF and 39 (60%) have used 
a fistula at some point during their HPN treatment. 
The stable and uneventful course of our patient after her first problematic years is 
remarkable, certainly when one realizes that catheter sepsis and occlusion in HPN patients 
occur with reported frequencies of 0.34 and 0.071 episodes per catheter year, respectively 
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[1]. To put the findings in our population in perspective, a comprehensive retrospective 
analysis of all our data on survival and complications of CVCs and arteriovenous fistulae 
is underway. 
Over the last years our patient has developed mild cholestatic liver function disturbances 
without evidence for liver failure or cirrhosis. In addition the DEXA evaluation suggests 
the presence of osteoporosis, without bone fractures or decreased height. These 
abnormalities are not unexpected, since severe or mild liver problems and metabolic 
bone disease are encountered with frequencies of 0.024, 0.42 and 0.05 per catheter year, 
respectively, in patients who have been on HPN for considerably shorter periods than our 
patient [1]. TPN-related cholestasis has been reported to occurr in 63% and 72% of all 
patients after 4 and 6 years of treatment, respectively [10]. The severity of liver damage, 
with ultimately the development of irreversible injury in the form of fibrosis and cirrhosis, 
is associated with short bowel syndrome, frequent sepsis, multisurgical procedures 
and Crohn’s disease, some of which risk factors are present in our patient [10]. It is also 
important to realize that long-term users of HPN, i.e. for a period of more than two years, 
constitute only 15-20% of those who originally started and that the most important factor 
that determines both patient and technique survival in HPN patients is the underlying 
diagnosis, which is benign in our patient [1]. With respect to bone mineral density, it has 
been shown that HPN does not necessarily result in decreased bone mass, but two other 
risk factor, age and female sex, are present in our patient [11]. 
In conclusion, the present case shows that surgical AVFs can be used to provide long-term 
parenteral nutrition and an active and relatively uneventful life is achievable in patients 
with severe intestinal failure. 
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a B s T R aC T 
The success of home parenteral nutrition (HPN) programs is compromised by 
complications of central venous catheters (CVCs), such as occlusions and bloodstream 
infections. We performed a retrospective analysis of complication rates of 
arteriovenous fistulae versus CVCs in patients on long-term HPN. Data were collected 
from 127 consecutive patients that received HPN between January 2000 and October 
2006, comprising 344 access years of CVCs and 194 access years of arteriovenous 
fistulae. We evaluated access-related bloodstream infection and occlusion incidence 
rates (number of complications per access year) using Poisson-normal regression 
analysis. Complication incidence rate ratios were calculated by dividing complication 
incidence rates of CVCs by those of arteriovenous fistulae, adjusting for HPN 
frequency, medication use, infusion fluid composition and underlying diseases. 
Bloodstream infection incidence rates were 0.03/year for arteriovenous fistulae, 
1.37/year for long-term CVCs (Port a Caths and tunnelled catheters) and 3.12/year for 
short-term CVCs (nontunnelled catheters). Occlusion incidence rates were 0.60/year 
for arteriovenous fistulae, 0.35/year for long-term CVCs and 0.93/year for short-term 
CVCs. Adjusted incidence rate ratios of long-term CVCs over arteriovenous fistulae 
were 47 (95% CI, 19-117) for bloodstream infections and 0.53 (95% CI, 0.31-0.89) for 
occlusions. In conclusion, the occlusion incidence rate was higher for arteriovenous 
fistulae than for certain types of CVCs. The incidence rate of the most serious access-
related complication (bloodstream infections) was much lower for arteriovenous 
fistulae than for all types of CVCs. Thus, arteriovenous fistulae are safe and valuable 
alternatives to CVCs for patients requiring long-term HPN. 
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In patients on long-term home parenteral nutrition (HPN), frequently occurring vascular access-related complications continue to result in multiple hospital admissions and, in the end, these problems pose the foremost 
threat to therapy continuation. Surgically created arteriovenous fistulae were the first 
intravenous access to be used for the administration of parenteral nutrition. However, 
since the development of intravenous catheters in the 1970s, the use of arteriovenous 
fistulae for HPN administration became rare. Ever since, worldwide it has remained 
common practice to administer HPN by means of central venous catheter devices (CVC), 
such as implantable subcutaneous ports (Port-a-Cath II [PAC], Smiths Medical MD, St 
Paul, MN) or externally (subcutaneously) tunnelled catheters. In addition, nontunnelled 
catheters are used for short-term total parenteral nutrition (TPN) administration, mostly 
during a hospital stay. The most frequent CVC-related complications are (potentially) 
life-threatening bloodstream infections and occlusions, both of the catheter and of the 
vessels wherein the catheter is located. Of note, the use of CVCs for TPN purposes has 
been recognized as an additional independent risk factor for the occurrence of catheter-
related bloodstream infections [1-4]. Therefore, when long-term HPN is required, a 
reliable vascular access with a low complication profile is mandatory. 
From the start of our HPN program in the early 1970s, in addition to CVCs, we have used 
surgically created arteriovenous fistulae for vascular access in HPN care on a regular 
basis. Similar to the situation in patients on hemodialysis, this has mostly concerned 
arteriovenous fistulae constructed in the forearm or, less ideally, in the lower extremity. 
After a maturation period of 6 weeks these fistulae are usually available for self-puncture by 
the patient or his or her partner. Apart from a straight-forward arteriovenous anastomosis, 
the fistulae may be created by the interposition of autologous venous, xenologous venous 
or prosthetic material (arteriovenous graft). In 1983, our group already reported on a 
series of 7 patients using an arteriovenous fistula, and concluded that these fistulae might 
be valuable alternatives for CVCs [5]. However, the information in the literature on the use 
of arteriovenous fistulae for this indication has remained anecdotal in the latest decades 
and solely concerns case-reports or case-series, with the largest series comprising only 17 
patients [6-11]. Recently, we have described our oldest patient who has been using HPN 
over an arteriovenous fistula for 32 years without major complications in the last decades 
[12]. Our impression that patients using arteriovenous fistulae for HPN administration 
do very well, in combination with the paucity of information coming from other sources, 
inspired us to reevaluate the feasibility of arteriovenous fistulae for long-term HPN 
administration and to perform a comprehensive retrospective analysis of all our data on 
access-related bloodstream infection and occlusion incidence rates in our own long-term 
HPN population. 
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PaTIeNTs aND MeTHoDs 
PaT I e N T s 
In the present investigation, we included all consecutive patients who were on long-term 
HPN between January 1st 2000 and October 1st 2006 (n=127), which comprises about 50% 
of all patients treated with HPN since the start of our program in the 1970s until October 
2006. Our HPN-team was reorganized in 2000 and from that time a focused team of HPN 
nurses started to document our HPN population in detail. Electronic patient files were also 
then introduced, enabling us to create a comprehensive database of our HPN-population. 
We did not include patients after October 2006, because then we started a successful trial 
evaluating antibiotic catheter lock therapy with taurolidine as an alternative to heparin 
[13]. Including patients after 2006 would therefore induce bias as this new lock therapy 
was designed to counter complications. 
Of the 127 included patients, 36 (28%) were already on HPN before January 2000. Excluding 
these 36 patients or the accesses they used before the year 2000 would have introduced 
a considerable source of selection bias. Therefore, and because all the necessary data for 
this study before January 2000 were available, we included these patients and all their 
accesses in our investigation.
Two independent reviewers reviewed the medical records of all patients. In each patient, 
all vascular accesses placed for HPN purposes between the start of HPN and October 1, 
2006 were analyzed for complications. All data were entered in a database (Microsoft 
Access 2000; Microsoft Corp, Redmond, WA). In accordance with the European Society 
for Clinical Nutrition and Metabolism guidelines for parenteral nutrition, long-term HPN 
was defined as a requirement for TPN and/or intravenous fluid support for more than 3 
months used in the home-setting. 
M e T H o D s
Access cleaning protocols
In general, we pay much attention to aseptic procedures during our 1- to 2-week inpatient 
training period. Our access cleaning protocols are described in the following text in more 
detail. 
For tunnelled and nontunnelled catheters; the catheter exit site is covered with a Tegaderm 
pad (3M Health Care, Neuss, Germany) which is replaced every 96 hours. The exit site is 
disinfected by circular movements from the exit site to the outer circumference. Every 
circle is disinfected with a new sterile swap. The first 10 cm of the catheter is disinfected 
with a sterile swap and chlorhexidine in ethanol. After drying, the exit site is covered with 
a new Tegaderm pad. After 3 weeks, the catheter cuff of tunneled catheters has grown 
in the surrounding tissues and sutures for line fixation are removed. From then on, the 
exit site of tunnelled catheters is no longer covered with a Tegaderm pad and is cleaned 
daily by washing with water and soap and drying with a clean towel. The nontunnelled 
catheters remain fixed with a suture and covered with a Tegaderm pad, which is replaced 
every 96 hours, during the complete period of their use. Before TPN-administration, the 
opening of the infusion-bag as well as the (non-)tunnelled catheter hub is disinfected with 
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chlorhexidine in ethanol. After drying, the infusion system is connected to the catheter 
hub. 
For PACs and arteriovenous fistulae; after placement the wound is covered with sterile 
compresses if necessary. Before HPN administration, the skin overlying the subcutaneous 
port is cleaned with chlorhexidine by the described circular movement method. After HPN 
administration, the puncture-site is covered with a sterile compress for a few minutes, 
until (minor) bleeding ends. 
Independent of the access type, the patient’s/care-giver’s hands are washed and 
subsequentially disinfected with chlorhexidine in ethanol prior to TPN-administration or 
cleaning of the exit site or skin.
Assessment of vascular access related bloodstream infections and occlusions 
Vascular access-related bloodstream infections were defined by the presence of symptoms 
(fever, chills), associated with positive blood cultures in absence of other evident infectious 
foci that likely could explain the bloodstream infection. Episodes with fever and/or chills 
without positive blood cultures were considered a bloodstream infection in case blood 
samples were drawn under antibiotic treatment or in case patients were showing signs 
of sepsis (fever with cold chills, low blood pressure requiring intravenous fluid support 
or oliguria) and other infectious foci that could explain the symptoms were excluded. If 
information could only be extracted from medical letters from referring hospitals, the 
vascular access was defined as being infected according to the criteria of the referring 
hospital. 
Concerning the occlusions, the time-span of development, (ie slowly [mainly due to 
precipitation of infused substrates] versus acute [mainly due to thrombus formation], 
was frequently undocumented and ultrasounds or contrast venography was not always 
performed. In this retrospective study design, it was therefore impossible to distinguish 
thrombotic from nonthrombotic occlusions. For this reason, and in accordance with a 
large investigation on CVC-related complications performed by Bozetti et al.[14], we 
report overall occlusion rates. 
Bloodstream infection and occlusion incidence rates (number of complications per access 
year) were calculated. Vascular accesses that were in situ but not used and therefore not 
likely at risk for complications, CVCs of which the exact type ([non-]tunnelled or PAC) was 
not reported (defined as ‘unspecified CVCs’), and accesses with missing data concerning 
the precise utilization period or the exact number of complications during use were 
excluded from the analysis. 
Statistical analysis 
We analyzed the bloodstream infection and occlusion incidence rates using random 
effects models with Poisson distributions for counts. The random effects for patients were 
incorporated in the modeling process to account for repeated vascular access periods in 
patients. Based on biological and clinical rationales, possible confounders in the relation 
between access type and complication rate were identified and reported for each access 
(Table 3.1). 
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Table 3.1: overview of confounders, specified per access type.
Tunnelled 
catheters 
(n=374)
PaCs
(n=166)
arteriovenous 
fistulae
(n=62)
Nontunnelled 
catheters
(n=83)
Immune suppressive use
Yes   58 (16)   27 (16)    8 (13)  14 (17)
No 316 (84) 139 (84)  54 (87)  69 (83)
Anticoagulants use
Yes 204 (55)  98 (59)  58 (94) 59 (71)
No 169 (45)  68 (41)    4 (6) 23 (28)
Partly     1 (0.3)    -    -   -
Unknown     -    -    -   1 (1)
Underlying diseases
Possible coagulative state   47 (13)  56 (34)  17 (27) 29 (35)
Inflammatory   92 (24)  38 (23)  11 (18)   8 (10)
Other 235 (63)  72 (43)  34 (55) 46 (55)
Composition of infusional fluid
Nutrition with fat 328 (88) 139 (84)  55 (89) 68 (82)
Fat free nutrition   26 (7)     8 (5)    1 (2)   7 (8)
Nutrition with/whithout fat 
(both partly)
    7 (2)     4 (2)    -   1 (1)
Only fluids and electrolytes   13 (3)   15 (9)    6 (10)   6 (7)
Unknown     -     -    -   1 (1)
HPN frequency (times/week)
1     3 (1)    4 (2)    -   3 (4)
2     4 (1)    2 (1)   2 (3)   -
3   18 (5)  22 (13) 16 (26)   2 (2)
4   31 (8)  19 (11)   6 (10)   3 (4)
5   32 (9)  21 (13) 11 (18)   3 (4)
6   32 (9)  19 (11)   5 (8)   5 (6)
7 251 (67)  76 (46) 22 (35) 64 (77)
unknown     3 (1)    3 (2)   -   3 (4)
Distribution of relevant confounders adjusted for in the analysis, presented as absolute number (%) of accesses 
with a certain confounder-status. Relevant confounders included medication use (immune suppressives or 
systemic anticoagulants), underlying disease and relevant comorbidities, the administration of nutrition 
(with or without lipids) versus solely fluids/electrolytes, and the frequency of HPN administration (ie, the 
frequency of access puncture or use per week). Underlying diseases and comorbidities were divided in 3 
categories: inflammatory diseases (mostly Crohn’s disease and ulcerative colitis), diseases related to a possible 
pro-coagulative state (mesenteric thrombosis and patients with >2 pulmonary emboli and/or deep venous 
thromboses not directly related to CVC use) and ‘other’ diseases (mostly patients with motility disorders, 
pancreatitis, enterocutaneous fistulae and so on). PACs, Port-a-Cath II.
Complication incidence rate ratios for CVCs over arteriovenous fistulae (ie the 
complication incidence rate that occurred with CVCs divided by those with arteriovenous 
fistulae) were calculated and adjusted for all these confounders using Poisson-normal 
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regression analysis. The NLMIXED procedure of SAS system for windows version 8.2 was 
used (SAS Institute Inc., Cary, NC). Statistical significance was accepted if the probability 
of a type I error did not exceed 5%. To provide information about statistical significance, 
we reported 95% confidence intervals (CI) where appropriate. We performed available 
case analysis because the number of missing data was limited and the missing process 
could be considered to be at random. 
ResUlTs 
D e s C R I P T I o N o F  T H e s T U DY P o P U l aT I o N
The studied HPN population comprised 127 consecutive patients (123 adults, 46 men). 
The mean (±SD) age at the start of HPN was 46 (±15) years (range 0.05-80 years). Sixty-
three patients terminated HPN between 2000 and 2006 because of resumption of enteral 
feeding (n=35), small bowel transplantation (n=2), progressive liver failure (n=1), death 
(n=24, of which 1 following catheter-sepsis and 23 due to progression of the underlying 
diseases or other non-HPN-related causes) or unknown reasons (n=1). The median 
duration of HPN use, counted from HPN start to termination or October 1, 2006 (the end 
of the study period), was 2.1 years (range, 0.25-30.2 years). Indications for HPN in our 
population mainly were motility disorders (31%) and short-bowel syndrome (46%), the 
latter mostly related to inflammatory bowel disease or mesenteric thrombosis (Table 3.2). 
Va s C U l a R aC C e s s e s 
Complication rate analysis was performed with 194 arteriovenous fistula access years 
and 344 CVC access years, represented by 62 arteriovenous fistulae and 623 CVCs. Table 
3.3 presents the 836 vascular accesses that were created to administer HPN in our 127 
patients (ie a median of 5 accesses per patient (range, 1-24)) and the reasons to exclude 
some accesses from incidence rate analysis. 
Arteriovenous fistulae
Fifty-eight patients (46%) had at least one arteriovenous fistula created at some point 
during their HPN treatment. During maturation of the fistula, these patients used a CVC. 
The median number of created arteriovenous fistulae in these 58 patients was two (range, 
1-7). In each patient, usually multiple factors steer the decision to create an arteriovenous 
fistula for HPN administration. Clinically, the most important factor is whether intestinal 
failure is expected to be permanent and at least longer than 1 year. Additionally, patient 
preference is essential and usually varies over time. From the perspective of the patient, 
complications associated with CVC use are often critical. In 42 patients (72%), prior 
CVC-related complications occurred and importantly contributed to the decision for 
arteriovenous fistula creation. In 16 patients, fistula creation was performed independent 
of CVC-related complications. The median duration from the start of HPN to the creation 
of the first fistula was 10 months (range 0.0-10.6 years). 
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Table 3.2: Indications for long-term HPN (N = 127).
Indication n
Motility disorder 39
Chronic Idiopathic Intestinal Pseudo-obstruction 9
Multiple adhesions 3
Sclerosing peritonitis 2
Sclerodermia 3
Slow transit obstipation 4
Neurogenic 3
Cause unknown 5
Other 10
High output stoma 11
Crohn’s disease 6
Ulcerative colitis 2
Resection; multiple adhesions 1
Resection; intestinal wall perforation 1
Mesenterial thrombosis 1
Short bowel 60
Mesenterial thrombosis 25
Crohn’s disease 12
Other vascular/ischemia 9
Malignancy 3
Volvulus 4
Other 7
Inadequately absorbing intestinal surface 4
B-cell non-Hodgkin lymphoma 1
Amyloidosis 1
Radiation enteritis 2
Other 13
(High output) Enterocutaneous fistulae 5
Pancreatitis 5
Other 3
In total, 120 arteriovenous fistulae were created (Table 3.3). Of these, 75 (63%) became 
functional; 6 failed during their creation (4 immediate occlusions and 2 because of 
inappropriate vasculature) and 39 failed during maturation (resulting from occlusion 
[32], inadequate maturation [2], wound infection [2], vascular steal phenomenon [1] 
or unspecified reasons [2]). We excluded 13 functional fistulae; 11 fistulae were never 
used (because of pain during puncturing [2], a preference to continue using a CVC after 
adequate maturing of the fistula [5], fistula maturing at the time of analysis [1] and 
nonspecified reasons [3]) and of 2 arteriovenous fistulae the complication rate could not 
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be fully ascertained. Of the 62 fistulae that were included in the incidence analysis, 32 
were straightforward arteriovenous anastomoses and 30 were arteriovenous grafts (20 
with autologous grafts, 2 with bovine grafts and 8 with Gore-Tex [Goremedical, Flagstaff, 
AZ] grafts). 
Central venous catheters
Overall, 716 CVCs were placed. In total, 671 (94%) CVCs became functional (Table 3.3), 
which is a significantly higher proportion when compared with the arteriovenous fistulae 
(p < 0.001); the insertion of 45 CVCs failed (due to vascular occlusion [24], malpositioning 
[8], failed punctures [6] and unspecified reasons [7]). Of these functional CVCs, 620 
could be used to analyze bloodstream infection incidence rates and 623 could be used 
to analyze occlusion rates. Twenty-five and 23 CVCs were excluded because bloodstream 
infection or occlusion incidence rates, respectively, could not be fully ascertained and 
26 were excluded because the exact CVC-type was not reported (defined as ‘unspecified 
CVC’ in Table 3.3). As a rule, catheters were single lumen and exclusively used for the 
administration of parenteral nutrition. In rare cases (ie, if multiple ports were essential for 
the management of the patient), multiple-lumen catheters were used. The catheter tips 
were mainly placed in the superior (86%) or inferior vena cava (9.6%) via insertion through 
the subclavian, internal jugular, axillary, cephalic, femoral or greater saphenous veins. 
Incidentally, the CVC was even placed in an uncommon vein such as the vena ovarica (1 
CVC) or directly in the right atrium via sternotomy (2 CVCs). In 4% of the CVCs, the exact 
vessel used was not documented. 
B l o o D s T R e a M I N F eC T I o N a N D o C C l U s I o N I N C I D e N C e R aT e s
Table 3.4 presents the complication incidence rates. In total, 507 vascular access-related 
blood stream infection episodes occurred. In 473 episodes (93%), blood cultures were 
positive. Eighteen episodes (4%) were counted based on information from referring 
hospitals without information about the results of the blood cultures (11 episodes in 
tunnelled CVCs, 3 in PACs, 1 in arteriovenous fistulae and 3 in nontunnelled CVCs). In 16 
episodes (3%), blood cultures were negative but the episode was defined to be an access 
related bloodstream infection because cultures were drawn under antibiotic treatment 
(6 in tunnelled CVCs, 2 in PACs and 1 in nontunnelled CVCs) or patients were showing 
evident signs of sepsis and other infectious foci that likely could explain the symptoms 
were excluded (3 episodes in tunnelled CVCs, 2 in PACs and 2 in arteriovenous fistulae). 
Blood stream infection incidence rates (number/access year) were 0.03/year for 
arteriovenous fistulae, 1.79/year for tunnelled catheters and 0.84/year for PACs (ie 
1.37/year for overall long-term CVCs). For short-term CVCs (ie, nontunnelled catheters), 
bloodstream infection rates were highest (3.12/year). The bloodstream infection incidence 
rate ratio, adjusted for confounders, of overall long-term CVCs over arteriovenous fistulae 
was 47 (95% CI, 19-117). Gore-Tex grafts were applied in 13% of analyzed arteriovenous 
fistulae but 33% of the fistulae-related bloodstream infections (2 of the 6) occurred in 
Gore-Tex grafts, suggesting that the use of artificial grafts is a risk factor for arteriovenous 
fistula-related blood stream infections. 
proefschrift Michelle.indb   42 18-12-2011   21:45:16
43
A
rterio
ven
o
u
s Fistu
lae V
ersu
s C
en
tral V
en
o
u
s C
ath
e
ters
Table 3.4: Blood stream infection and occlusion incidence rates and incidence rate ratios in 
CVCs compared with arteriovenous fistulae, used for the administration of TPN. 
Bloodstream 
infection
incidence ratea
adjusted IRR
CVCs/aVFb
occlusion
incidence ratea
adjusted IRR
CVCs/aVFb
Long-term TPN accesses
Arteriovenous fistulae 0.03 (0.01-0.06) 0.60 (0.43-0.84)
Overall long-term CVCsc 1.37 (1.14-1.66) 47 (19-117) 0.35 (1.27-0.47) 0.53 (0.31-0.89)
Tunnelled CVC 1.79 (1.47-2.18)  61 (25-150) 0.26 (0.24-0.37) 0.37 (0.21-0.67)
PAC    0.84 (0.64-1.09) 29 (12-73) 0.50 (0.36-0.70) 0.81 (0.45-1.45)
Short-term TPN access
Nontunnelled CVC   3.12 (2.04-4.78) 89 (33-237) 0.93 (0.48-1.80) 1.27 (0.55-2.94)
aBloodstream infection and occlusion incidence rates (unadjusted for confounders) of arteriovenous fistulae 
and CVCs presented as number of bloodstream infections or occlusions per access year (95% CI). bBloodstream 
infection and occlusion incidence rate ratios of CVCs over arteriovenous fistulae adjusted for the confounders 
presented in Table 3.1. cOverall long-term CVCs; tunnelled catheters and Port a Cath’s II (PACs) combined.
Organisms responsible for the CVC-related bloodstream infections were mainly gram-
positive organisms (mainly Staphylococcus Epidermidis and Staphylococcus Aureus; 51% 
in tunnelled CVCs, 68% in PACs and 93% in nontunnelled CVCs). Less frequently, gram-
negative organisms (40% in tunnelled CVCs, 28% in PACs, and 4% in nontunnelled CVCs) 
and fungi (9% in tunnelled CVCs, 4% in PACs, and 4% in nontunnelled CVCs) were cultured. 
In arteriovenous fistula-related bloodstream infections, 3 organisms were cultured; 2 
Staphylococci Aureus and 1 Candida Albicans. 
Occlusion rates were slightly lower in tunnelled CVCs (0.26/year) than in arteriovenous 
fistulae (0.60/year). Occlusion rates in PACs (0.50/year) did not significantly differ from 
arteriovenous fistulae-related occlusion rates. In short-term (nontunnelled) CVCs, 
occlusion rates were highest (0.93/year). For overall long-term CVCs (tunnelled CVCs and 
PACs), the adjusted occlusion incidence rate ratio with respect to arteriovenous fistulae 
was 0.53 (95% CI, 0.31-0.89). 
DIsCUssIoN 
Vascular access related complications remain a major problem in patients on long-term 
HPN. In our patients, the incidence rate of vascular access related blood stream infections 
was much lower during arteriovenous fistula use than during CVC use. The occlusion rate 
was slightly higher in arteriovenous fistulae, but only compared with certain types of CVCs. 
Our centre is the larger of the 2 HPN centres in The Netherlands and we take care of 
60-70% of the nationwide HPN population, which currently approximates 130 patients. 
The main indications for long-term HPN in our 127 analyzed patients are in accordance 
with other studies [15, 16]. The present study is by far the largest to evaluate the use of 
surgically created arteriovenous fistulae as an alternative for CVCs in patients on long-
term HPN.
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The observed bloodstream infection rates in CVCs correspond with the rates reported 
in other studies, ranging from 0.17 to 2.19 episodes per year [1, 17-22]. In our study 
population, the arteriovenous fistula-related bloodstream infection rate was 0.03/year 
which even in comparison with the lowest CVC-related bloodstream infection incidence 
rate reported in literature constitutes a clinically relevant reduction. Therefore, also in 
other populations with lower bloodstream infection incidence rates, the conclusions 
and recommendations of our study would remain unchanged. The lower bloodstream 
infection rate (up to 61 times lower) in arteriovenous fistulae in comparison with long-
term CVCs (PACs and tunnelled catheters) is in line with case reports or small case-series 
that even describe a complete absence of infections related to arteriovenous fistula use 
in patients treated with HPN [8, 10, 11]. The considerably lower bloodstream infection 
rate observed during arteriovenous fistula use is of major importance since, in patients 
treated with HPN, bloodstream infection is the most frequent and most life-threatening 
catheter-related complication. In fact, 20-50% of the causes of death directly related to 
HPN is represented by catheter-related infections [19, 23]. In our population, the death 
of 1 patient was directly related to HPN treatment and was caused by an episode of 
catheter-sepsis. It can be argued that the incidence rate of arteriovenous fistula-related 
bloodstream infection benefits from the fact that patients who have been using (multiple) 
CVCs prior to arteriovenous fistula creation, have been better trained in aseptic techniques. 
However, all our patients who require long-term HPN receive in-hospital training on 
aseptic vascular access care and proper HPN administration for 1-2 weeks. They are 
allowed to administer TPN at home, only if they can satisfactorily care for their access. 
We therefore do not believe that a more extended access-care experience has skewed 
our results in that patients with an arteriovenous fistula have a better aseptic technique. 
We consider it more likely that the patients who eventually end up using an arteriovenous 
fistula represent a selection of patients that is more vulnerable to infections. Improper 
access care, which more likely is a trait of character that improbably will change with a 
switch to a fistula, might in fact be a factor that contributes to this risk. 
Although based on a low number of arteriovenous fistula-related bloodstream infections 
(n=6), we observed a relatively high bloodstream infection rate with artificial Gore-
Tex grafts; 33% of the arteriovenous fistula-related bloodstream infections occurred 
in Gore-Tex grafts while only 13% of the arteriovenous fistula were Gore-Tex grafts. 
Higher bloodstream infection rates in artificial grafts compared with autologous grafts 
have also been shown in patients on hemodialysis [24]. Therefore, we propose that the 
artificial grafts, such as those constructed from Gore-Tex, might be more susceptible 
to bloodstream infections than the autologous grafts and that arteriovenous fistula-
related bloodstream infection rates in HPN patients can even further be decreased if only 
autologous grafts are used. 
The main problem in arteriovenous fistulae is the risk of fistula occlusion. In our patients, 
4 fistulae could not be created because of immediate occlusion during surgery and 32 
fistulae never matured because of early occlusion. However, once adequately matured, 
the occlusion incidence rate in the arteriovenous fistulae was only slightly higher than in 
tunnelled catheters, while it was not significantly different from the occlusion rate in PACs. 
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In our study population, arteriovenous fistulae were mainly used in patients in whom CVCs 
repeatedly proved ineffective; in 72% of the patients prior CVC-related complications 
decisively contributed to the decision for fistula creation. This might have contributed 
to the higher occlusion rates in arteriovenous fistulae with respect to CVCs because the 
prior insertion of multiple CVCs may damage the proximal vasculature and make fistula 
creation impossible or increase fistula occlusion rates due to an already compromised 
blood flow. This latter hypothesis can, however, only be proven in a prospective study 
in which detailed data on thrombotic clot localization are correlated to prior catheter 
placements in the exact same vessels. Nevertheless, we propose that arteriovenous 
fistulae should be considered early, if not immediately, after the decision to start long-
term HPN. Alternatively, we promote the use of jugular instead of subclavian veins to 
place CVCs, thus minimizing the risk of obliteration of the venous circulation which might 
be required for future creation of an arteriovenous fistula. 
The retrospective study design confers favorable as well as less favorable aspects. It 
caused a limited number of incomplete data concerning access use, the occurrence of 
complications and covariates. It is highly unlikely, however, that bias due to incomplete 
data has colored our conclusions. We reviewed both the surgical and gastroenterological 
records as well as all letters from referring hospitals. In addition, to further increase the 
reliability of data collection, two independent reviewers reviewed all medical records and 
differences in interpretation were evaluated until consensus could be reached. Eventually 
only a very small and in all likelihood random number of accesses could not be included 
in the analysis due to lacking data (3% of arteriovenous fistulae and 7% of CVCs). The 
retrospective study design of a study period of over 30 years was favorable because it 
enabled us to evaluate access-related complication incidences during more than 500 
access years and to include a large cohort of unselected patients on long-term HPN. We 
propose that no apparent bias was introduced by the relatively long study period because 
medical and surgical procedures, as well as complication prevention protocols, have not 
changed dramatically in the studied decades. As previously mentioned, arteriovenous 
fistulae have been used by a selected group of our patients, mainly patients in whom 
CVCs (repeatedly) proved ineffective. In the present population, it is impossible to correct 
for this apparent selection bias, but in absence of likely other causes, most likely these 
patients are more vulnerable to complications. Therefore, the arteriovenous fistula-
related complication rates are more probably overestimated than underestimated. This 
strengthens our conclusion that arteriovenous fistulae are save alternatives for CVCs. In 
our opinion, complication rate analysis of all accesses created in our entire HPN population 
best represents complication rates that occur in daily practice. It has been argued that 
in each patient only the first access should be included since inclusion of accesses that 
were placed in patients with prior access-related complications might bias the results [14]. 
However, in clinical practice, patients on long-term HPN mostly need multiple accesses, 
so only comparing the first accesses would probably result in decreased generalizability 
for a complete study population over the total duration of HPN. Therefore, instead of 
only 127 first accesses, we decided to include all 685 accesses in our analysis. We used a 
Poisson-normal regression model with account for repeated measurements to control for 
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overrepresentation of some patients. 
In conclusion, in our patients on long-term HPN, the occlusion incidence rate was 
higher in arteriovenous fistulae compared with some types of CVCs. The incidence 
rate of potentially life-threatening bloodstream infections, however, was extremely 
low in arteriovenous fistulae compared with CVCs, independent of CVC type. These 
data suggest that arteriovenous fistulae are safe and valuable alternatives for CVCs in 
patients in whom (life-)long-term dependency on HPN can be expected. Finally, within 
the limitations of a retrospective study design, we propose that the risk of arteriovenous 
fistula-related bloodstream infections and occlusions can probably be further decreased 
if only autologous grafts are used and if arteriovenous fistula creation is performed prior 
to (multiple) catheter placement(s).
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leukocyte Phenotypes in Whole 
Blood, Depending on Their Fatty acid 
Composition
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a B s T R aC T 
To characterize the immunological effects of various lipids that are applied as part 
of total parenteral nutrition (TPN) formulations, we analyzed phenotypical changes 
in leukocytes following lipid exposure. Importantly, the study was performed 
with whole blood in order to prevent the functional changes that are induced by 
isolation procedures. Briefly, blood samples from 10 healthy volunteers were 
incubated with lipids containing pure long-chain triglycerides (LCT), mixed long- and 
medium-chain triglycerides (LCT/MCT), synthetic structured lipids (SL), or emulsions 
based on olive- (OO), or fish oil (FO). After immune fluorescent staining, leukocyte 
phenotype characteristics were analyzed by flowcytometry. Exposure to LCT/
MCT increased in a dose-dependent manner the expression of membrane surface 
markers for adhesion (CD11b) and degranulation (CD66b), while decreasing CD62L, 
on neutrophils and monocytes. These findings demonstrate that LCT/MCT activates 
leukocytes in peripheral whole blood. On the other hand, decreased expression of 
activation markers was observed with LCT and FO. Lipid effects on the phenotype 
of T lymphocytes and Natural Killer cells were not seen during incubation for up to 4 
hours. In conclusion, these results indicate that i) the composition of TPN formulations 
with regard to lipid structure has implications for the function of exposed immune 
competent cells and ii) medium chain triglycerides, which have been regarded as 
functionally inert deliverers of fuel calories, have distinct biological effects. 
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Infectious complications remain the major clinical problem in patients treated with total parenteral nutrition (TPN) [1]. These infections apparently result not only from catheter-related problems, but also from altered 
immune responses induced by TPN components [2]. A long debate has been going on as 
to whether, and if so to what extent, effects of lipids in TPN formulations play a role in 
these complications [3,4]. Unfortunately, this matter has remained unsolved so far, due 
to disparate and inconsistent study results and because specific effects of various lipids 
that are applied in the context of TPN have not been characterized separately so far [5]. 
We have previously reported on the effects of lipids on neutrophilic granulocytes, 
because the type of infections in TPN patients suggests that especially the function of 
this phagocyte is compromised. When comparing emulsions that contain pure ω-6 long 
chain triglycerides (LCTs) with mixed long- and medium-chain triglycerides (LCT/MCT) in 
the in vitro setting, i.e. with lipid incubation of isolated neutrophils, we have consistently 
found that LCT/MCT impair crucial neutrophil functions, such as directional migration and 
killing of yeast pathogens [6,7]. We also found LCT/MCT- and MCT-induced signs of cell 
activation, such as increased oxygen radical production and expression of adhesion and 
degranulation markers [8,9]. These findings corroborate studies from other investigators 
[10,11]. In the in vivo setting, after lipid administration to healthy volunteers, LCT/MCT, 
but not LCT or placebo changed the production of pro- and anti-inflammatory cytokines 
by mononuclear cells, suggesting an altered balance between T-helper-1 and T-helper-2 
lymphocytes and an increased susceptibility for fungal infections [12]. 
Nearly all of the information regarding lipid effects on immune cells comes from 
experimental studies in which leukocytes were isolated from whole blood prior to 
lipid incubation. This implies that the cells are placed in an artificial environment and 
are detained from interaction with their natural counterparts. Furthermore, isolation 
procedures invariably introduce functional changes, especially pre-activation, or ‘priming’ 
[13]. Flowcytometry is a technique that enables the phenotypic analysis of all leukocyte 
populations in whole blood without the need for cell isolation. We therefore decided 
to use this technique to study the expression of membrane surface activation markers 
on leukocytes following whole blood incubation with structurally different lipids. This ex 
vivo design was chosen to avoid a pitfall of true in vivo studies, i.e. analysis of whole 
blood following lipid infusion in study subjects, in which leukocytes may be excluded 
from analysis due to vascular adhesion following activation by lipids. Such sequestration 
of activated leukocytes in the capillary beds of the lungs and kidneys has for instance 
been demonstrated in patients on hemodialysis [14,15]. Importantly, emulsions that have 
recently been introduced in the clinical arena, based on synthetic long- and medium-chain 
fatty acid-containing structured lipids (SL), olive oil (OO) or fish oil (FO), were included in 
the present analysis. An overview of lipid emulsion characteristics is presented in tables 
4.1 and 4.2. 
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Table 4.2: Composition and characteristics of lipid emulsions. 
emulsion (% w/v)
sl 
(20%)
lCT/MCT 
(20%)
Fo 
(10%)
oo 
(20%)
lCT 
(20%)
Mean molecular weight 683 634 882 873             865
Egg phospholipids (g/l) 12 12 12 12                       12
Glycerol (g/l) 22  25 25 22.5           22
Osmolarity mOsm/l 350 380 273 270 350
pH 8 8.0 7.5-8.7 7-8            8
Data provided by the manufacturers.
MaTeRIals aND MeTHoDs
After overnight fasting, blood samples were drawn from 10 healthy volunteers (5 males, 
mean age 34 ± 8 years, range 27-50), none of whom was on medication, and processed 
as described below. Serum triglyceride content of the blood samples was always in the 
normal range (0.55-1.56 mmol/L), as determined colorimetrically on a Hitachi 747 analyzer 
(Hitachi Ltd., Tokyo, Japan).
 
M aT e R I a l s
Bovine serum albumin (BSA) was from Behring (Westwood, MA). Hank’s balanced salt 
solution (HBSS) was from Life Technologies (Paisley, Scotland). Phosphate-buffered saline 
(PBS) contained Na+ 163.9 mmol/L, Cl- 140.3 mmol/L, HPO
4
2- 10.9 mmol/L and H
2
PO4- 1.8 
mmol/L (pH 7.4). Incubation medium contained HBSS supplemented with 0.5% (w/v) 
HSA. LCT (Intralipid 20%, w/v), SL (Structolipid 20%, w/v) and FO (Omegaven 10%, w/v) 
were from Fresenius Kabi (Bad Homburg, Germany). LCT/MCT (Lipofundin 20%, w/v) was 
from B. Braun Melsungen AG (Melsungen, Germany). OO (Olive oil emulsion (ClinOleic 
20%, w/v) was provided by Baxter SA (Lessines, France). Phorbol myristate acetate (PMA) 
was from Sigma Chemical Co (St. Louis, MO, USA) and was stored as a 0.1 mg/ml stock 
in dimethylsulfoxide at -20°C. Blood samples were collected in 10-ml Monoject tubes 
(Sherwood Medical, Ballymoney, N. Ireland) with 143 USP units of lithium heparin. 
M e T H o D s
Lipid incubation, immune fluorescent staining and flowcytometric analysis
Blood samples (0.5 mL) were incubated for 2 h with medium or lipids at a triglyceride 
concentration of 5 mmol/L by gentle head-over-head turning at 37°C. Next, immune 
fluorescent staining was performed as according to the lyse/no wash method [16]. Briefly, 
following lipid incubation, 100 μL whole blood was incubated (15 min, rT) with 5μL of each 
directly fluorochrome-labeled antibody. The following mouse anti-human IgG antibodies 
were used: CD66b (Clone 80H3), CD62L (Clone Dreg 56), CD3 (Clone KCHT1) labeled with 
fluorescein isothiocyanate (FITC), CD4 (Clone 13 B 8.2), CD11b (Clone Bear 1), CD56 (Clone 
NCAM16.2) labeled with phycoerytrin (PE), CD45 (Clone J33 BC) labeled with PE-texas 
red (ECD) and CD14 (Clone RMO 52), CD25 (Clone B1.49.9) and CD8 (Clone SFCI21 ThyD3) 
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labeled with PE-cychrome5 (PE-CY5). All antibodies were purchased from Beckman 
Coulter, Miami, FL, USA, except CD56 (Becton, Dickinson and Company, San Jose, CA, USA) 
and CD66b (Immunotech, Marseille, France). Next, all erythrocytes were lysed (10 min, 
in the dark) by means of 155 mmol/L NH
4
Cl. (pH 7.4). Staining of cells was determined in 
multi-color analysis by using a Beckman Coulter Epics XL flowcytometer (Beckman Coulter, 
Hileah, FL). All measurements were performed on minimally 50,000 cells. An overview of 
relevant activation markers is presented in table 4.3.
 
Tabel 4.3:  Immune fluorescence markers for neutrophils and monocytes. 
antibody alternative names Function / involvement expression
CD11b
α-chain of β
2
 integrin CD11b/
CD18, Mac-1
degranulation, adhesion, 
phagocytosis, respiratory burst
monocytes
neutrophils
CD66b CD67, CGM6, NCA-95
specific / gelatinase granule 
degranulation, activation
granulocytes
CD62L L-selectin homing, tethering, rolling
mononuclears,
neutrophils
CD25 Interleukin-2 receptor, Tac activated B- and T-lymphocytes
lymphocytes, 
monocytes
Statistical analysis
Values are expressed as mean ± SD. Wilcoxon’s signed rank test was used to compare 
variables. With Bonferroni’s correction for multiple comparisons, the significance level 
was set at 0.01. 
ResUlTs
Leukocyte subpopulations were identified by flowcytometric scatter patterns in 
combination with immune fluorescence characteristics. Neutrophil and monocyte 
phenotypes were distinctly influenced by exposure to various lipids (see Table 4.4). LCT/
MCT significantly increased the expression of CD11b on neutrophils and monocytes. 
Accordingly, the marker for degranulation of specific granules (CD66b) was upregulated, 
whereas L-selectin (CD62L) expression decreased. Taken together, these findings are 
compatible with leukocyte activation by LCT/MCT [13]. This activation takes place within 
minutes following lipid exposure, since with increasing incubation periods from 15 up to 
120 minutes no further increases in surface marker expression were observed (Figure 
4.1). The leukocyte-activating effect of LCT/MCT was lipid-dose dependent within a 
concentration range of 1 to 10 mmol/L (Figures 4.2 and 4.3). 
In clear contrast with the effects of LCT/MCT, LCT and FO decreased the expression of 
CD11b and CD66b on neutrophils, with increased expression of CD62L, while OO and SL 
only increased CD62L (Table 4.4).
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Figure 4.1: Expression of 
CD11b and CD66b on 
neutrophils after incuba-
tion in lipid emulsions (5 
mmol/L) or lipid-free me-
dium for several periods. 
Results are representative 
for 3 separate experiments 
performed in duplo.
  
Table 4.4:  adhesion molecule expression of  leukocytes in whole blood from volun-
teers (n=10) after lipid incubation (2h, at 5 mmol/l).
CD11b CD66b CD62l
Neutrophils
Medium 1.00 ± 0.36 1.00 ± 0.16 1.00 ± 0.60
LCT 0.71 ± 0.24* 0.74 ± 0.06* 1.60 ± 0.36*
LCT/MCT 1.96 ± 0.30* 2.25 ± 0.03* 0.51 ± 0.32*
FO
OO
SL
0.66 ± 0.21*
0.84 ± 0.22
0.82 ± 0.26
0.76 ± 0.09*
0.89 ± 0.03
0.91 ± 0.04
1.48 ± 0.45*
1.48 ± 0.45*
1.32 ± 0.46*
Monocytes
Medium
LCT
LCT/MCT
FO
OO
SL
1.00 ± 0.13
1.03 ± 0.21
1.43 ± 0.18*
0.96 ± 0.26
1.11 ± 0.19
1.09 ± 0.17
1.00 ± 0.29
0.95 ± 0.19
1.95 ± 0.76*
0.90 ± 0.14
1.00 ± 0.24
1.05 ± 0.24
1.00 ± 0.86
1.21 ± 0.75
0.32 ± 0.18*
0.89 ± 0.59
0.80 ± 0.34
0.98 ± 0.70
Data presented as relative fluorescence (mean ± SD) compared to incubation in medium. Significant 
changes all had p<0.01 and are indicated with *.
Similar to a potent stimulating agent, the phorbol ester PMA, neither lipid induced 
phenotypical changes in T-lymphocytes (CD4+ T-helper and CD8+ T-cytotoxic 
subpopulations) and Natural Killer cells (identified by CD3-/CD16,CD56+ immune 
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fluorescence, respectively) as represented by expression of the lymphocyte activation 
marker CD25 (see also Table 4.3) during exposition periods for up to 4 hours (data 
summarized in Figure 4.4). 
Figure 4.2: Expression of 
CD11b on neutrophils and 
monocytes after incuba-
tion of whole blood at 
various lipid concentrations 
for 1 hour. Results are re-
presentative for 3 separate 
experiments performed in 
duplo.  
Figure 4.3: Expression of 
CD66b on neutrophils and 
monocytes after incuba-
tion of whole blood at 
various lipid concentrations 
for 1 hour. Results are re-
presentative for 3 separate 
experiments performed in 
duplo.  
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Figure 4.4: Expression of 
CD25 on T lymphocytes 
(CD3+) and natural killer 
cells (CD3-/CD16, CD56+) 
after incubation in lipid 
emulsions (5 mmol/L) or 
stimulation with phorbol 
ester (PMA, 100 ng/mL) for 
4 hours. Fluorescence is 
presented as relative to 
lipid free control and the 
data are representative for 
3 separate experiments 
performed in duplo.
DIsCUssIoN
The present study clearly shows that parenteral lipids modulate the function of cells of 
both the innate and the adaptive branches of the immune system, such as neutrophils and 
mononuclear leukocytes, respectively. Importantly and novel, these observations were 
made in the natural habitat of these cells and included data on the effects of OO- and FO-
based emulsions, which have been introduced in TPN only recently. Triglyceride fatty acid 
structure was found to be of critical importance with regard to the immunological effects 
of parenteral lipids. Especially medium-chain triglyceride-containing lipids (LCT/MCT) 
alter the phenotype of leukocytes in a manner that is compatible with cell activation, 
with increased expression of adhesion (CD11b) and degranulation (CD66b) markers and 
decreased expression of L-selectin (CD62L), the latter being most probably due to receptor 
shedding [17-19]. By contrast, pure long-chain triglycerides (LCT), structured lipids (SL) 
and emulsions based on OO and FO depress the expression of activation markers on 
leukocytes. Our data corroborate previous findings with isolated neutrophils showing 
increased expression of the α subunit of β
2
 integrins LFA-1 (CD11a), Mac-1 (CD11b), p150,95 
(CD11c) and α
D
β
2
 (CD11d) under influence of LCT/MCT and pure MCT [9]. Interestingly, in 
the latter experimental setting, LCT and SL did not influence leukocyte phenotype. 
Plusa et al. have previously investigated neutrophil phenotype in blood samples from 
patients following the administration for 24 hours of a pure LCT-containing TPN formulation. 
This treatment did not alter CD11b expression [20]. Differences in experimental design as 
well as the presence of various underlying diseases in these patients may explain different 
outcomes from our study. To our knowledge, studies regarding neutrophil phenotype in 
whole blood under influence of SL, OO and FO are lacking so far. 
Close comparison of the fatty acid composition of the emulsions used in the present study 
(Table 4.1) reveals that LCT/MCT is unique in that this emulsion contains triglycerides 
composed of the medium-chain fatty acids caprylic acid (C8:0) and capric acid (C10:0), 
suggesting that these triglycerides are responsible for the MCT-specific effects. This 
supports findings in studies where saturated medium-chain lipids were found to stimulate 
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neutrophil oxidative metabolism [21,22]. In agreement with this notion, our group has 
shown that tricaproin (TC6:0), tricaprylin (TC8:0) and trilaurin (TC12:0) induce oxygen 
radical production in human neutrophils [23]. In this respect it is intriguing that synthetic 
lipids (SL), which contain structured triglycerides with medium- and long-chain fatty 
acids randomly distributed within one triglyceride molecule, apparently do not stimulate 
leukocytes. 
The activating effect of LCT/MCT was lipid-dose dependent within a concentration range 
of 1-10 mmol/L (Figures 4.2 and 4.3), while in a previous study with isolated neutrophils 
a plateau was already reached at 2.5 mmol/L [9]. Figures 4.2 and 4.3 suggest that further 
increments might be expected at higher lipid concentrations. However, this was not 
investigated since triglyceride concentrations in vivo hardly ever exceed 10 mmol/L in 
TPN practice. 
The LCT/MCT-induced increase in expression of CD11b and CD66b reached a plateau 
within 15 minutes of lipid exposure (Figure 4.1). This rapid effect is in accordance with 
previous findings in isolated neutrophils and is not surprising since Mac-1 (CD11b/CD18) 
is stored in peroxidase-negative granules that degranulate immediately upon stimulation 
and thus increase the surface expression of these molecules [9,24,25]. 
Our study also sheds light on the effects of the novel FO and OO emulsions. While FO 
is rich in ω-3 polyunsaturated fatty acids with an anti-inflammatory profile, such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), OO is rich in the ω-9 
mono-unsaturated oleic acid. In line with the effects of the pure ω-6 long-chain emulsion 
LCT, and in accordance with immunological concepts for their use, FO and OO did not 
display any activating effects on leukocytes [26]. Decreased adhesion of macrophages and 
monocytes in the presence of EPA and DHA has been described before in experimental 
studies [27,28]. The more immune-neutral effect of OO confirms findings in a clinical 
study by Granato et al. [29]. On the other hand, increased expression of the IL-2 receptor 
(CD25), an early activation marker, on spleen lymphocytes under influence of OO has also 
been reported [30]. 
Because integrins must be activated to become functional, increased adhesion molecule 
expression not necessarily implies increased adhesion. However, both LCT/MCT and 
pure MCT, but not LCT and SL, substantially increase the expression of a Ca2+-dependent 
activation epitope of LFA-1 (CD11a/CD18) and increase actual neutrophil adhesion to 
endothelial intercellular adhesion molecule-1 (ICAM-1) [9].
The mechanism behind the activating effect of LCT/MCT remains unclear so far. However, 
lipid effects on membrane fluidity and signal transduction pathways provide possible 
mechanisms to explain our observations [31,32]. Based on previous investigations, in the 
present study a relatively brief lipid incubation period (2 to 4 hours) was implemented 
to rule out artefacts due to extra-corporal decomposition of biological components [6-
9]. This approach renders it less probable that the lipid effects can actually be attributed 
to incorporation of lipids in biomembranes. Also, we cannot rule out that with longer 
incubation periods lipids might affects T-lymphocyte and Natural Killer cell phenotypes 
since even a potent activating substance such as the protein kinase C activator PMA did 
not elicit any signs of cell activation within this time frame (Figure 4.4). 
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Differences in metabolic breakdown between LCT/MCT and other lipids might play a role. 
For instance, in contrast with long-chain fatty acids, their medium-chain counterparts 
do not require carnitine for transport into mitochondria [33]. Also, medium-chain fatty 
acids, unlike long-chain fatty acids are also oxidized in the peroxisomal system [34]. Finally, 
MCT preferentially interact with cells in the environment because of their location on the 
outside of the lipid droplets of a physical LCT/MCT mixture [35]. The latter might explain 
why mixed LCT/MCT, where MCT can freely move to the droplet surface, may have such 
different effects from SL, where the medium-chain fatty acids are more spatially restricted.
In conclusion, the present study shows that exposure of neutrophils and monocytes 
in whole blood to parenteral lipids in a concentration range that is clinically relevant 
distinctly influence leukocyte phenotype depending on fatty acid composition. 
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Lipid-induced modulation of phagocyte function seems to contribute to increased 
susceptibility to infections in patients on parenteral nutrition, and an increased risk 
for development of pneumonia has been observed in this group. The role of various 
structurally different lipid emulsions, however, remains unclear. In the present study, 
we therefore assessed phagocyte function, as the capacity of neutrophils to eliminate 
Streptococcus pneumoniae (i.e. combined result of phagocytosis and killing), in the 
presence of these lipids. Neutrophils from 6 healthy volunteers were incubated 
for 1 hour in emulsions (5 mmol/L) derived from soybean- (LCT), fish- (VLCT), olive- 
(LCT-MUFA), mixed soybean/coconut oils (LCT/MCTs) or structured lipids (SL). After 
opsonization of the pneumococci (strain OREP-4) by human immunoglobulins, bacteria 
and neutrophils were incubated in the presence of complement. Next, pneumococcal 
elimination was evaluated and expressed as the percentage of bacteria eliminated 
relative to the initial bacterial numbers in neutrophil-free samples. Neutrophils that 
were not exposed to lipids showed a pneumococcal elimination capacity of 75 ± 3% 
(mean ± SD). This significantly decreased after exposure to LCT-MUFA (70 ± 6%), VLCT 
(67 ± 2%), SL (63 ± 9%), LCT (66 ± 10%) and LCT/MCT (47 ± 15%). In conclusion, these 
data demonstrate that parenteral lipids impair the microbial elimination capacity 
of neutrophils in a structure-dependent manner. In accordance with our previously 
reported in vitro effect on a range of phagocyte functions, LCT/MCT is by far the most 
potent in this respect.
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Patients with an insufficient uptake or intolerance for enteral nutrition or fluids, mostly because of short bowel syndrome or motility disorders, are treated by means of total parenteral nutrition (TPN). TPN formulations 
usually include fat, in the form of an aqueous lipid emulsion, to cover the needs for 
fuel calories, (essential) fatty acids and lipid-soluble vitamins. Unfortunately, infectious 
complications are frequently encountered in these patients. For instance, the Veterans 
Affairs Study showed that mildly malnourished surgical patients have an increased risk 
for the development of infectious complications, mainly in the form of pneumonia and 
abscesses [1]. These complications suggest a TPN-induced modulation of particularly 
phagocyte function, for which the lipid component appears to be responsible [2, 3]. The 
role of various available structurally different lipid emulsions on phagocyte function, 
however, remains unclear. 
Neutrophil phagocytosis and microbial killing establish major phagocytic functions within 
the human nonspecific defense system. The effect of both Intralipid, containing long-chain 
triglycerides (LCTs), and Lipofundin, containing a physical mixture of long- and medium-
chain triglycerides (LCT/MCTs), on neutrophil functions has been extensively studied, with 
conflicting results so far [4-11]. Somewhat more uniform data have been reported from 
studies on more recently developed lipid emulsions, based on fish oil (containing very 
long-chain [poly-unsaturated] triglycerides [VLCT]) and olive oil (containing long-chain 
triglycerides mono-unsaturated fatty acids [LCT-MUFA]) [12-17]. 
We have previously shown that emulsions containing medium-chain triglycerides, such 
as mixed long- and medium-chain triglycerides (LCT/MCT and tocopherol-enriched LCT/
MCT), or pure MCT emulsions in contrast to pure LCT emulsions, significantly impair the 
capacity of isolated neutrophils to kill Candida albicans [18]. This organism is frequently 
responsible for life-threatening infections during parenteral nutrition use. In addition, 
and even more frequent, infections with gram-positive bacteria, such as Staphylococcus 
spp., occur [19]. 
Given the increased risk for pulmonary infections observed in a large previous study in 
surgical patients on parenteral nutrition (Veterans Affairs Study), in this study we evaluated 
the elimination capacity of Streptococcus pneumoniae by neutrophils in the presence of 
various structurally different lipid emulsions, complement and immunoglobulins, which 
can be regarded as a combined outcome of neutrophil phagocytosis and killing.
sUBJeCTs, MaTeRIals aND MeTHoDs
s U B J eC T s
Before initiation, appropriate informed consent from all participating volunteers was 
obtained. The human experimentation guidelines of the author’s institution were 
followed in the conduct of this study. After overnight fasting, blood samples drawn from 
6 healthy volunteers [2 males/4 females, mean age 29 ± 5.6 years (mean ± SD) range 22-38 
years], none of whom was on medication, were collected in 10 mL Monoject tubes with 
170 IU of lithium heparin (Beliver Industrial Estate, Plymouth PL6 7BP, UK) and processed 
as described. 
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M aT e R I a l s
Reagents were from Sigma Chemicals (St Louis, MO, USA), unless stated otherwise. Hanks’ 
balanced salt solution (HBSS) was purchased from Life Technologies (Paisley, Scotland, UK). 
Percoll (ρ 1.130 g/mL at 20°C) was obtained from GE Healthcare Biosciences AB (Uppsala, 
Sweden) and phosphate buffered saline (PBS) was produced by B. Braun Melsungen AG, 
Melsungen Germany. Isotonic lysis solution (pH 7.4) contained 155 mmol/L NH
4
Cl and 10 
mmol/L KHCO
3
. LCT/MCT emulsion (Lipofundin, 20% w/v) was from B. Braun Melsungen 
AG (Melsungen, Germany), LCT emulsion (Intralipid, 20% w/v), SL (Structolipid, 20% w/v) 
and VLCT (Omegaven, 10% w/v) were from Fresenius Kabi (Bad Homburg, Germany) and 
LCT-MUFA (Clinoleic, 20% w/v) was from Baxter (Maurepas, France). Opsonization buffer 
consisted of HBSS supplemented with 0.1% gelatin and 10% fetal calf serum. The latter 
was obtained from Invitrogen, Breda, the Netherlands. Nanogam (containing 50 mg/mL 
human immunoglobulin) was purchased from Sanquin (Amsterdam, the Netherlands). 
Streptococcus pneumoniae, strain OREP-4 (serotype 4), which was a kind gift from M.H. 
Nahm, was stored at -80°C. Rabbit complement was purchased from Pel-Freez Biologicals 
(Rogers, Arkansas) and stored at -80°C. THYA medium (for agar plates) consisted of 15 
g Todd Hewitt Broth, 2.5 g Yeast Extract and 7.5 g Bacto agar (all from BD Biosciences, 
Sparks, USA) in 500 mL ultrapure water. THYA overlay medium consisted of 15 g Todd 
Hewitt Broth, 2.5 g Yeast Extract and 3.75 g Bacto agar in 500 mL ultrapure water. Square 
petri dishes were from BD Falcon, BD Biosciences, USA. 96-wells U-plates were from Nunc, 
Thermofisher Scientific, USA. TCC (2,3,5-triphenyl tetrazolium chloride, stock 25 mg/mL in 
ultrapure water was filter sterilized and stored at 4°C until use. 
M e T H o D s
Neutrophil isolation
Neutrophils were purified by means of density centrifugation from blood anti-coagulated 
with lithium heparin. The blood, diluted 1:1 with PBS, was placed on Percoll (ρ 1.076 g/mL) 
and centrifuged (700xg, 20 min, RT). The granulocyte-containing pellet was suspended 
in 50 mL ice-cold lysis solution and lysis of erythrocytes was performed on ice for 10-15 
min. After centrifugation (400xg, 5 min, RT), remaining erythrocytes were lysed on ice 
in fresh lysis solution for another 5 min. The granulocytes were then washed twice in 
HBSS, suspended to 10x106 cells/mL in opsonization buffer and kept at RT. This method 
of neutrophil isolation yields > 97% pure and > 99% viable cell samples as determined by 
May-Grünwald/Giemsa and trypan blue staining [20].
Lipid incubation
Neutrophils (10x106 cells/mL in opsonization buffer) were incubated with lipid emulsions 
(5 mmol/L final concentration) for 1 h by gentle head-over-head turning at 37°C. As a 
positive control for inhibition of bacterial killing by neutrophils we incubated the cells 
with a Phospholipase C (PLC) inhibitor (U-73122, 5 µM final concentration). PLC activation 
is responsible for various intracellular responses which contribute to the physiological 
defense against bacterial infection and cell disruption [21]. As negative control, the 
inactive analog of U-73122, i.e. U-73343 (5 µM final concentration), was used.
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Opsonophagocytic killing assay (OPKA)
With some modifications, the method for the OPKA by Nahm was used [22, 23]. 
Briefly, bacteria were thawed, span down (3 min, 13000xg) and resuspended in 1 mL 
opsonization buffer. Then the bacteria were diluted with opsonization buffer to 2x105 
CFU/mL and kept on ice until use. Pooled and purified human IgG (Nanogam) was serially 
diluted in opsonization buffer (final concentrations as described in the results section). 
Opsonization of bacteria was performed by incubating 10 µL of bacteria suspension and 
20 µL IgG for 30 min. at 37°C/5% CO2 in a 96-wells U-plate on an microplate orbital shaker 
(1.21xg, Heidolph Titramax, Schwabach, Germany). Subsequently, 40 µL of neutrophil 
suspension and 10 µL of complement were added and the mixture was incubated for 
45 min. at 37°C/5% CO
2
 on an orbital shaker (1.21xg). All incubations were performed 
in triplicate. Then, 5 µL of the suspension was spotted in duplicate on THYA medium in 
square petri dishes by use of the reverse pipette technique and the plate was tilted to 
shape the spot into a small strip. Spots were air dryed for a few minutes. Then, 12 mL THYA 
overlay medium with TCC (25 µg/mL) was added. The plates were incubated overnight at 
37°C/5% CO
2
 and photographed. Thereafter CFUs were counted using TotalLab (Nonlinear 
Dynamics Ltd. Newcastle, UK). The elimination capacity (i.e. combined phagocytosis and 
killing) of neutrophils was expressed as the percentage eliminated bacteria in samples 
incubated with neutrophils relative to the bacterial count in samples without neutrophils 
(i.e. with complement and IgG).
Statistical analysis
Wilcoxon’s signed rank test (two tailed) was used to evaluate treatment effects. A P-value 
≤ 0.05 was considered significant. Values are expressed as means ± SD unless stated 
otherwise. All statistical analyses were performed using SPSS (version 12.0; SPSS, Inc., 
Chicago, IL, USA). 
ResUlTs
The elimination capacity of isolated neutrophils from healthy volunteers depended 
on the used IgG dilution; when using IgG dilutions lower than 1:80, all bacteria were 
eliminated whereas the elimination capacity decreased with increasing IgG dilutions, 
reaching a plateau of ‘basal elimination capacity’ at IgG dilutions higher than 1:40960 
(Figure 5.1). Pre-incubation of isolated neutrophils in different parenteral lipid emulsions 
in a triglyceride concentration of 5 mmol/L which is considered to be physiological, i.e. 
reached during infusion of TPN in clinical practice, impaired the elimination capacity 
of neutrophils, with LCT/MCT being the most potent (Figure 5.1). The positive control, 
U-73122, showed a clear inhibiting effect on bacterial elimination, whereas the inactive 
analog U73343 did not show any effect (Figure 5.1). To exclude a direct effect of the lipids 
on bacterial growth, controls where opsonized bacteria were incubated with lipids in the 
absence of neutrophils were included. In this setting, no direct lipid effect whatsoever on 
bacterial survival was observed (data not shown). 
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Figure 5.1: Relative elimination of Streptococcus pneumoniae strain OREP-4 by neutrophils 
after 1 hour of incubation with (A) different parenteral lipid emulsions (5 mmol/L) or medium or 
(B) U-73122; phospholipase C inhibitor (positive control) or U73343 (inactive analog of U-73122, 
negative control). Data are expressed as percentage elimination relative to bacterial CFU count 
in samples without neutrophils and presented as mean ± SEM (n=6). 
The basal elimination capacity, i.e. the elimination capacity at very high IgG dilutions 
(dilution of 1:81920), of neutrophils that were not exposed to lipids was 75 ± 3% (mean ± 
SD). This basal capacity decreased significantly after exposure to LCT-MUFA, VLCT, LCT, SL 
and LCT/MCT, i.e. 70 ± 6% (p = 0.045), 67 ± 2% (p = 0.028), 66 ± 10% (p = 0.046), 63 ± 9 (p = 
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0.028) and 47 ± 15% (p = 0.028), respectively. The neutrophil inhibiting effect of the most 
potent emulsion, i.e. LCT/MCT, was lipid-dose dependent within a concentration range of 
1-10 mmol/L (Figure 5.2). 
Figure 5.2: Relative elimination of Streptococcus pneumoniae strain OREP-4 by neutrophils 
after 1 hour of incubation with LCT/MCT at various lipid concentrations. Data are presented as 
means of two different experiments performed in duplicate.
DIsCUssIoN
The present investigation demonstrates that parenteral lipid emulsions, in a clinically 
relevant triglyceride concentration of 5 mmol/L, negatively affect the capacity of human 
neutrophils to eliminate Streptococcus pneumoniae, and that this effect depends on 
the triglyceride structure of the lipids that are present in the emulsion. These findings 
corroborate observations from a previous clinical study where lipid-containing PN 
increased the risk for pneumonia in surgical patients [1]. We observed by far the 
strongest inhibition of neutrophil microbial elimination capacity by emulsions containing 
MCTs, i.e. LCT/MCT and to a lesser extent SL. An explanation for this observation may 
be provided by the chemical structure of these emulsions. Whereas LCT/MCT contain 
mixed oils from soybean and coconut that are rich in long-chain and medium-chain 
triglycerides, respectively, structured lipids contain medium- and long- chain fatty acids 
(MCFAs and LCFAs) that have been randomly attached to the glycerol backbone of the 
triglyceride following hydrolysis of the fatty acids from the triglycerides in the oils [17]. 
Lipid emulsions have been designed to resemble natural chylomicrons, with a triglyceride 
core enveloped by an emulsifier that is most frequently derived from egg yolk. A closer 
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look at the architecture of the lipid droplets shows that the physicochemical properties 
of MCT-containing emulsions result in the preferential position of MCT on the outer lipid 
droplet surface, whereas in structured lipids the MCFAs and LCFAs are evenly distributed 
over the lipid droplets [17]. In accordance with our previous investigations, the neutrophil 
modulating effect of LCT/MCT was lipid-dose dependent within a concentration range of 
1-10 mmol/L. Our data suggests that further inhibition can be expected with higher lipid 
concentrations. However, as serum triglyceride concentrations in TPN patients hardly 
ever exceed 10 mmol/L, higher concentrations were not investigated.
The inhibitory effect on neutrophil basal microbial elimination capacity of LCT incubation 
differs from our previous observations where LCT displayed no clear immune modulating 
effects in vitro [18, 20, 24, 25] , but again corroborates the findings of the clinical Veterans 
Affairs Study. In the latter study, the impairment of immune function was suspected to be 
caused by the lipid component, which was an LCT-based formulation based on the notion 
that these are the only lipid emulsions registered for clinical use in the United States. 
To our knowledge, this study is the first to describe the effects of emulsions containing 
VLCT or LCT-MUFA on bacterial phagocytosis and killing. These more recently developed 
emulsions also had a moderate, but significant, inhibitory effect on bacterial elimination. 
Our results are in accordance with prior investigations which evaluated pathogen killing 
by lipid-exposed neutrophils. We previously assessed phagocytosis and killing of Candida 
albicans by neutrophils after pre-incubation with different lipid emulsions and could show 
that emulsions containing MCTs, such as pure MCT or LCT/MCT exhibit similar effects 
in that they reduce the Candida albicans killing capacity of isolated neutrophils [18]. In 
that study, it was shown that the elimination process of Candida albicans was decreased 
because of a sole effect on killing; yeast cell phagocytosis appeared completely unaffected. 
A limitation of this study is that phagocytosis and killing were not evaluated separately. Any 
impaired bacterial elimination might, therefore, partly be due to decreased phagocytosis. 
This is in accordance with the study of Bellinati et al. who showed that MCTs inhibit both 
the phagocytosis and killing capacity of Staphylococcus aureus by neutrophils while LCTs 
had no effect [5]. 
MCTs, in contrast to LCTs, have earlier been shown to induce cell activation, i.e. the 
production of reactive oxygen species (ROS) and degranulation, and to modulate 
intracellular calcium signalling and increase the expression and function of adhesion 
markers on neutrophils and monocytes and inhibit cellular migration [20, 24-26]. The 
exact mechanisms behind these MCT effects have so far not been elucidated. We 
previously assessed the role of G-protein coupled receptors (GPCR) in MCT-induced 
immune modulation. The pertussis toxin sensitive GPR84, which has been shown to 
have medium chain fatty acids as ligands [27], however appeared not to play a role in 
the observed MCT-effects [28]. The possible role of pertussis toxin insensitive GPCR or 
downstream intracellular factors, have to be further assessed. By inducing cell activation, 
pre-incubation with MCTs might lead to exhaustion of the neutrophil cellular metabolism 
due to lipid induced continuous, and therefore probably inadequate, cell activation. 
Consequently, cellular exhaustion might result in decreased pathogen elimination 
capacity. Moreover, PLC activation is known to be responsible for various biochemical 
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responses that contribute to the physiological defense against bacterial infection and 
cell disruption [21]. Since the lipids show a comparable, although less intense, effect 
on pneumococcal elimination as the PLC-inhibitor U-73122, inhibition of PLC might be 
involved in the observed lipid effects.
 Studies concerning the effect of LCTs on neutrophil function, including phagocytosis, 
are numerous but results are equivocal and consist of stimulatory, inhibitory as well as 
neutral effects [7, 29-33]. Studies on the use of LCT-MUFA and VLCT are more sparse. LCT-
MUFA has so far mostly been shown to be immune neutral [12, 13, 34-36]. VLCTs have 
shown promising results as their use reduces the length of stay in or readmissions to an 
intensive medical ward, the length of total hospital stay, mortality rates, the need for 
mechanical ventilation, and the postoperative normalization rate of liver and pancreatic 
function [37-41]. 
In summary, our study demonstrates that in vitro exposure of neutrophils to parenteral 
triglycerides results in increased microbial survival. This finding might explain the 
previously observed increased risk for the development of pneumonia in patients on 
TPN. Since previous studies have shown conflicting results regarding immune modulatory 
effects of parenteral lipids due to different experimental settings, e.g. in vitro versus in- or 
ex vivo [10, 42], future in vivo studies are needed to clarify our observations and to assess 
the clinical impact of these effects in patients on TPN. 
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Lipid-induced immune modulation might contribute to the increased infection 
rate that is observed in patients using parenteral nutrition. We previously showed 
that emulsions containing medium-chain triglycerides (LCT/MCTs or pure MCTs), 
but not pure long-chain triglycerides (LCTs), impair neutrophil functions, modulate 
cell-signaling and induce neutrophil activation in vitro. It has recently been shown 
that medium-chain fatty acids are ligands for GPR84, a pertussis toxin(PT)-sensitive 
G-protein-coupled receptor (GPCR). This finding urged us to investigate whether 
MCT-induced neutrophil activation is mediated by PT-sensitive GPCRs. Neutrophils 
isolated from blood of healthy volunteers were pre-incubated with PT (0.5-1 µg/mL, 
1.5 h) and analyzed for the effect of this pre-incubation on LCT/MCT (2.5 mmol/L)-
dependent modulation of serum-treated zymosan (STZ)-induced intracellular Ca2+ 
mobilization and on LCT/MCT (5 mmol/L)-induced expression of cell surface adhesion 
(CD11b) and degranulation (CD66b) markers and oxygen radical (ROS) production. PT 
did not inhibit the effects of LCT/MCT on the STZ-induced increase in cytosolic free 
Ca2+ concentration. LCT/MCT increased ROS production to 146% of unstimulated 
cells. However, pre-incubation with PT did not inhibit the LCT/MCT-induced ROS 
production. Furthermore, the LCT/MCT-induced increase in CD11b and CD66b 
expression (196% and 235% of unstimulated cells, respectively) was not inhibited by 
pre-incubation with PT. In conclusion, LCT/MCT-induced neutrophil activation does 
not involve the action of a PT-sensitive G-protein-coupled receptor.
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A major problem in patients on Total Parenteral Nutrition (TPN) remains the occurrence of infectious complications. Immune modulating properties of nutritional components, mainly lipids, may play a role herein [1]. 
In accordance with others [2, 3], we previously reported that in vitro (pre-)incubation 
with parenteral lipid emulsions containing medium-chain triglycerides, such as mixed 
long- and medium-chain triglycerides (LCT/MCTs) or pure MCT emulsions, in contrast to 
pure LCT emulsions, induces neutrophil activation and neutrophil function impairment 
[4]. For example, we could show that MCTs, in this experimental setting, induce the 
production of reactive oxygen species (ROS) [5], sensitize neutrophils for opsonized yeast 
particles (serum-treated zymosan [STZ])-induced intracellular calcium signaling [6] and 
induce an increment in the expression of relevant adhesion and degranulation markers 
(CD11b, CD66b, CD63 and CD62L) on neutrophils and monocytes [7]. Furthermore, we 
demonstrated that MCTs inhibit the migration of neutrophils [8] and decrease their 
capacity to kill Candida albicans [9]. The latter might be explained by exhaustion of 
the neutrophil cellular metabolism due to LCT/MCT-induced continuous, and therefore 
probably inadequate, cell activation.
The exact mechanism by which MCTs exert these effects is still not elucidated. However, 
several G-protein-coupled receptors (GPCRs) have recently been identified as receptors 
for free fatty acids on leukocytes and might, therefore, play a role in the lipid-induced 
immune modulation. For example, the GPR40, which is expressed in monocytes, mediates 
the effects of medium-chain free fatty acids (MCFFAs) and/or long-chain free fatty acids 
(LCFFAs) [10, 11], whereas the GPR41 and GPR43, which are expressed in neutrophils, 
have short-chain free fatty acids (SCFFAs) as their ligands [10,12,13]. In a recent study, the 
GPR84 was de-orphanized and shown to have MCFFAs as ligands and to be abundantly 
expressed in monocytes and neutrophils [14]. This GPCR might, therefore, be involved in 
MCT-induced neutrophil activation. 
The G-proteins involved in GPCR-signaling are heterotrimeric proteins that bind guanine-
nucleotides. They constitute a large and diverse family and are involved in many 
physiological processes. G-proteins are classified into the G
i/o
, G
s
, G
q
 and G
12
 families, 
each of which interacts with its own effector molecules to modulate the production of 
intracellular second messengers. Effector molecules include adenylyl cyclase, cGMP-
phosphodiesterase, phospholipase C-β (PLC-β) and ion-channels [15]. Members of the 
G
i
 family are pertussis toxin (PT)-sensitive; ADP-ribosylation of their α
i
-subunit by this 
toxin prevents coupling of the ligand-bound receptor to the Gi-protein and consequent 
exchange of GDP for GTP on this α
i
-subunit. Because the GTP-bound α
i
-subunit inhibits 
adenylyl cyclase, its PT-induced ADP ribosylation prevents the receptor-mediated 
inactivation of this enzyme. In addition, PT can inhibit G
i
-protein-induced PLC-β activation 
since Gβγ-dimers, that are released from the heterotrimeric G
i
-proteins, have been 
shown to activate PLC-β2 in granulocytes [16]. Members of the G
s
, G
q
 and G
12
 family are 
PT-resistant but the α
s
-subunit is ADP-ribosylated by Cholera toxin (CT). PT and CT have 
been shown to be useful in identifying the involvement of heterotrimeric G-proteins in 
signaling systems. MCFFA-induced activation of the GPR84 has been shown to be PT-
sensitive [14]. 
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The present study was conducted to evaluate the involvement of a PT-sensitive GPCR, 
such as the GPR84, in the immune-modulating effects of MCT-based parenteral lipid 
emulsions. 
sUBJeCTs aND MaTeRIals 
s U B J eC T s
Appropriate informed consent from all participating volunteers was obtained and the 
human experimentation guidelines of the author’s institution were followed in the conduct 
of this study. After overnight fasting, blood samples drawn from 7 healthy volunteers, 
none of whom was on medication, were collected in 10 mL Monoject tubes with 170 
IU of lithium heparin (Beliver Industrial Estate, Plymouth PL6 7BP, UK) and processed as 
described. 
M aT e R I a l s
Reagents were from Sigma Chemicals (St Louis, MO, USA), unless stated otherwise. Hank’s 
balanced salt solution (HBSS) was purchased from Life Technologies (Paisley, Scotland, UK). 
Percoll (ρ 1.130 g/mL at 20°C) was obtained from GE Healthcare Biosciences AB (Uppsala, 
Sweden) and phosphate buffered saline (PBS) was produced by B. Braun Melsungen AG, 
Melsungen Germany. Isotonic lysis solution (pH 7.4) contained 155 mmol/L NH
4
CL and 10 
mmol/L KHCO
3
. Neutrophil medium consisted of HBSS supplemented with 0.5% (wt/vol) 
bovine serum albumin (BSA). N-formyl-methionyl-leucyl-phenylalanine (fMLP) was stored 
as a 0.04 mmol/L stock in DMSO at –20°C and Luminol as a 10 mmol/L stock in DMSO at 
room temperature (RT). PT was stored as a 100 µg/mL stock in aquadest at 4°C. Serum-
treated zymosan (STZ) (10 mg/mL stock) was prepared as described previously [17]. Fura-
2/AM was from Molecular Probes Inc. (Eugene, OR, USA). LCT/MCT emulsion (Lipofundin, 
20% w/v) was from B. Braun Melsungen AG (Melsungen, Germany). All antibodies used 
for the measurement of leukocyte membrane surface antigen expression were purchased 
from Beckman Coulter (Miami, FL, USA). 
M e T H o D s
Neutrophil isolation
Neutrophils were purified from blood anti-coagulated with lithium heparin. The blood, 
diluted 1:1 with PBS, was placed on Percoll (ρ 1.076 g/mL) and centrifuged (700 x g, 20 min, 
RT). The granulocyte-containing pellet was suspended in 50 mL ice-cold lysis solution and 
lysis of erythrocytes was performed on ice for 10-15 min. After centrifugation (400xg, 5 
min, RT), remaining erythrocytes were lysed on ice in fresh lysis solution for another 5 
min. The granulocytes were then washed twice, suspended to 8x106 cells/mL in neutrophil 
medium and kept at RT. This method of neutrophil isolation yields >97% pure and >99% 
viable cell samples as determined by May-Grünwald/Giemsa and trypan blue staining [5].
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PT (pre-) incubation
Neutrophils (8x106 cells/mL in neutrophil medium) were incubated with PT (0.5 or 1.0 µg/
mL) for 1.5 h by gentle head-over-head turning at 37°C. Then, the cells were washed (5 
min, 400 x g, RT) and resuspended in neutrophil medium to the desired final concentration. 
The efficacy of PT treatment was tested by determining its effect on the fMLP (0.3 nmol/
L)-induced increase in cytosolic free Ca2+ concentration, shown to be abolished by this 
toxin in isolated neutrophils [18,19].
STZ-induced cytosolic calcium signaling 
After PT incubation and washing, neutrophils (4x106 cells/mL) were loaded with 5 μmol/L 
Fura-2/AM for 15 min at 37°C. Excess Fura-2/AM was removed by washing the neutrophils 
first with neutrophil medium and second with HBSS. Subsequently, the neutrophils were 
transferred to a cuvette placed in a Shimadzu RF-5301 spectrofluorophotometer equipped 
with a magnetic stirrer and a thermostated cuvette holder (37°C). In the cuvette, cells 
were pre-incubated with LCT/MCT, in a clinically relevant concentration of 2.5 mmol/L, for 
3 minutes and thereafter stimulated with STZ. The change in fura-2 fluorescence emission 
ratio at 490 nm was monitored as a measure of the average of the individual changes in 
cytosolic free Ca2+ concentration of all cells in the suspension after excitation at 340 and 
380 nm [6,20]. All measurements were performed in duplicate.
Oxygen radical production
Oxygen radical production was evaluated by means of luminol-enhanced 
chemiluminescence, as measured in an automated LB96V Microlumat Plus Luminometer 
(EG & G Berthold, Bad Wildberg, Germany) [21]. Briefly, after PT pre-incubation, 200 
µL of neutrophil suspension (1x106 cells/mL) was added to a 96-well microplate; either 
with no stimulus or with LCT/MCT emulsion, in a clinically relevant concentration of 5 
mmol/L, and the reaction was started by the addition of 20 µL of luminol (stock 1:10 
diluted in neutrophil medium). Each measurement was performed in fivefold and 
chemiluminescence was monitored every 145 sec at 37°C for 1h. Luminescence was 
expressed as relative light units per second (RLU/sec). The area under the curve (AUC), 
representing the overall oxygen radical production during 1 h, was calculated. Data were 
analyzed with Winglow software (EG & G Berthold, Bad Wildberg, Germany). 
Leukocyte membrane surface antigen expression 
After PT pre-incubation and washing, neutrophils (2x106 cells/mL) were incubated 
with LCT/MCT (5 mmol/L final concentration) or neutrophil medium for 30 minutes by 
gentle head-over-head turning at 37°C . The neutrophil membrane surface expression of 
activation molecules was evaluated by immune-fluorescent staining and subsequent flow-
cytometric analysis. Characterization was performed using antibodies directed against an 
adhesion molecule of the β2 integrin family (CD11b), as well as a marker for degranulation 
of specific granulae (CD66b). Briefly, after lipid incubation, 100 μL of cell suspension was 
incubated for 15 min at RT with 5 μL of each of the following direct mouse anti-human 
IgG antibodies; CD66b (Clone 80H3) labeled with fluorescein isothiocyanate (FITC), CD11b 
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(Clone BEAR1) labeled with phycoerytrin (PE) and CD45 (Clone J33), a leukocyte marker, 
labeled with PE-Texas red (ECD). Next, neutrophils were washed in 2 mL PBS (500xg, 5 
min, RT) and finally fixed in 0.5 mL 1% paraformaldehyde and stored at 4°C until analysis, 
which was performed within 24 h. Staining of cells was determined in multi-color analysis 
by using a Beckman Coulter Epics XL flow-cytometer (Beckman Coulter, Hileah, FL). All 
measurements were performed in duplicate and on a minimum of 10,000 cells.
Statistical analysis 
Wilcoxon’s signed rank test (two tailed) was used to evaluate treatment effects. A P-value 
≤0.05 was considered significant. Values are expressed as means ± SEM unless stated 
otherwise. All statistical analyses were performed using SPSS (version 12.0; SPSS, Inc., 
Chicago, IL, USA).
ResUlTs
I N T R aC e l l U l a R C a l C I U M s I g N a l I N g 
Addition of the GPCR agonist fMLP transiently increases the fura-2 fluorescence 
emission ratio in a suspension of isolated neutrophils (Figure 6.1A, solid line). This 
change in fluorescence emission ratio represents the average of the individual changes 
in cytosolic free Ca2+ concentration of all cells in the suspension. The dotted line shows 
that pre-incubation with PT virtually abolishes the fMLP-induced increase in cytosolic Ca2+ 
concentration. STZ typically evokes a biphasic increase of the fura-2 ratio signal, consisting 
of an initial slow phase followed by a second fast phase and finally resulting in a plateau 
phase that is maintained for a prolonged period of time [6,17] (Figure 6.1B, solid line). Pre-
incubation with PT does not influence the first phase, slows down the second phase, and 
has no effect on the final plateau phase (Figure 6.1B, dotted line). Our previous studies 
showed that in vitro pretreatment of neutrophils with LCT/MCT or pure MCT, in contrast 
to pure LCT but similar to Phorbol 12-Myristate 13-Acetate (PMA), a potent activator of 
protein kinase C (PKC), accelerates the first phase and abolishes the second phase of the 
STZ-induced increase of the fura-2 ratio signal [6,17] (Figure 6.1C, solid line). Here we 
show, however, that none of these effects of LCT/MCT are abolished by PT pre-incubation 
(dotted line). 
ox Yg e N R a D I C a l  P R o D U C T I o N 
Figure 6.2 presents the results of the LCT/MCT-induced oxygen radical production 
measurement in one representative subject. Figure 6.2A shows that pre-incubation with 
PT by itself does not induce an increase in the luminol-enhanced chemiluminescence 
signal in a suspension of isolated neutrophils. Figure 6.2B shows that addition of LCT/
MCT (5 mmol/L) transiently increases the luminol-enhanced chemiluminescence signal. 
This change in luminescence signal reflects the average of the individual changes 
in overall oxygen radical production of all cells in suspension. Calculation of the total 
chemiluminescence produced during 1 h after LCT/MCT stimulation (area under the curve 
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in Figure 6.2) reveals that LCT/MCT increases the total oxygen radical production to 146% 
of unstimulated levels and that pre-incubation with PT has no effect on this parameter 
(Figure 6.3).
Figure 6.1: Spectrofluoro-
metric measurement of the 
stimulus induced increase in 
average cytosolic free Ca2+ 
concentration, reflected by 
the Fura-2 fluorescence 
emission ratio after 
excitation at 340 and 380 nm 
(ratio 340/380 nm), in a 
suspension of isolated 
neutrophils loaded with the 
cytosolic Ca2+ indicator Fura-
2. (A) fMLP- and (B) STZ-
induced cytosolic Ca2+ 
concentration increase with/
without Pertussis Toxin (PT) 
pre-incubation (0.5-1 µg/
mL). (C) Effect of PT pre-
incubation on the LCT/MCT-
dependent modulation of 
the STZ-induced cytosolic 
Ca2+ concentration increase. 
Data are representative for 7 
volunteers (measurements 
performed in duplicate). 
fMLP; N-formyl-methionyl-
leucyl-phenylalanine (0.3 
nmol/L), STZ; serum-treated 
zymosan (0.2 mg/mL) and 
LCT/MCT; physical mixture 
of long- and medium-chain 
triglycerides (2.5 mmol/L) 
were added where indicated. 
e x P R e s s I o N o F  M e M B R a N e s U R FaC e a N T I g e N s 
Exposure to LCT/MCT increases the expression of CD11b and CD66b on isolated 
neutrophils to 196% and 235% of unstimulated levels, respectively (Figure 6.4), which is 
consistent with our previous findings [7]. Again, pre-incubation with PT has no effect on 
the LCT/MCT-induced increase in CD11b and/or CD66b expression. 
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Figure 6.2: Luminol-enhan-
ced chemiluminescence in 
isolated neutrophils pre-
incubated with 0.5-1 µg/mL 
Pertussis Toxin (PT), without 
(A) and with (B) subsequent 
LCT/MCT (5 mmol/L) stimu-
lation, expressed in relative 
light units/s (RLU/s) and 
measured during a post-
stimulatory period of 1 h. 
LCT/MCT was added at time 
= 0 minutes. The curves are 
representative for 7 subjects 
(measurements performed 
in fivefold). 
Figure 6.3: Overall luminescence in 1 h (area under the curve in Figure 6.2), representing total 
oxygen radical production. Results are depicted as relative chemiluminescence in comparison 
with non-PT pre-incubated, unstimulated cells (first black bar) and presented as mean ± SEM 
(n=7). Absolute overall chemiluminescence in unstimulated cells was 172113 ± 18421 RLU/h. 
The LCT/MCT (5 mmol/L)-induced increase in total oxygen radical production (p = 0.02) was not 
inhibited by PT pre-incubation (Wilcoxon Signed Rank test). 
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Figure 6.4: Expression of 
membrane surface antigens, 
CD11b (A) and CD66b (B), on 
isolated neutrophils after 
pre-incubation with/without 
0.5-1 µg/mL Pertussis Toxin 
(PT) and subsequent 
incubation with/without 5 
mmol/L LCT/MCT (physical 
mixture of long- and 
medium-chain triglycerides). 
Results are depicted as 
relative fluorescence in 
comparison with non-PT 
pre-incubated, unstimulated 
cells (first black bar) and 
presented as mean ± SEM 
(n=7). Absolute fluorescence 
in unstimulated cells was 
1787 ± 152 and 203 ± 23 for 
CD11b and CD66b, 
respectively. The LCT/MCT-
induced increase in CD11b 
and CD66b expression (both 
p = 0.01) were not inhibited 
by PT pre-incubation 
(Wilcoxon Signed Rank test).
DIsCUssIoN
The main finding of the present study is that previously reported effects of parenteral 
medium-chain triglycerides on in vitro neutrophil activity appear not to be mediated by a 
PT-sensitive G-protein-coupled receptor, such as the GPR84. 
Immune modulating effects of parenteral lipids might contribute to the increased infection 
rate that is observed in patients on TPN [1,22]. In our previous in vitro studies, we have 
shown that MCT-based lipid emulsions activate neutrophils and modulate their functions. 
The effects of these emulsions were observed in all investigated aspects of neutrophil 
activation (intracellular calcium signaling, oxygen radical production, the expression of 
cell adhesion and degranulation markers) and function (migration and candida killing) [5-
9]. The fact that other emulsions based on LCTs, olive oil or fish oil were without activating 
effect indicates that these effects are truly MCT-specific and not due to lipid per se or 
to other emulsion components. The mechanism behind these MCT-specific neutrophil 
activating effects is, so far, unclear. In a recent study, it was shown that the previously 
orphan PT-sensitive GPCR, GPR84, has medium-chain fatty acids (MCFFAs) as its ligand. 
The most potent MCFFAs appeared to be capric acid (C10:0), undecanoic acid (C11:0) 
and lauric acid (C12:0). Of these, mainly capric acid is abundantly present in the LCT/
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MCT emulsion used in our studies (Table 6.1). The present study was conducted to assess 
whether the MCTs exert their effects via a PT-sensitive GPCR, such as the GPR84. 
Table 6.1: Composition and characteristics of the lCT/MCT emulsion (lipofun-
din®) according to the manufacturer.
lCT/MCT lipofundin®
Triglyceride source Coconut oil/soy bean oil (1:1)
Fatty acid (% wt/wt of total)
     Caproic acid (C6:0) 0.5
     Caprylic acid (C8:0) 28.5
     Capric acid (C10:0) 20
     Lauric acid (C12:0) 1
     Palmitic acid (C16:0) 6.5
     Stearic acid (C18:0) 2
     Oleic acid (C18:1) 11
     Linoleic acid (C18:2) 26
     α-Linolenic acid (C18:3) 4
     Arachidonic acid (C20:4) 0.5
Mean molecular triglyceride weight 634
Fractionated egg phospholipids (g/l) 12
glycerol (g/l) 25
In concordance with our previous studies, pre-incubation with LCT/MCT primed the 
neutrophils for STZ-induced intracellular Ca2+ mobilization [6]. Here we show, however, 
that PT has no effect on the STZ-induced increase in cytosolic Ca2+ concentration in LCT/
MCT-treated neutrophils, thus excluding the involvement of a PT-sensitive GPCR in the 
effect of LCT/MCT on this response. On the other hand, in neutrophils not treated with 
LCT/MCT, PT significantly slows down the second fast phase of the STZ-induced increase in 
cytosolic Ca2+ concentration without affecting the height of the subsequent plateau phase. 
This may suggest the involvement of a fast acting PT-sensitive receptor and a slow acting 
PT-insensitive receptor. Previous studies provided evidence that the second fast phase 
of the STZ-induced cytosolic Ca2+ rise, which is abolished by LCT/MCT, is brought about 
by stimulation with endogenously produced platelet activating factor (PAF) [20,23]. PAF 
is a well known leukocyte activator which exerts its effects through G
i
- and G
q
-coupled 
GPCRs [41]. Together these results suggest that the second fast phase of the STZ-induced 
increase in cytosolic Ca2+ concentration occurs primarily through fast acting Gi-coupled 
(PT-sensitive) PAF receptors. Inhibition of these receptors by PT then unveils the action 
of slower acting Gq-coupled (PT-insensitive) PAF receptors. Furthermore, PT did not 
inhibit the LCT/MCT-induced increase in oxygen radical production and/or adhesion and 
degranulation markers expression, thus excluding the involvement of a PT-sensitive GPCR 
in these LCT/MCT effects as well. 
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It can be argued that higher PT concentrations would have had different effects. However, 
several studies have demonstrated evident inhibition of neutrophil GPCR signaling with 
PT concentrations of 0.1-0.5 µg/mL and incubation times of 10 min to 2 hrs [18, 25-29]. 
Nevertheless, the use of concentrations as high as 450 μg/mL has been described [30]. In 
our opinion, the use of such high PT concentrations has no physiologic relevance and can 
lead to nonspecific effects. In addition, the fMLP-induced increase in cytosolic calcium 
was inhibited by the used PT dose. Therefore, it is unlikely that the inability of PT to inhibit 
the effects of LCT/MCT was due to insufficient PT dosing.
The study of Wang et  al. showed that MCFFAs act as ligands for PT-sensitive GPCRs [14]. 
Our results indicate that a triglyceride, i.e. three MCFFAs bound to a glycerol molecule, 
activates the neutrophil differently from a MCFFA. Our previous studies showed that 
MCTs mimic the effects of activators of protein kinase C (PKC), suggesting a role of 
one or more isoforms of this kinase in the mechanism of action of the MCTs [6]. The 
PKCs are a complex family consisting of multiple isoforms with diverse, isoform-specific, 
distributions, substrates and functions. They can be activated in several ways, including 
PLC activation by PT-sensitive and PT-insensitive GPCRs as well as by means of cross-talk 
with other members of the PKC family, by nitration, by caspase-mediated proteolytic 
cleavage or by reactive oxygen species [16,31-34]. Since the present study shows that 
MCT-induced neutrophil activation appears not to act directly on PT-sensitive GPCR 
activation, it can be suggested that MCTs act by interfering with PT-insensitive receptors 
or with downstream activation mechanisms (second messengers) of PKC. Clearly, further 
investigation concerning these possibilities is required.
In conclusion, the results of the current study argue against a role of PT-sensitive GPCRs in 
the mechanism of action of parenteral medium-chain triglycerides on human neutrophils.
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Immune Function and leukocyte 
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a B s T R aC T 
It remains unclear whether immune modulation by lipids contributes to the high risk 
for infectious complications that is associated with the use of parenteral nutrition. 
Although mixed long- and medium-chain triacylglycerol-containing emulsions (LCT/
MCT), but not pure LCT emulsions, activate neutrophils and impair crucial leukocyte 
functions in vitro, in vivo studies have failed to corroborate these findings. The present 
investigation was conducted to evaluate the effects of LCT and LCT/MCT on immune 
function in healthy humans and to assess whether the lack of in vivo effects results 
from sampling errors due to extravascular sequestration of activated neutrophils. 
Saline, LCT/MCT, and LCT emulsions were administered intravenously for 4.5 h 
to 12 healthy volunteers in a randomized crossover design. Plasma triacylglycerol 
concentrations were clamped at a clinically relevant concentration of 3-5 mmol/L. 
Leukocyte population counts and neutrophil activation were assessed before and 
after infusion. Leukocyte sequestration was evaluated by monitoring the distribution 
of Technetium-99m-labeled autologous leukocytes during infusions. Whereas 
LCT exerted no greater effects than did saline, LCT/MCT significantly decreased 
lymphocyte counts. However, no evidence for neutrophil activation was found 
with either lipid. More over, the clearance of radiolabeled leukocytes from the liver, 
spleen and lungs was not altered by any lipid, which suggested that lipid emulsions 
do not induce leukocyte sequestration. In conclusion, short-term infusion of LCT/
MCT (but not LCT) to healthy humans modulates leukocyte population counts, but, in 
clear contrast with the in vitro situation, does not induce neutrophil activation. These 
disparate findings cannot be explained by MCT-induced leukocyte sequestration.
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Total parenteral nutrition (TPN) is a life-saving strategy in patients with severe intestinal failure [1]. Its associated high rate of infectious complications, however, remains a major drawback. Although many of these 
problems result from the use of a venous access device, immune modulation by the 
lipids in TPN may also play a role [2-4]. 
The source for the most widely used parenteral lipid emulsion, Intralipid, is soybean oil, 
which mainly contains long-chain triacylglycerols (LCT) and which is especially rich in the 
polyunsaturated fatty acid linoleic acid, the parent of the n-6 family of polyunsaturated 
fatty acids [5]. Metabolism of linoleic acid yields arachidonic acid, which is converted into 
eicosanoids that have pro-inflammatory immunological properties. The high content of 
n-6 PUFAs in soybean oil has thus been considered a drawback, especially in patients with 
an already imbalanced inflammatory response. Awareness of this drawback sparked the 
development of new lipids, in which part of the n-6 polyunsaturated fatty acids has been 
replaced by coconut oil, which is rich in saturated medium-chain triacylglycerols (MCT)
[5]. The favorable metabolic profile of MCT, because of their rapid metabolic breakdown 
and insusceptibility to lipid peroxidation, together with the notion that essential fatty 
acids can only be supplied by giving LCT, led to the development of mixed LCT- and MCT-
containing emulsions (LCT/MCT) such as Lipofundin.
Numerous studies with in vitro, in vivo and ex vivo designs investigating the immunological 
characteristics of parenteral lipids [2-4;6-13] have yielded inconsistent outcomes, so that 
a clear picture of the immune modulating effects of these lipids is still lacking [5;14-16]. 
Other groups [9,17] and our group [18-23] previously showed that in the in vitro setting –ie, 
in isolated neutrophils- LCT/MCT and pure MCT, in clear contrast to pure LCT, impaired 
crucial neutrophil functions and induced signs of neutrophil activation. These effects 
cannot be attributed to functional changes induced by isolation procedures, because 
similar observations were made when leukocytes in whole blood were exposed to these 
lipids [24]. However, in vivo studies on the immune-modulating effects of LCT and LCT/
MCT emulsions are sparse. Waitzberg et al. [10,25] showed that LCT/MCT infusion, in 
contrast to in vitro exposition, did not affect human leukocyte functions, whereas LCT 
exposition did not have any effect in both settings. Given our in vitro data showing that LCT/
MCT increases the expression of CD11b [19], a cell surface adhesion molecule, a problem 
that might be encountered in vivo is capillary adhesion and extravascular migration of 
activated neutrophils. This phenomenon is called leukocyte sequestration, and it results 
in the disappearance of activated leukocytes from the circulating blood pool from which 
samples are taken [26;27]. An evaluation of lipid-induced neutrophil modulation in vivo 
may thus result in false negative findings due to blood-sampling error. 
The present study was conducted to investigate whether short-term infusion of LCT and 
LCT/MCT distinctly modulates leukocyte functions in vivo. To rule out underlying diseases 
that may influence immune function, the study was performed in healthy subjects. For 
the first time, to our knowledge, a possible effect on leukocyte sequestration is taken 
into account by in vivo monitoring the distribution of autologous Tc-99m-exametazime 
(Tc-99m-HMPAO)-labeled leukocytes during saline or lipid infusions. 
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Twelve healthy volunteers (6 women, 6 men; mean age 30 y [range 19-53 yrs]; mean body 
mass index [BMI; in kg/m2]: 23; [range 19-30]), none of whom was on medication, were 
included in the study. Written informed consent was obtained from all participants. The 
Ethical Review Board of the Radboud University Nijmegen Medical Center approved the 
study. 
M aT e R I a l s  a N D M e T H o D s
Lipid administration
After an overnight fast, lipid-free control (saline 0.9%) or lipid emulsions containing LCT 
(Intralipid 20%, Fresenius Kabi, Bad Homburg, Germany) or LCT/MCT (Lipofundin 20%, B. 
Braun Melsungen AG, Melsungen, Germany) were administered intravenously for 4.5 h 
in a randomized crossover design (blinded for subjects) with a washout period of 2 wk 
(Figure 7.1). To stabilize triacylglycerol concentrations at a clinically relevant level over 
the infusion period, emulsions were infused according to the plasma triacylglycerol 
clamp technique as described by Iriyama et al. [28]. Because lipid elimination rates are 
considered to be higher in whites than in Japanese persons, we used infusion rates that, 
in the Japanese setting, yielded a triacylglycerol clamp of 4-5 mmol/L [29] in order to aim 
at slightly lower concentrations in the white subjects in the present study. To resemble 
the clinical situation, in which infusion rates are based on caloric needs, we kept equal 
weight-based infusion rates for LCT and LCT/MCT. To reach a stable plasma concentration 
of 3-5 mmol/L (priming), lipid emulsions were infused at a rate of 0.5 g/kg BW/h for the 
first 10 min and at 0.3 g/kg BW/h for the following 40 min. Subsequently, this plasma 
triacylglycerol concentration was clamped by infusion at 0.15 g/kg BW/h for another 220 
min. Blood samples were drawn prior to and after 3.5 h of infusion. 
Figure 7.1: Time frame of experimental set-up. Saline or lipid emulsions, containing long-chain 
triacyglycerols (LCT) or mixed long- and medium chain triacylglycerols (LCT/MCT), were 
administered intravenously for 4.5 h to 12 healthy volunteers (randomized crossover design 
with a 2 wk wash-out interval). Plasma triacylglycerol concentrations were clamped at a 
clinically relevant concentration (3-5 mmol/L) over the infusion period. Blood samples were 
drawn before and after 3.5 h of infusion. A, neutrophil isolation and activation assessment, B, 
determination of hematologic and chemical plasma variables, C, leukocyte isolation for labeling 
with Tc-99m-HMPAO, D, infusion of labeled leukocytes. Imaging of labeled leukocytes was 
performed during the last hour of saline or lipid infusions.
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Laboratory parameters
Blood cell counts (specimens collected in EDTA-coated tubes), including an automated 
leukocyte differentiation, renal function, sodium, potassium, liver enzymes, total bilirubin, 
LDH, C-reactive protein, and triacylglycerol concentrations (specimens collected in 
lithium-heparin tubes) were assessed on an automated analyzer (AdviaTM120, Siemens 
Medical Solutions, The Hague, the Netherlands). Parameters were assessed before and 
after the infusion.
Materials
Reagents were from Sigma Chemicals (St Louis, MO, USA), unless stated otherwise. Hank’s 
balanced salt solution (HBSS) was purchased from Life Technologies (Paisley, United 
Kingdom), Percoll (ρ 1.130 g/mL at 20°C) was obtained from GE Healthcare Biosciences 
AB (Uppsala, Sweden) and phosphate-buffered saline (PBS) was produced by B Braun 
Melsungen AG. Isotonic lysis solution (pH 7.4) contained 155 mmol NH
4
CL/L and 10 mmol 
KHCO
3
/L. Neutrophil medium consisted of HBSS supplemented with 0.5% (wt:vol) bovine 
serum albumin. Phorbol 12-myristate 13-acetate (PMA) was stored as a 0.1 mg/mL stock 
in dimethyl sulfoxide (DMSO) at –20°C and Luminol was stored as a 10 mmol/L stock in 
DMSO at room temperature (RT). Serum-treated zymosan (STZ) (10 mg/mL stock) was 
prepared by dissolving 250 mg zymosan in 30 mL PBS, homogenizing the mixture in a 
sonificator (for 1 h at 48 kHz) and centrifuging it (850xg for 5 min at RT). The pellet was 
suspended in 6 mL human serum, incubated for 45 min in a 37°C shaking water bath, 
washed 3 times, and resuspended in PBS to a final concentration of 10 mg/mL. A high-
affinity fluorescent intracellular calcium indicator (Fura-2/AM) was from Molecular Probes 
Inc (Eugene, OR). All antibodies used for the measurement of leukocyte membrane surface 
antigen expression were purchased from Beckman Coulter (Miami, FL). Blood samples 
were collected in 10 mL Monoject tubes with 170 I.U. of lithium heparin (Beliver Industrial 
Estate, Plymouth, United Kingdom).
Leukocyte isolation
Leukocytes were purified from blood anti-coagulated with lithium heparin. The blood, 
diluted 1:1 with PBS, was placed on Percoll (ρ 1.076 g/mL) and centrifuged (700xg for 
20 min at RT). The granulocyte-containing pellet was suspended in 50 mL ice-cold lysis 
solution and lysis of erythrocytes was performed on ice for 10-15 min. After centrifugation 
(400xg for 5 min at RT), remaining erythrocytes were lysed on ice in fresh lysis solution for 
another 5 min. The granulocytes were then washed twice and suspended in medium to 
the desired final concentration and kept at room temperature. This method of neutrophil 
isolation yields >97% pure and >99% viable cell samples as determined by May-Grünwald/
Giemsa and trypan blue staining [18].
Oxygen radical production by isolated neutrophils and whole blood cells
Oxygen radical production was evaluated by means of luminol-enhanced 
chemiluminescence, as measured in an automated luminometer (LB96V Microlumat Plus; 
EG & G Berthold, Bad Wildberg, Germany), as described previously [30]. Briefly, in a 96-
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well microplate 200 µL diluted whole blood (1:100 in HBSS) or isolated neutrophil cell 
suspension (1 x 106 cells/mL) was added, either with no stimulus or with 20 µL of PMA 
(receptor independent stimulus, stock 1:20 diluted in HBSS) or STZ (receptor-dependent 
stimulus). To each well, 20 µL luminol (stock 1:10 diluted in medium) was added. Each 
measurement was performed in fivefold. Chemiluminescence was monitored every 145 
s for 1 h at 37°C. In this period, stimulus induced oxygen radical production normally 
returns to baseline. Luminescence was expressed as relative light units per second. The 
area under the curve, representing the overall oxygen radical production during 1 h, and 
luminescence peak time were calculated. Data were analyzed with WINGLOW software 
(version 1:10; EG & G Berthold, Bad Wildberg, Germany). After subtraction of background 
signal, the signal intensity in whole blood samples was correlated to the neutrophil 
population count.
Leukocyte membrane surface antigen expression on whole blood cells
The expression of activation molecules on the membrane surface of whole blood leukocytes 
was evaluated by immune-fluorescent staining and subsequent flow-cytometric analysis. 
Characterization was performed using antibodies directed against an adhesion molecule 
of the β2 integrin family, CD11b; against markers for degranulation of azurophilic (CD63) 
or specific granulae (CD66b); and against an activation marker, CD62L, that is normally 
downregulated during cell activation due to receptor shedding. Immunefluorescence 
staining was performed according to the “lyse and wash” method. Briefly, 100 μL whole 
blood was incubated (15 min at RT) with 5 μL of each directly fluorochrome-labeled 
antibody. The following direct mouse anti-human IgG antibodies were used: CD66b 
(Clone 80H3) and CD62L (Clone DREG56) labeled with fluorescein isothiocyanate, CD11b 
(Clone BEAR1) and CD63 (Clone CLB-gran12) labeled with phycoerytrin (PE); CD45 (Clone 
J33) a leukocyte marker, labeled with PE-Texas red (ECD) and CD14 (Clone RMO52); and 
a monocyte marker, labeled with PE-cychrome5 (PE-CY5). Next, erythrocytes were lysed 
(15 min in the dark at RT) using 155 mmol NH
4
Cl/L (pH 7.4). The cell suspension was 
centrifuged at 500xg for 5 min at RT. Next, neutrophils were washed in PBS and then fixed 
in 1% paraformaldehyde and stored at 4°C until analysis the next day. Staining of cells was 
determined in multicolor analysis by using a flow-cytometer (Epics XL; Beckman Coulter, 
Hialeah, FL). All measurements were performed on a minimum of 50 000 cells.
STZ-induced cytosolic calcium signaling in isolated neutrophils
Isolated neutrophils (4 x 106/mL) were loaded with 5 μmol Fura-2/AM/L for 15 min at 37 
°C. Excess Fura-2/AM was removed by washing the neutrophils first with medium (HBSS 
with 0.5% bovine serum albumin [wt/vol]) and second with HBSS. Subsequently, the 
neutrophils were transferred to a cuvette placed in a spectrofluorophotometer (RF-5301; 
Shimadzu, Tokyo, Japan) equipped with a magnetic stirrer and a thermostated cuvette 
holder (37°C). The fluorescence emission ratio at 490 nm was monitored as a measure 
of the average cytosolic free Ca2+ concentration after excitation at 340 and 380 nm [22].
proefschrift Michelle.indb   94 18-12-2011   21:45:55
95
P
aren
teral Lip
id
s an
d
 Im
m
u
n
e Fu
n
ctio
n
 in
 V
ivo
Tc-99m -HMPAO leukocyte scintigraphy 
• Cell isolation and labeling 
Before the start of saline or lipid emulsion infusion, a 50-mL venous blood sample was 
drawn into a 60-mL syringe containing 10 mL of a 0.33% solution of methyl cellulose and 
acid citrate dextrose. All cell isolation and labeling procedures were carried out at RT. 
After sedimentation for 2 h, the leukocyte-rich plasma was removed and centrifuged at 
49xg for 15 min. The cell pellet was washed twice in 5 mL saline with 1% (wt/vol) human 
serum albumin and resuspended in 2 mL of saline with 1% human serum albumin, after 
which 750 MBq of Tc-99m-HMPAO was added. After centrifugation (49xg for 10 min), 
the pellet containing the radiolabeled leukocytes was resuspended in 2 mL 5% glucose 
solution, and 3 mL of saline with 1% human serum albumin was added. A dose of 100 
MBq Tc-99m-labeled autologous leukocytes was administered as an intravenous bolus 
injection to the volunteer 3.5 h after the start of the saline or lipid infusion (Figure 7.1). 
• Image acquisition and processing
Immediately after injection of the Tc-99m-labeled autologous leukocytes, anterior 
and posterior series of 1-min dynamic images of the chest and upper abdomen scans 
were recorded for 1 h using a double head gamma camera equipped with low-energy 
collimators (ECAM; Siemens, Hofman Estates, IL). The infusion of saline or lipid emulsions 
was continued during this hour. A reference tube, containing a known aliquot of the 
injected dose, was placed in the midaxial line within the field of view. The observer was 
blinded for the treatment during analysis of the images. The images were analyzed by 
drawing regions of interest over the reference tube, the right lung (posterior and anterior), 
liver (posterior and anterior) and spleen (posterior only), because these organs are major 
organs of the reticuloendothelial system, and the most probable areas of leukocyte 
sequestration. From the counts in the regions of interest, the percentages of injected Tc-
99m-labeled leukocytes in lung, liver and spleen were calculated and time-activity curves 
were plotted. 
Statistical analysis
Overall differences among treatments were analyzed with the nonparametric Friedman’s 
test. When significant to a level of P ≤0.05, differences between treatment pairs were 
analyzed further by Wilcoxon’s signed-rank test (2-tailed) with Bonferroni correction for 
multiple comparisons. A corrected P-value ≤0.05 was considered significant. Differences 
in preinfusion and postinfusion levels within treatments were also analyzed by means 
of Wilcoxon’s signed-rank test. Values are expressed as means ± SEM unless stated 
otherwise. All statistical analyses were performed with the use of SPSS software (version 
12.0; SPSS Inc, Chicago, IL).
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l a B o R aT o RY Pa R a M e T e R s
In all subjects, serum urea, creatinine, sodium, potassium, liver enzymes, total bilirubin, 
LDH and C-reactive protein were within normal ranges. They remained unaffected by 
either saline or lipid infusion (data not shown).
Triacylglycerol concentration
Infusion of both lipid emulsions, according to the plasma triacylglycerol clamp technique, 
significantly increased plasma triacylglycerol concentrations from 1 mmol/L to 3-4 mmol/L. 
There were no significant differences between serum triacylglycerol concentrations after 
LCT and LCT/MCT infusion (Table 7.1).
Table 7.1: Plasma triacylglycerol concentrations before and after intravenous saline or lipid 
infusion.
Before after after - before
Saline 1.02 ± 0.08 0.99 ± 0.09 -0.04 ± 0.05
LCT 0.98 ± 0.08 3.81 ± 0.31*  2.83 ± 0.28**
LCT/MCT 0.96 ± 0.09 3.12 ± 0.32*  2.15 ± 0.26**
All values are mean ± SEM (mmol/L). LCT, Long-chain triacylglycerols; LCT/MCT, mixture of long- and medium-
chain triacylglycerols. Plasma triacylglycerol concentrations before and after a 3.5-h intravenous infusion of 
saline or lipid emulsions to healthy humans (n=12). Pre-infusion triacylglycerol concentrations did not differ 
significantly between treatments. There were no significant differences between LCT and LCT/MCT infusion. 
*Significant changes from pre-infusion concentrations, P <0.05 (Wilcoxon’s signed rank test). **Significant 
differences in absolute increment (after minus before) between lipids and saline, P <0.05 (Wilcoxon signed 
rank test with Bonferroni correction).
Leukocyte counts
Pre-infusion (baseline) cell counts did not differ significantly between treatments. A 
significant increase in total leukocyte and absolute neutrophil counts was observed after 
all 3 infusions (Table 7.2). These increases appeared highest after LCT/MCT administration, 
but the differences from saline and LCT were not significant (Table 7.2 and Figure 7.2). In 
contrast, the absolute number of lymphocytes remained unaltered after infusion of saline 
or LCT, but significantly decreased after infusion of LCT/MCT. Absolute monocyte counts 
did not change on infusion of saline or lipids. 
ox Yg e N R a D I C a l  P R o D U C T I o N
In isolated neutrophils and whole blood cells, the relative change in spontaneous 
(unstimulated) and PMA- or STZ-induced overall oxygen radical production, as presented 
by the ratio of the area under the curve after infusion to that before infusion, did not 
differ significantly between treatments (Table 7.3). Chemiluminescence in unstimulated 
whole blood samples was within the background range. Absolute changes in PMA- or 
STZ-induced chemiluminescence peak time were minimal and did not differ significantly 
between groups (Table 7.4). 
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Table 7.2: absolute plasma leukocyte counts before and after lipid or saline infusion.
saline lCT lCT/MCT
Before After Before After Before After
Leukocytes 5.10 ± 0.33 6.50 ± 0.66* 5.25 ± 0.38 7.05 ± 0.79* 5.33 ± 0.37 8.15 ± 1.03*
Neutrophils 2.68 ± 0.19 4.18 ± 0.64* 2.83 ± 0.24   4.61 ± 0.67* 3.00 ± 0.31 6.63 ± 0.93*
Lymphocytes 1.83 ± 0.22 1.83 ± 0.12 1.87 ± 0.19 1.93 ± 0.14 1.81 ± 0.18 1.01 ± 0.14*
Monocytes 0.43 ± 0.06 0.38 ± 0.04 0.34 ± 0.03   0.33 ± 0.02 0.35 ± 0.04 0.49 ± 0.10
All values are mean ± SEM (x109/L). LCT, Long-chain triacylglycerols; LCT/MCT, mixture of long- and medium-
chain triacylglycerols. Absolute plasma leukocyte counts before and after 3.5-h intravenous infusion of saline or 
parenteral lipid to healthy humans (n=12). Pre-infusion cell counts did not differ significantly between treatments 
for all leukocyte subsets. *Significant changes compared to pre-infusion cell counts, P ≤0.05 (Wilcoxon’s signed 
rank test). For differences in treatment effects between groups, see Figure 7.2. 
Figure 7.2: Effects of a 3.5-h intravenous administration of saline or parenteral lipid emulsions 
to healthy humans (n=12) on plasma leukocyte counts, depicted as the mean (± SEM) ratios of 
cell counts after infusion to those before infusion. LCT, long-chain triacylglycerols; LCT/MCT, 
mixture of long- and medium-chain triacylglycerols. *Significant differences between lipids and 
saline. #Significant differences between lipids (P ≤0.05 for both, Wilcoxon’s signed-rank test 
with Bonferroni correction).  
s T Z- I N D U C e D I N T R aC e l l U l a R C a l C I U M s I g N a l I N g I N  N e U T R o P H I l s 
Stimulation of a suspension of neutrophils loaded with the cytosolic Ca2+-indicator fura-
2 with STZ typically results in a biphasic increase in the fura-2 fluorescence emission 
ratio. This reflects a biphasic change of the average cytosolic free Ca2+ concentration 
of all cells in suspension, consisting of an initial slow phase followed by a second fast 
phase and finally resulting in a plateau phase that is maintained for a prolonged period 
of time (Figure 7.3). In previous studies, we have demonstrated that in vitro pretreatment 
of isolated neutrophils with LCT/MCT or pure MCT, rather than pure LCT, sensitizes the 
neutrophils to stimulation by STZ in a PMA-like manner; the rate of Ca2+-rise during the 
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first slow phase is increased and the second fast phase is abolished [22] (Figure 7.3d-f). 
The present study shows that intravenous infusion of LCT/MCT failed to alter the biphasic 
shape of the STZ-induced increase in average cytosolic free Ca2+-concentration (Figure 
7.3a-c). However, if neutrophils from subjects infused with either saline, LCT/MCT or LCT 
were pretreated ex vivo with LCT/MCT for 3 min, normal sensitization to STZ stimulation 
was observed (Figure 7.3d-f). As expected, ex vivo pretreatment of these cells with LCT 
did not affect the biphasic shape of the intracellular calcium response.
Table 7.3: The ratio of neutrophil oxygen radical production after to that before intravenous 
saline or lipid infusion.
saline lCT lCT/MCT
Isolated neutrophils
Unstimulated 1.12 ± 0.19 1.38 ± 0.22 1.94 ± 0.91
PMA 1.03 ± 0.04 1.08 ± 0.06 1.09 ± 0.07
STZ 1.17 ± 0.10 1.30 ± 0.11 1.32 ± 0.13
Whole blood cells
Unstimulated Within background range Within background range Within background range
PMA 1.27 ± 0.12 1.44 ± 0.09 1.38 ± 0.05
STZ 1.28 ± 0.14 1.60 ± 0.12 1.49 ± 0.09
All values are mean ± SEM. LCT, Long-chain triacylglycerols; LCT/MCT, mixture of long- and medium-chain 
triacylglycerols; PMA, phorbol 12-myristate 13-acetate; STZ, serum treated zymosan. Effect of a 3.5-h intravenous 
administration of saline or lipid emulsions to healthy humans (n=12) on the unstimulated and PMA- or STZ-induced 
overall oxygen radical production (after 60 minutes), as measured with luminol-enhanced chemiluminescence, 
in isolated neutrophils and whole blood cells, depicted as the ratios of after to before infusion. There were no 
significant differences between treatments, P ≤0.05 (Friedman’s test).
 
Table 7.4: oxygen radical production peak time before and after saline or lipid infusion.
PMa sTZ
Before After After-before Before After  After-before 
Isolated neutrophils
Saline 11.68 ± 0.32 12.11 ± 0.50 0.43 ± 0.35 10.15 ± 0.31 10.30 ± 0.31 0.14 ± 0.35
LCT 11.36 ± 0.42 11.86 ± 0.48 0.50 ± 0.39 10.07 ± 0.22 10.09 ± 0.36 0.02 ± 0.38
LCT/MCT 11.56 ± 0.46 12.90 ± 0.37 1.34 ± 0.32 10.30 ± 0.57 10.02 ± 0.25 -0.28 ± 0.49
Whole blood cells
Saline 16.47 ± 0.74 17.71 ± 0.56 1.24 ± 0.62 16.96 ± 1.15 20.05 ± 1.49 3.09 ± 1.54
LCT 16.16 ± 0.59 18.15 ± 0.53 2.35 ± 0.48 19.45 ± 1.10 20.06 ± 1.30 0.62 ± 1.25
LCT/MCT 16.28 ± 0.48 19.11 ± 0.69 2.22 ± 1.00 18.15 ± 1.53 20.73 ± 1.32 2.58 ± 1.45
All values are mean ± SEM. LCT, Long-chain triacylglycerols; LCT/MCT, mixture of long- and medium-chain 
triacylglycerols; PMA, phorbol 12-myristate 13-acetate; STZ, serum treated zymosan. Effect of a 3.5-h intravenous 
administration of saline or lipid emulsions to healthy humans (n=12) on chemiluminescence (oxygen radical 
production) peak time of PMA- or STZ stimulated isolated neutrophils and whole blood leukocytes, presented 
in minutes. Changes in peak time (after-before infusion) did not differ significantly between treatments, P ≤0.05 
(Friedman’s test). 
proefschrift Michelle.indb   98 18-12-2011   21:45:58
99
P
aren
teral Lip
id
s an
d
 Im
m
u
n
e Fu
n
ctio
n
 in
 V
ivo
Fi
gu
re
 7
.3
: 
Eff
ec
ts
 o
f 
a 
3.
5-
h 
in
tr
av
en
ou
s 
sa
lin
e 
or
 l
ip
id
 a
dm
in
is
tr
ati
on
 (
lo
ng
-c
ha
in
 t
ri
ac
yl
gl
yc
er
ol
s 
[L
C
T]
 o
r 
a 
m
ix
tu
re
 o
f 
lo
ng
- 
an
d 
m
ed
iu
m
-c
ha
in
 
tr
ia
cy
lg
ly
ce
ro
ls
 [L
C
T/
M
C
T]
) t
o 
he
al
th
y 
hu
m
an
s (
n=
12
) o
n 
th
e 
se
ru
m
-t
re
at
ed
 z
ym
os
an
 (S
TZ
)-
in
du
ce
d 
in
cr
ea
se
 in
 a
ve
ra
ge
 c
yt
os
ol
ic
 fr
ee
 C
a2
+ 
co
nc
en
tr
ati
on
, 
re
fle
ct
ed
 b
y 
th
e 
Fu
ra
-2
 fl
uo
re
sc
en
ce
 e
m
is
si
on
 r
ati
o 
aft
er
 e
xc
it
ati
on
 a
t 3
40
 a
nd
 3
80
 n
m
, i
n 
a 
su
sp
en
si
on
 o
f i
so
la
te
d 
ne
ut
ro
ph
ils
 lo
ad
ed
 w
it
h 
th
e 
cy
to
so
lic
 
C
a2
+  i
nd
ic
at
or
 F
ur
a-
2.
 A
-C
, S
TZ
-i
nd
uc
ed
 in
cr
ea
se
 in
 a
ve
ra
ge
 c
yt
os
ol
ic
 f
re
e 
C
a2
+  c
on
ce
nt
ra
ti
on
 in
 n
eu
tr
op
hi
ls
 is
ol
at
ed
 b
ef
or
e 
(g
ra
y 
lin
e)
 a
nd
 a
ft
er
 (b
la
ck
 
lin
e)
 in
fu
si
on
 o
f 
ei
th
er
 s
al
in
e 
(A
), 
LC
T 
(B
) 
or
 L
C
T/
M
C
T 
(C
). 
ST
Z 
w
as
 a
dd
ed
 w
he
re
 in
di
ca
te
d.
 D
-F
, 
ST
Z-
in
du
ce
d 
in
cr
ea
se
 in
 a
ve
ra
ge
 c
yt
os
ol
ic
 f
re
e 
C
a2
+  
co
nc
en
tr
ati
on
 in
 n
eu
tr
op
hi
ls
 is
ol
at
ed
 b
ef
or
e 
(s
ol
id
 li
ne
) a
nd
 a
ft
er
 (d
ott
ed
 li
ne
) i
nf
us
io
n 
of
 e
it
he
r s
al
in
e 
(D
), 
LC
T 
(E
) o
r L
C
T/
M
C
T 
(F
) a
nd
 p
re
tr
ea
te
d 
ex
 v
iv
o 
w
it
h 
ei
th
er
 L
C
T 
(g
ra
y 
lin
es
) o
r 
LC
T/
M
C
T 
(b
la
ck
 li
ne
s)
 fo
r 
th
e 
in
di
ca
te
d 
pe
ri
od
 o
f ti
m
e 
(3
 m
in
). 
ST
Z 
w
as
 a
dd
ed
 a
ft
er
 2
40
 s
. 
proefschrift Michelle.indb   99 18-12-2011   21:46:03
C
h
a
pt
er
 7
100
e x P R e s s I o N o F  M e M B R a N e s U R FaC e a N T I g e N s
The modulation of the expression of membrane surface activation, adhesion and 
degranulation markers on whole blood neutrophils and monocytes, did not differ 
significantly between treatments, except for a slight but significantly (P = 0.024) higher 
relative CD62L expression after LCT/MCT infusion than after saline infusion (Table 7.5). 
Table 7.5: Neutrophil membrane surface antigen expression before and after intravenous 
saline or lipid administration.  
saline lCT lCT/MCT
CD11b
Granulocytes 0.68 ± 0.10 0.79 ± 0.11 0.81 ± 0.09 
Monocytes 0.90 ± 0.09 1.06 ± 0.14 1.23 ± 0.14 
CD66b
Granulocytes 0.72 ± 0.07 0.94 ± 0.10 0.96 ± 0.08 
CD63
Granulocytes < detection limit < detection limit < detection limit
CD62L
Granulocytes 1.05 ± 0.09 1.15 ± 0.11 1.39 ± 0.12
Monocytes    0.94 ± 0.06 1.09 ± 0.10 1.43 ± 0.15* 
All values are mean ± SEM. LCT, Long-chain triacylglycerols; LCT/MCT, mixture of long- and medium-chain 
triacylglycerols. Effect of a 3.5-h intravenous administration of saline or lipids emulsions to healthy humans 
(n=12) on the expression of membrane surface antigens (adhesion [CD11b], degranulation [CD66b and CD63] 
and activation markers [CD62L]) on whole blood neutrophils and monocytes, depicted as the ratios of after 
to before infusion. Because monocytes do not contain granulae, the expression of CD63 and CD66b was only 
evaluated in granulocytes. *A significant difference of lipids with saline, P ≤0.05 (Wilcoxon’s signed rank test 
with Bonferroni correction). 
s C I N T I g R a P H Y W I T H T C- 9 9 M - H M Pao l a B e l e D l e U ko C Y T e s 
The clearance of autologous 99mTc-HMPAO-labeled leukocytes from the pulmonary, 
hepatic and splenic circulations was not slower during any lipid infusion than during saline 
infusion, which suggested that these emulsions do not induce extravascular or capillary 
leukocyte sequestration in these organs (Figure 7.4). During the infusion of LCT/MCT, the 
total uptake of radiolabeled leukocytes in the spleen (area under the curve in Figure 7.4) 
even tended to be lower than that with saline (P = 0.06) but not lower than that with LCT 
(P = 0.27). There were no differences between saline and LCT.
DIsCUssIoN
The main finding in the present study is that, in the absence of underlying diseases and in 
a clinically relevant plasma triacylglycerol concentration range, there are no indications 
for significant modulation of neutrophil functions and activation during short-term 
infusion of LCT and LCT/MCT emulsions. Second, lipid-induced leukocyte activation and 
subsequent sequestration leading to blood sampling error is not a mechanism that could 
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Figure 7.4: One hour 
monitoring of the clearance of 
T c - 9 9 m - H M P A O - l a b e l e d 
autologous leukocytes from the 
right lung, the liver and the 
spleen uptake during the 
infusion of saline, or lipid 
emulsions, containing long-
chain triacyglycerols (LCT) or 
mixed long- and medium chain 
tricylgelycerols (LCT/MCT), in 
healthy humans (n=12). To 
analyze leukocyte sequestration, 
the distribution of radiolabeled 
autologous leukocytes, which 
were obtained before the start 
of the infusions and next were 
labeled with Technetium-99m-
HMPAO, was monitored 
scintigraphically during the last 
hour of lipid or saline infusion. 
The relative signal intensity 
represents the percentage of 
radio-labeled leukocytes in the 
organ as a percentage of the 
totally administered dose of 
labeled leukocytes. Data are 
presented as mean (± SEM). 
There were no significant 
differences in leukocyte 
clearance among treatments (P 
≤0.05, Friedman’s test).
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explain any discrepancies between results of investigations with different (in vitro versus 
in vivo) designs. 
We have shown in earlier studies that MCT-containing lipids (pure MCT or LCT/MCT), in 
contrast to pure LCT emulsions, modulate cell functions of isolated and whole blood 
neutrophils, obtained from healthy humans in vitro [18-24;31]. However, whereas in vitro 
exposure to MCT increases the stimulus-induced oxygen radical production [18], that 
response was not distinctly altered by any intravenous lipid infusion (Table 7.3 and 7.4). 
In addition, MCT, which sensitize the zymosan-induced intracellular calcium signaling of 
neutrophils in a protein kinase C-dependent manner in vitro [22], did not alter the biphasic 
morphology of this response after intravenous lipid infusion (Figure 7.3a-c). The finding 
that ex vivo treatment with LCT/MCT of cells that were isolated before and after infusion 
with LCT/MCT, LCT and saline reinstituted the sensitization to STZ stimulation observed in 
the in vitro experiments suggests that the ability of neutrophils to be modulated by ex vivo 
LCT/MCT treatment is not changed by either infusion (Figure 7.3d-f). As was seen in vitro, 
ex vivo treatment with LCT did not affect the biphasic character of the calcium response. 
Finally, neither lipid infusion affected the expression of degranulation markers (CD63 and 
CD66b) significantly more than did saline, which indicated that in vivo exposure to these 
lipids does not induce neutrophil degranulation (Table 7.5). With respect to monocytes, 
a small but significant increase in the expression of cell activation marker CD62L was 
observed after LCT/MCT infusion. This observation is striking, but its relevance is unclear, 
because leukocyte activation normally is accompanied by a lower expression of CD62L 
due to receptor shedding [32;33]. Taken together, these results, which are in accordance 
with those of other studies [9;10;17;25], indicate that, in clear contrast to in vitro exposure, 
neutrophils are not activated by in vivo exposure to MCT. 
For the first time (to our knowledge) in this field of research, the hypothesis that 
extravascular or capillary sequestration of activated leukocytes plays a role in the observed 
absence of (measurable) neutrophil activation after lipid exposure in vivo was tested. 
The fact that the clearance of radiolabeled leukocytes from pulmonary and hepatic and 
splenic circulations, the major organs of the reticuloendothelial system, was not delayed 
during any lipid infusion makes it unlikely that, in vivo, neutrophils are activated by LCT/
MCT or that sampling error due to leukocyte sequestration does occur. 
With respect to the effects of lipids on leukocyte population counts, we found that the 
infusion of LCT/MCT but not LCT or saline significantly decreased absolute lymphocyte 
numbers. Although, all lymphocyte numbers remained within normal ranges (Table 7.2), 
this decrease is remarkable and might be relevant in patients with an already imbalanced 
immune response. This issue should be addressed in future studies of the effect of 
LCT/MCT on the cell numbers and the function of specific lymphocyte subsets, such as 
B-lymphocytes, helper- and cytotoxic T-lymphocytes and Natural Killer cells. The increase 
in leukocyte and neutrophil counts, which were observed after all infusions, was most 
pronounced (although not significantly so) after the LCT/MCT infusion (Table 7.2 and 
Figure 7.2). Because absolute leukocyte counts also increased after saline infusion, saline 
should be regarded as a lipid-free control rather than as a true placebo. It is also not 
unlikely that procedure-related stress may play a role. Pure LCT exerted no greater effects 
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than did saline, and thus it is unlikely that emulsion components other than lipids, such as 
the emulsifier or antioxidants, are responsible for the observed MCT effects. 
Because leukocyte sequestration does not explain the contrasting results between in 
vitro and in vivo studies, other explanations should be considered. First, it is possible that, 
in vivo, the plasma concentrations of MCT are too low to exert the neutrophil activating 
effects that were observed in vitro. As in clinical practice, infusion rates of LCT/MCT and 
LCT emulsions were weight-based, which resulted in a higher molar infusion rate during 
LCT/MCT infusion than during LCT infusion. Despite this higher molar infusion rate, the 
plasma triacylglycerol concentration was not higher after LCT/MCT infusion (3.12 mmol/L) 
than after LCT infusion (3.81 mmol/L) (Table 7.1). Because MCT are cleared from the plasma 
and metabolized at much higher rates than are LCT [34;35], triacylglycerol clamping 
with LCT/MCT may result in a relative accumulation of plasma LCT and low plasma MCT 
concentrations. Second, plasma may contain components that inhibit or neutralize any 
immune modulating effects of MCT in vivo. The observation that the potency of MCT to 
upregulate the expression of adhesion and degranulation markers is highest in isolated 
cells [19], lower in whole blood cells [24] and absent in the present in vivo setting supports 
this hypothesis. 
Most in vivo studies on immune modulation by LCT and LCT/MCT in humans have been 
performed in critically ill or malnourished persons or in trauma- or postoperative patients 
[7;8;36-39]. As mentioned, results to date have been very disparate, most probably as a 
result of widely varying clinical conditions, medication use and experimental settings. The 
present study, therefore, was performed in a more homogeneous group. It can be argued 
that short-term administration of parenteral lipid emulsions to healthy subjects does not 
resemble clinical practice because the incorporation of fatty acids into cell membranes 
takes more time to become significant. However, it should be also considered that in all our 
in vitro studies effects on neutrophil functions were observed within 1 h of lipid exposure 
and also that a 48-h infusion revealed comparable results [10;18;19]. Eventually, larger 
randomized trials in patients on long-term TPN and patients with specific acute conditions 
requiring short-term TPN will probably be indispensable to clear the dust in this field. It is, 
however, unlikely that the many practical problems concerning the performance of such 
studies in the past will change in the near future. 
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short-term Infusion of a Fish oil-Based lipid 
emulsion Modulates Fatty acid status, 
but Not Immune Function or (anti)oxidant 
Balance: a Randomized Cross-over study
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Studies suggest clinical benefits of parenteral fish oil (FO), rich in n-3 polyunsaturated 
fatty acids (PUFAs), over soybean oil (SO), rich in n-6 PUFAs, in patients with pro-
inflammatory conditions such as sepsis and trauma. Because the mechanisms 
behind these observations remain unclear, the present study explored the effects of 
intravenous infusion of FO and SO on fatty acid incorporation, immune functions and 
(anti)oxidant balance in healthy human volunteers. Saline, a SO emulsion and a FO 
emulsion were administered for one hour on three consecutive days at a rate of 0.2 g/
kg BW/hr to eight subjects in a randomized cross-over design with a 3-week interval 
between treatments. Plasma phospholipid and peripheral blood mononuclear cell 
(PBMC) fatty acid compositions, and leukocyte counts and functions were assessed 
prior to the first infusion (T=0, baseline) and 1 day (T=4, early effects) and 8 days 
(T=11, late effects) after the third infusion. FO infusion significantly increased n-3 
PUFA proportions and decreased n-6 PUFA proportions in plasma phospholipids 
and PBMCs. There were no differences in immune functions or (anti)oxidant balance 
between treatments at any time. In conclusion, the present lipid infusion protocol 
appears to be safe and well tolerated and provides significant incorporation of n-3 
PUFAs into plasma phospholipids and PBMCs. In the absence of overt inflammation, 
no direct effects of FO were observed on immune function or (anti)oxidant balance. 
This model may be useful to evaluate effects of parenteral lipids in other settings, for 
example in individuals displaying an inflammatory state. 
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In patients using Total Parenteral Nutrition (TPN), the high rate of infectious complications remains a major concern [1]. There have been hints that certain fatty acids in TPN impair human immune defenses, while others seem to 
have beneficial effects [1]. 
Soybean oil (SO) provides the basis for the oldest and still most widely used lipid emulsion, 
Intralipid®. SO contains a high proportion of omega-6 (n-6) polyunsaturated fatty acids 
(PUFAs), predominantly linoleic acid (18:2n-6). Linoleic acid is the precursor of arachidonic 
acid (AA, 20:4n-6), which is in turn the precursor of eicosanoids with predominantly pro-
inflammatory activity. Thus, the high content in n-6 PUFAs of SO based emulsions has 
been considered a possible drawback in clinical situations with an already imbalanced 
inflammatory response, such as sepsis or trauma [1]. 
Fish oil (FO) contains long chain n-3 PUFAs, including eicosapentaenoic (EPA, 20:5n-30) and 
docosahexaenoic acid (DHA, 22:6n-3), that directly compete with AA for incorporation 
into cellular membranes and for metabolism by the enzymes that produce eicosanoids [2]. 
EPA and DHA give rise to less pro-inflammatory mediators than AA [2, 3]. 
Several studies have focused on clinical outcomes of parenteral FO in septic and 
gastrointestinal surgical patients, such as the length of hospital stay, mortality rates 
and the postoperative normalization of organ function [4-8]. Generally, the findings 
suggest a clinical benefit of parenteral FO, with several studies showing that FO infusion 
to postoperative and septic patients indeed modulates the generation of inflammatory 
cytokines and eicosanoids [9-11]. 
Further research is required to unravel the mechanisms behind the biological effects of 
parenteral lipids and identify clinical situations in which they can benefit. This notion urges 
us to start an investigation in the non-disease state, in the absence of any perturbances 
of immune function, and by employing a safe and simple protocol that delivers adequate 
amounts of fatty acids under investigation. In the present study, we therefore assessed 
plasma and cellular fatty acid profiles after SO and FO infusion in healthy volunteers, and 
evaluated various aspects of immune cell function and (anti)oxidant balance.
sUBJeCTs, MaTeRIals aND MeTHoDs
The report of this study is in accordance with the CONSORT statement [12, 13] The study 
was registered at ClinicalTrials.gov (NCT00734916).
s U B J eC T s
Eight healthy adult volunteers (4 women and 4 men, mean age 39 (range 23-61) year, 
mean body mass index 24 (range 20-29) kg/m2), none of whom was on medication, were 
included in the study. Subjects with a history of inflammatory or cardiovascular disease, 
metabolic disorders, use of (multi)vitamin or fish oil supplements, a consumption of fatty 
fish of more than two times a week, or who smoked more than five cigarettes per day, 
were excluded. The Ethical Review Board of the Radboud University Nijmegen Medical 
Center approved the study. All procedures were performed after obtaining written 
informed consent.
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M aT e R I a l s
Reagents were obtained from Sigma Chemicals (St Louis, MO, USA) and laboratory 
manipulations were performed at room temperature (RT) unless stated otherwise. 
M e T H o D s
Lipid administration
After an overnight fast, lipid-free control (saline 0.9%) or lipid emulsions based on SO 
(Lipoveneus 10% wt/vol) or FO (Omegaven® 10% wt/vol), both from Fresenius Kabi, Bad 
Homburg, Germany, were administered intravenously for 1 h (0.2 g/kg body weight/h) on 
three consecutive days (i.e. day 1-3). This infusion rate has been shown to be safe for both 
emulsions with respect to peak plasma triacylglycerol and free fatty acid concentrations 
[14, 15]. In order to resemble the clinical situation, where infusion rates are based on 
caloric needs, we kept equal weight-based infusion rates for both SO and FO. Blood 
samples were drawn after an overnight fast at 8.00 h in the morning prior to the first 
infusion (t=0), on day 4 (i.e. t=4, for assessment of early effects) and on day 11 (i.e. t=11 
for assessment of late effects). The study was performed in a randomized crossover 
design (blinded for subjects and laboratory co-workers); after three weeks, the treatment 
procedure was repeated for the other emulsion or lipid free control and after a second 
wash-out period for the third treatment (Figure 8.1). All 6 possible treatment orders were 
used at least once. Treatment order saline/FO/SO and SO/FO/saline were used twice. This 
way, 4 volunteers received FO prior to SO and 4 volunteers used SO prior to FO. Treatment 
orders were randomly assigned by envelope selection.
Figure 8.1: Time-frame of experimental set-up. Blood collection (60 ml) was performed at 
three time points, T=0, T=4 and T=11. The intravenous infusions were administered on day 1, 
day 2 and day 3. Between each treatment there was a wash-out period of two weeks. T=0 
indicated prior to the first infusion, T=4 indicated one day after the last infusion and T=11 
indicates eight days after the last infusion.
Leukocyte isolation
Blood samples were collected in 10 mL Monoject tubes with 170 IU of lithium heparin 
(Beliver Industrial Estate, Plymouth PL6 7BP, UK). The blood, diluted 1:1 with phosphate 
buffered saline (B. Braun Melsungen AG, Melsungen Germany) was layered onto Percoll 
(ρ 1.076 g/mL (ρ 1.130 g/mL at 20°C)) which was obtained from GE Healthcare Biosciences 
AB (Uppsala, Sweden)) and centrifuged (700 g, 20 min). Neutrophils and peripheral blood 
mononuclear cells (PBMCs) were then isolated as described in detail previously [16-18].
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Fatty acid composition assessment
Total lipid was extracted from thawed plasma (0.5 mL, collected in EDTA and stored 
at -80°C) and PBMCs (1x107/mL RPMI medium supplemented with 2 mM L-Glutamine, 
1 mM pyruvate and 0.05 mg/mL gentamycin and stored at -80°C) with 5 mL of 
Chloroform:methanol (2:1) containing the antioxidant butylated hydroxytoluene (50 
mg/L). Solid phase extraction (SPE) was used to isolate phosphatidylcholine (PC) from 
the total plasma lipid extract. Next, fatty acid methyl esters (FAMEs) from plasma PC and 
from PBMC total lipid were formed by incubation in methanolic H
2
SO
4
 for two hours at 
50°C. FAMEs were separated using gas chromatography (GC) on a Hewlett Packard 6890 
gas chromatograph fitted with a BPX70 fused silica capillary column (0.25 µm x 30 m x 
0.22 mm); helium was used as the carrier gas. Following injection, the temperature was 
rapidly raised to 115 °C for 2 min. Then the temperature was raised to 200°C at the rate 
of 10°C/min, where it was held for 18 min. Finally the temperature was raised to 245°C at 
a rate of 60 °C/min where it was held for 8 min. FAMEs were detected by flame ionization 
detection. FAMEs were identified by comparison with run times of authentic standards. 
ChemStation software was used to calculate peak areas and the percentage contribution 
of each peak to the total. 
Leukocyte function assessment 
• Leukocyte membrane surface antigen expression 
The expression of activation molecules on the membrane surface of neutrophils and 
monocytes was evaluated in whole blood by immune-fluorescent staining and subsequent 
flow-cytometric analysis. Characterization was performed using antibodies directed 
against an adhesion molecule of the β2 integrin family (CD11b) as well as markers for 
degranulation of azurophilic (CD63) or specific granulae (CD66b) and an activation marker 
(CD62L) that is normally downregulated during cell activation due to receptor shedding. 
Immune-fluorescent staining was performed according to the “lyse and wash” method 
and all antibodies used were purchased from Beckman Coulter (Miami, FL, USA), as 
described previously [17, 19]. 
• Assessment of cytokine and prostaglandin E
2
 production by PBMCs
After PBMC isolation, cell counts were adjusted to 5x106 cells in 0.5 mL RPMI supplemented 
with 20% heat inactivated fetal calf serum/10% DMSO and cryopreserved in liquid N
2
. 
Before cell stimulation, the cryopreserved cells were rapidly thawed in a water bath of 
37°C in a sterile cabinet. The cells were then transferred to a 15 mL tube and 10 mL ice-
cold RPMI was added dropwise to dilute the medium that was used for freezing and storing 
the cells. Subsequently, the cells were thoroughly mixed with the RPMI medium. Next, 
the tube was centrifuged at 840xg for 7 min. After centrifugation, the supernatant was 
discarded in one motion and the cells resuspended in 1 mL of RPMI medium kept at RT. 
The concentration of viable cells in the suspension was counted. PBMCs were stimulated 
with phytohemagglutinin (PHA), which stimulates T lymphocytes, or lipopolysaccharide 
(LPS), which stimulates monocytes. For both stimulants, unstimulated cell cultures were 
included as a control. For culturing, the thawed cells were resuspended in the appropriate 
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medium (1x106 cells/ml) and 250 µL of this cell suspension was added to wells of a 96 well 
round bottom plate.  
The cells that were stimulated by PHA (final concentration 1 µg/ml) were cultured in AIM-V 
medium containing 5x10-4 M 2-mercapthoethanol. The cell cultures were incubated for 48 
h at 37°C and 5% CO
2
. After incubation, the supernatants were collected and stored at 
-20°C for evaluation of cytokine concentrations. The cells that were stimulated with LPS 
(final concentration 10 ng/ml) were cultured in RPMI medium containing 10% non-heat 
inactivated fetal calf serum (NHI-FCS). The cell cultures were incubated for 24 h at 37°C 
and 5% CO
2
. After incubation, the supernatants were collected and stored at -20°C for 
evaluation of cytokine concentrations.
Cytokine concentrations were assessed by cytometric bead array using FlowCytomix 
Human Th1/Th2 11plex Kit (IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, TNF-α, 
TNF-β) provided by Bender MedSystems, eBioscience, Hatfield, UK. Limits of detection 
for these assays were 1.6 pg/mL (IFN-γ), 4.2 pg/mL (IL-1β), 16.4 pg/mL (IL-2), 20.8 pg/
mL (IL-4), 1.6 pg/mL (IL-5), 1.2 pg/mL (IL-6), 0.5 pg/mL (IL-8), 1.9 pg/mL (IL-10), 1.5 pg/
mL (IL-12), 3.2 pg/mL (TNF-α) and 2.4 pg/mL (TNF-β). Manufacturer’s instructions were 
followed throughout and samples were analyzed on a Becton Dickinson FACSCalibur flow 
cytometer. Data was analyzed using FlowCytomixPro software. 
The concentration of prostaglandin E
2
 (PGE
2
) was measured by specific ELISA (R&D Systems 
Europe, Abingdon, UK). The limit of detection was 30.9 pg/mL.
• Oxygen radical production by isolated neutrophils and whole blood cells
Oxygen radical production was evaluated by means of luminol-enhanced 
chemiluminescence, as measured in an automated LB96V Microlumat Plus Luminometer 
(EG& G Berthold, Bad Wildberg, Germany), as described in detail previously [17, 19, 20]. 
Briefly, in a 96-well microplate whole blood or isolated neutrophils were added; either with 
no stimulus, with phorbol 12-myristate 13-acetate (PMA, receptor independent stimulus) 
or serum-treated zymosan (STZ, receptor dependent stimulus). To each well, luminol was 
added. Each measurement was performed in five replicates. Chemiluminescence was 
monitored every 145 sec at 37°C for 1h. In this period stimulus-induced oxygen radical 
production normally returns to the baseline level. Luminescence was expressed as relative 
light units per second (RLU/sec). The area under the curve (AUC), representing the overall 
oxygen radical production during 1 h, and luminescence peak time were calculated. 
Data were analyzed with Winglow software (EG & G Berthold, Bad Wildberg, Germany). 
After subtraction of background signal, the signal intensity in whole blood samples was 
correlated to the neutrophil population count.
• Elimination of Streptococcus pneumoniae by isolated neutrophils
With some modifications, the method for the opsonophagocytic killing assay (OPKA) by 
Nahm was used [21, 22]. The method has recently been described in detail [23]. Briefly, 
bacteria (Streptococcus pneumoniae, strain OREP-4 (serotype 4)), were opsonized with 
a dilution series of pooled and purified human IgG (Nanogam 50 mg/mL, Sanquin, 
Amsterdam, the Netherlands), Subsequently, bacterial elimination by neutrophils was 
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started after adding neutrophils and rabbit complement (Pel-Freez Biologicals, Rogers, 
AR, USA). All incubations were performed in triplicate. Then, samples were spotted in 
duplicate on agar plates and after drying, overlay medium with 2,3,5-triphenyl tetrazolium 
chloride, which stains viable CFUs was added. The plates were incubated overnight and 
photographed the next day. Thereafter CFUs were counted using TotalLab (Nonlinear 
Dynamics, Newcastle, UK). The elimination capacity of neutrophils was expressed as the 
percentage elimination in samples incubated with neutrophils relative to the bacterial 
count in samples without neutrophils (i.e. with complement and IgG).
Evaluation of oxidative stress
Oxidative stress was assessed by measuring both lipid and protein peroxidation and 
antioxidant capacity. 
• Lipid peroxidation 
The peroxidation of lipids was measured as the amount of Thiobarbituric Acid Reactive 
Substances (TBARS) in plasma (blood collected in EDTA tubes), as described previously 
[24]. Briefly, malondialdehyde (MDA) generated during lipid peroxidation reacts with 
thiobarbituric acid. After incubation, TBARS are extracted using butanol. Analysis of the 
supernatants was performed by fluorometry on a Shimadzu RFF-5000 spectrofluorometer 
(Shimadzu, Kyoto, Japan), with an excitation wavelength of 530 nm and an emission 
wavelength of 545 nm. A standard curve was prepared using 1,1,3,3-tetramethoxy-
propane (Fluka Chemika, Buchs SG, Switzerland). Concentration of TBARS was expressed 
as micromolar. 
• Protein oxidation
Plasma protein carbonyls as a marker of oxidative protein damage were measured by 
an ELISA according to the method of Buss et al. [25] and as described previously [24]. 
Briefly, standards and samples were diluted in PBS to a protein concentration of 4 mg/
mL. Proteins were derivatized with 2,4-dinitrophenyl-hydrazine and coated on an ELISA 
plate (Nunc-Immuno plate maxisorp, Nunc, Roskilde, Denmark). After probing with 
biotinylated anti 2,4-dinitrophenyl-hydrazine antibody (Molecular Probes Inc, Eugene, 
OR, USA), the wells were incubated with streptavidin biotinylated horseradish peroxidase 
(Amersham Life Science Inc, Arlington Heights, IL, USA). Staining was carried out with 
o-phenylenediamine. Absorbance was read at 490 nm in a ThermoMax microplate reader 
(Molecular Devices Corp, Sunnyvale, CA, USA). Concentrations of carbonyls are expressed 
in nmol/mg protein.
• Glutathione
Glutathione was determined in whole blood by HPLC, as described previously [24, 26]. 
Whole blood (500 µL) was added to 500 µL ice-cold 12% perchloric acid (PCA), containing 
2.0 mmol/L bathophenanthrolinedisulfonic acid (for the assessment of total free 
glutathione). Another 500 µL whole blood was added to the same solution plus 40 mmol/L 
N-ethylmaleimide (for the assessment of oxidized glutathione). Samples were thoroughly 
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mixed and centrifuged at 16000xg for 15 min at 4°C. Supernatants were stored at -80°C 
until analysis. For the assay of oxidized gluthatione, 100 µL of the appropriate supernatant 
was taken and 70 µL KOH (2.0 M) was added, followed by 60 µl HCL (0.01 M in 3.0 M MOPS 
buffer) to remove the excess of N-ethylmaleimide. This was centrifuged at 16000xg for 
3 min at 4°C. For every type of glutathione assay, 100 µl of sample was run in parallel 
with the GSH standards. To the samples and standards 10 µL tris (carboxyethylene) 
phosphine (10% w/v) in 0.9% (w/v) NaCl/4mM EDTA) was added, mixed and incubated 
for 30 min. After the reduction, 100 µL PCA/EDTA (0.6 M/1 mM) was added and mixed. 
The samples were left for 5 min to precipitate and then centrifuged for 5 min at 16000xg. 
The supernatants (100 µL) were incubated for 60 min at 60°C with 240 µL reaction-mix 
containing 20 µL NaOH (1.55 M), 200 µL borate buffer (125 mM K
2
B
4
O
7
-4H
2
O and 4 mM 
EDTA) and 20 µL 7-fluorobenzoflurazane sulfonic acid) (2 mg/mL in borate buffer, Fluka 
Chemika). After cooling, the derivatized samples were neutralized with 10 µL 6 M HCl and 
a 20 µL sample was injected in the HPLC system with fluorescent detection (Jasco Inc., 
Easton, MD, USA). Data obtained were analyzed using the ChromPass Chromatography 
Data System (Jasco Inc.). Glutathione concentrations were calculated using a four-point 
calibration curve and expressed in µM. 
• Overall antioxidant capacity of plasma
The overall antioxidant capacity of plasma was measured using the ‘ferric reducing ability 
of plasma’ (FRAP)-assay adapted from Benzie and Strain [27] as previously described [24]. 
Standards (FeSO
4
-7H
2
O) and samples were added to the FRAP working solution [2.5 mL 10 
mM 2,4,6,-tripyridyl-s-triazine (Fluka Chemika) in 40 mM HCl, 2.5 ml 20 mM FeCl
3
-6H
2
O 
and 25 mL 300 mM acetate buffer pH 3.6]. In the presence of antioxidants, ferric ions are 
reduced to ferrous ions, which cause a colored ferrous-2,4,6-tripyridyl-s-triazine complex 
to be formed. Absorbance was measured at 593 nm on a Perkin-Elmer Spectrophotometer. 
Values are expressed in mmol Fe2+/L. 
Laboratory variables 
Blood cell counts, which included an automated leukocyte differentiation, renal 
function, liver enzymes and concentrations of sodium, potassium, total bilirubin, lactate 
dehydrogenase, C-reactive protein, triacylglycerols, Vitamin E, Vitamin C and selenium 
were measured on an automated analyzer (AdviaTM120, Siemens Medical Solutions, The 
Hague, The Netherlands). 
Statistical analysis
Overall differences among treatment effects were analyzed with the non-parametric 
Friedman’s test. When significant to a level of P ≤0.05, differences between treatment 
pairs were analyzed further by Wilcoxon’s signed rank test (two tailed) with Bonferroni 
correction for multiple comparisons. A corrected P-value ≤0.05 was considered significant. 
Unless stated otherwise, treatment effects are presented as ratio T=4/T=0 and ratio T=11/
T=0 which indicated early and late treatment effects respectively. Values are expressed as 
means ± SEM unless stated otherwise. All statistical analyses were performed using SPSS 
(version 12.0; SPSS, Inc., Chicago, IL, USA).
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ResUlTs 
P l a s M a P C  FaT T Y aC I D C o M P o s I T I o N 
In contrast to saline and SO, FO significantly increased the proportion of total n-3 PUFAs 
and decreased the proportion of total n-6 PUFAs in plasma PC (Figure 8.2). This effect 
was the most pronounced 1 day after the last infusion (T=4), but significant changes 
in comparison with T=0 persisted 8 days after FO infusion (T=11). More specifically, 
FO infusion significantly increased the proportions of EPA, DPA and DHA (at T=4 and 
T=11) and significantly decreased the proportion of precursors of the proinflammatory 
arachidonic acid (AA), i.e. linoleic acid and dihomo-γ-linolenic acid (at T=4). Remarkably, 
AA itself significantly increased early (T=4) after FO infusion. This relative increase in AA 
proportion (ratio T=4/T=0) after FO infusion was, however, not significantly different from 
saline- or SO-induced early effects on relative AA proportions (ratio T=4/T=0). SO infusion 
significantly decreased the proportion of EPA at T=4. Proportions of other individual or of 
total n-3 or n-6 PUFAs were not significantly modulated by either saline or SO. None of the 
three treatments significantly affected the proportions of saturated fatty acids (14:0, 16:0, 
18:0, 20:0 and 22:0) or monounsaturated fatty acids (16:1n-7, 18:1n-9, t18:1n-9, 20:1n-9 
and 24:1n-9) in plasma PC.
P B M C FaT T Y aC I D C o M P o s I T I o N
The changes in plasma PC fatty acid profiles described above were reflected in PBMCs. 
Infusion of FO significantly increased the proportions of EPA, DHA and total n-3 PUFAs 
at T=4 (Figure 8.3). DPA proportions did not significantly increase at T=4 and tended to 
increase at T=11 after FO infusion. FO significantly decreased the proportions of linoleic 
acid and 22:4n-6 at T=4. Except for a tendency to a decreased linoleic acid proportion 
at T=11 (compared to T=0) after SO infusion, saline and SO infusion did not show any 
significant modulation of n-3 or n-6 PUFA proportions. No treatment significantly affected 
the proportions of saturated or monounsaturated fatty acids in PBMCs. 
P l a s M a T R I aC Y l g lYC e R o l C o N C e N T R aT I o N
Plasma triacylglycerol concentrations at T=4 or T=11 were not significantly affected by 
saline or by either lipid emulsion and all triacylglycerol concentrations remained within 
normal ranges at all time points (Table 8.1).
l e U ko C Y T e  C o U N T s
Absolute leukocyte counts before and after treatments are shown in Table 8.2. Saline 
minimally, but significantly, decreased lymphocyte counts at T=11 compared to T=0. This 
late treatment effect (ratio T=11/T=0) appeared significantly more pronounced than the 
late FO effect and tended to be higher than the late SO effect. For all treatments, leukocyte 
counts remained within normal ranges. 
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Figure 8.2: Overview of change in total n-3 PUFAs and n-6 PUFAs and some important 
individual PUFAs over time in plasma phosphatidylcholine for the three different treatment 
groups, i.e. saline (solid line), SO (soybean oil, broken line) and FO (fish oil, dotted line). Data 
are presented as percentage (means ± SEM). Total n-3 PUFAs indicate 18:3n-3, 20:4n-3, 20:5n-3 
(EPA), 22:5n-3 (DPA) and 22:6n-3 (DHA). Total n-6 PUFAs indicate 18:2n-6 (linoleic acid), 18:3n-6, 
20:3n-6 (DGLA), 20:4n-6 (AA), 22:4n-6 and 22:5n-6. A significantly different short- or long term 
treatment effect (i.e. the ratio of T=4/T=0 or T=11/T=0, respectively from saline is indicated by 
† and from SO by ‡ (P ≤0.05, Wilcoxon’s signed rank test). Trends to a different short- or long 
term treatment effect (i.e. 0.05 < P < 0.10, Wilcoxon’s signed rank test) from saline is indicated 
by § and from SO by $. For clarity of the figures significant differences within treatments are 
only described in the text.
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Figure 8.3: Overview of change in total n-3 PUFAs and n-6 PUFAs and some important individual 
PUFAs over time in PBMCs for the three different treatment groups, i.e. saline (solid line), SO 
(soybean oil, broken line) and FO (fish oil, dotted line). Data are presented as percentage (means 
± SEM). Total n-3 PUFAs indicate 18:3n-3, 20:4n-3, 20:5n-3 (EPA), 22:5n-3 (DPA) and 22:6n-3 
(DHA). Total n-6 PUFAs indicate 18:2n-6 (linoleic acid), 18:3n-6, 20:3n-6 (DGLA), 20:4n-6 (AA), 
22:4n-6 and 22:5n-6. A significantly different short- or long term treatment effect (i.e. the ratio 
of T=4/T=0 or T=11/T=0, respectively from saline is indicated by † and from SO by ‡ (P ≤0.05, 
Wilcoxon’s signed rank test). Trends to a different short- or long term treatment effect (i.e. 0.05 
< P < 0.10, Wilcoxon’s signed rank test) from saline is indicated by § and from SO by $. For clarity 
of the figures significant differences within treatments are only described in the text.
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Table 8.1: Plasma triacylglycerol concentrations before and after IV saline or lipid infusion.
T=0 T=4 T=11
Saline 1.24 ± 0.15 1.12 ± 0.14 1.14 ± 0.17
SO 0.99 ± 0.19 1.00 ± 0.15 1.23 ± 0.15 
FO 0.98 ± 0.17 1.05 ± 0.12 1.03 ± 0.15*
Plasma triacylglycerol concentrations before (T=0 days) and after (T=4 and T=11 days) i.v. parenteral lipid 
(SO, soybean oil; FO, fish oil) or saline administration for 1 h on three consecutive days to healthy humans 
(n=8). Data presented in mmol/L (mean ± SEM). There were no significant differences (P ≤0.05, Friedman’s 
test) in short- or long term treatment effects (ratio of T=4/T=0 or T=11/T=0, respectively) among treatments. 
*Indicates a trend (i.e. 0.05< P <0.10) to a different treatment effect (ratio t=11/T=0) from saline (P ≤0.05 
Wilcoxon’s signed rank test).
 
l e U ko C Y T e  aC T I VaT I o N 
Leukocyte activation was evaluated by assessing the expression of membrane surface 
activation, adhesion and degranulation markers on whole blood neutrophils and monocytes 
(Table 8.3), LPS- and PHA-induced cytokine production and LPS-induced PGE
2
 production 
by PBMCs (Table 8.4) and the spontaneous and stimulus (STZ and PMA)-induced oxygen 
radical production of isolated neutrophils and whole blood cells (expressed as overall 
oxygen radical production in 60 min and oxygen radical production peak time, Tables 8.5 
and 8.6). There were no significant differences in early- or late treatment effects on these 
activation and functional parameters among groups. 
Table 8.3: Neutrophil and monocyte membrane surface antigen expression before and after 
lipid or saline infusion.
saline so Fo
T=4/T=0       T=11/T=0 T=4/T=0 T=11/T=0 T=4/T=0 T=11/T=0
CD11b
Neutrophils 0.89 ± 0.19 1.00 ± 0.16 1.15 ± 0.38 1.05 ± 0.15 0.83 ± 0.17 0.70 ± 0.14
Monocytes 0.75 ± 0.09 0.85 ± 0.12 0.94 ± 0.20 0.96 ± 0.14 0.73 ± 0.12 0.67 ± 0.10
CD66b
Neutrophils 0.99 ± 0.14 0.96 ± 0.10 0.99 ± 0.18 1.06 ± 0.09 0.92 ± 0.10 0.79 ± 0.09
CD62L
Neutrophils 1.16 ± 0.08 1.00 ± 0.09 1.36 ± 0.14  1.61 ± 0.22 1.27 ± 0.12 1.31 ± 0.17
Monocytes 1.21 ± 0.05  0.99 ± 0.07 1.23 ± 0.13 1.37 ± 0.15 1.17 ± 0.11 1.17 ± 0.13
Early (ratio T=4/T=0) and late (T=11/T=0) effects of i.v. saline or parenteral lipid (SO, soybean oil; FO, fish 
oil) administration for 1 h on three consecutive days to healthy humans (n=8) on neutrophil and monocyte 
membrane surface antigen expression. Data are presented as means ± SEM. CD63 on neutrophils was below 
the detection limit and therefore not depicted in the table. No significant differences in (or trends to) short- or 
long term -treatment effect (i.e. the ratio of T=4/T=0 or T=11/T=0) among treatments were observed (P ≤0.05, 
Friedman’s test). 
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Table 8.5: PMa- or sTZ-induced overall oxygen radical production before and after lipid or 
saline infusion.
saline so Fo
T=4/T=0 T=11/T=0 T=4/T=0 T=11/T=0 T=4/T=0 T=11/T=0
Isolated neutrophils
Unstimulated 1.93 ± 0.65 1.29 ± 0.16 4.73 ± 1.98 3.37 ± 1.35 2.47 ± 1.08 1.06 ± 0.14
PMA 0.99 ± 0.09 1.24 ± 0.14 0.87 ± 0.12 0.86 ± 0.18 1.14 ± 0.19 1.04 ± 0.09
STZ 1.08 ± 0.15 1.24 ± 0.15 0.89 ± 0.19 0.71 ± 0.16 1.07 ± 0.23 1.09 ± 0.17
Whole blood cells
Unstimulated Within background range Within background range Within background range
PMA 1.04 ± 0.08 1.18 ± 0.12 1.06 ± 0.09 1.08 ± 0.12 1.22 ± 0.11 1.23 ± 0.13
STZ 1.15 ± 0.11 1.24 ± 0.15 1.09 ± 0.10 1.17 ± 0.18 1.25 ± 0.12 1.23 ± 0.22
Early (ratio T=4/T=0) and late (T=11/T=0) effects of i.v. saline or parenteral lipid administration (SO, soybean oil; 
FO, fish oil) for 1 h on three consecutive days to healthy humans (n=8) on the unstimulated and PMA- or serum 
treated zymosan (STZ)-induced overall oxygen radical production (area under the curve after 60 minutes), as 
measured with luminol-enhanced chemiluminescence, in isolated neutrophils and whole blood cells. Data are 
presented as means ± SEM. No significant differences in (or trends to) short- or long term treatment effect 
(ratio of T=4/T=0 or T=11/T=0) among treatments were observed (P ≤0.05, Friedman’s test).  
Table 8.6: PMa- or sTZ-induced oxygen radical production peak time before and after lipid 
or saline infusion.
PMa sTZ
T=4/T=0   T=11/T=0 T=4/T=0 T=11/T=0  
Isolated cells
Saline 1.04 ± 0.07 0.93 ± 0.03 0.97 ± 0.06 0.96 ± 0.05
SO 0.96 ± 0.08 1.01 ± 0.08 0.91 ± 0.04 0.97 ± 0.04
FO 0.93 ± 0.03 1.03 ± 0.06 0.90 ± 0.05 0.97 ± 0.07
Whole blood cells
Saline 0.99 ± 0.02 0.91 ± 0.03 1.04 ± 0.02 0.92 ± 0.06
SO 0.98 ± 0.03 1.02 ± 0.04 1.00 ± 0.03 1.04 ± 0.04
FO 0.98 ± 0.05 1.00 ± 0.03 1.08 ± 0.06 1.10 ± 0.03
Early (ratio T=4/T=0) and late (T=11/T=0) effects of i.v. saline or parenteral lipid (SO, soybean oil; FO, fish oil) 
administration for 1 h on three consecutive days to healthy humans (n=8) on the unstimulated and PMA- or 
serum treated zymosan (STZ)-induced chemiluminescence (oxygen radical production) peak time in isolated 
neutrophils and whole blood cells. Data are presented as means ± SEM. No significant differences in (or trends 
to) short- or long term treatment effect (ratio of T=4/T=0 or T=11/T=0) among treatments were observed (P 
≤0.05, Friedman’s test).
e l I M I N aT I o N o F  S T R E P TO C O C C U S P N E U M O N I AE  BY  N e U T R o P H I l s
The elimination of Streptococcus pneumoniae by isolated neutrophils depended on the 
used IgG dilution; when using IgG dilutions lower than 1:80, all bacteria were eliminated 
whereas the elimination capacity decreased with increasing IgG dilutions, reaching a 
plateau of ‘basal elimination capacity’ at IgG dilutions higher than 1:40960 (Figure 8.4). 
Intravenous administration of parenteral lipids or lipid free control did not significantly 
affect the pneumococcal elimination capacity of neutrophils.
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Figure 8.4: Relative elimination of Streptococcus pneumoniae strain OREP-4 by neutrophils 
before (T=0 (solid line)) and after (T=4 days (broken line) and T=11 days (dotted line)) i.v. saline or 
parenteral lipid (SO, soybean oil; FO, fish oil) administration for 1 h on three consecutive days to 
healthy humans (n=8).  Data are expressed as percentage elimination relative to bacterial CFU 
count in samples without neutrophils and presented as means ± SEM.  No significant differences 
in (or trends to) short- or long term treatment effect (i.e. the ratio of T=4/T=0 or T=11/T=0) 
among treatments were observed (P ≤0.05, Friedman’s test). 
ox I DaT I V e  s T R e s s
Results on antioxidant levels in blood (Vitamins C and E and selenium in plasma and 
glutathione levels in whole blood), total antioxidant capacity of plasma (FRAP-assay) 
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and oxidative damage, measured as lipid peroxidation (evaluated as plasma TBARS 
concentration) and protein oxidation (plasma carbonyl concentrations) are presented in 
Table 8.7. Vitamin E concentrations were significantly increased at T=4 after both SO and 
FO infusion and tended to remain increased at T=11 after SO infusion. This SO-induced 
late effect and FO-induced early effect was significantly higher when compared with 
saline infusion (Table 8.7). Between SO and FO, no differences in vitamin E concentrations 
were observed. There were no other differences between groups. 
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In all subjects, urea, creatinine, sodium, potassium, liver enzymes, total bilirubin, 
lactate dehydrogenase and C-reactive protein were within normal ranges and remained 
unaffected after either saline or lipid infusion on T=4 or T=11 (data not shown).
DIsCUssIoN
The main findings of our investigation are that a repeated, brief infusion of pure FO and SO 
emulsions produces a long-term modulation of n-3 and n-6 PUFA proportions in plasma 
phospholipids and PBMCs in healthy humans that reflects the composition of the lipid 
formulation, and does so in a safe and well-tolerated manner. Our data show that FO 
significantly increases plasma phospholipid n-3 PUFAs, mainly EPA, DPA and DHA, up to 
8 days after the last infusion. These changes in plasma are reflected in higher n-3 PUFA 
proportions in PBMCs. It is remarkable that the fatty acid composition of immune cells can 
be altered by such short exposure to n-3 PUFAs while, in contrast, oral exposure requires 
several days to weeks before relevant changes are detectable [28, 29]. This difference 
is probably due to the 100% bioavailability upon intravenous infusion. Frequently, a 
decrease in the proportion of AA together with the increase of the n-3 PUFAs, EPA and 
DHA with FO infusion is described [30-33], whereas in our study the proportion of AA 
in PBMCs remained unchanged. The latter might be explained by the presence of AA in 
Omegaven® 10%. Eight days after the last infusion (T=11) the proportion of EPA, but not 
DHA, in plasma phospholipids and PBMCs had nearly returned to baseline. The slower 
disappearance of DHA after discontinuation of (oral) FO administration has been observed 
before [34, 35]. This retention of DHA suggests a different metabolism or turnover rate of 
DHA compared to EPA. That the proportion of DPA remained elevated at T=11 might be 
explained by conversion between EPA and DPA. 
In addition to increased n-3 PUFA proportions, decreased n-6 PUFAs (mainly linoleic acid 
and dihomo-γ-linolenic acid) were observed in plasma PC after FO infusion, whereas the 
proportion of AA did not decrease. In accordance with a study of Mayer et al. [36], in 
fact, a tendency to increased AA proportions on T=4 compared to T=0 was observed after 
infusion of FO. Carpentier et al.[37] recently reported a significant increment in n-3 PUFAs, 
mainly EPA, in blood cells early after a single fast intravenous injection (50 ml in 5 min) of a 
novel 20% (wt/vol) MCT:FO (80:20; vol/vol) emulsion in humans. Such bolus infusion might 
indeed be feasible in (sub)acute situations, such as prior to revascularization procedures 
in patients with myocardial ischemia. The absolute amount of n-3 PUFAs (2 g of FO total) 
that was administered was however low in comparison to our study (42 g of FO over 3 
days in a 70 kg person) and the modulation of n-3 PUFAs in cell membranes was moderate 
and lasted for no longer than 24-48 h.
Our infusion protocol holds promise to further explore lipid effects in various clinical 
settings with a perturbed immune function. In surgical patients, FO infusion has been 
shown to be safe [7] and possible improvements in immune function and reduced 
inflammatory response [11] have been observed and linked to clinical outcome measures 
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[5-7]. Beneficial effects were, however, mainly observed when n-3 PUFAs administration 
started preoperatively [5], indicating that the composition of cellular membranes before 
the initiation of inflammation is crucial. Studies on FO use in patients with abdominal 
sepsis showed lower infection rates and shorter ICU stay after FO infusion (0.05 g/
kg). In addition, mortality rates were decreased when higher amounts (>1 g/kg) were 
administered [4]. 
Simplified, sepsis starts with a hyperinflammatory phase followed by immune suppression. 
The early administration of SO may augment this hyperinflammatory state resulting in 
clinical deterioration of the patient whereas early FO infusion would be beneficial. A 
recent study of Barbosa et al. [8] indeed showed that a 5-day continuous administration 
of SO/MCT/FO in comparison with SO/MCT to patients with systemic inflammatory 
response syndrome and sepsis results in a faster reduction of plasma IL-6 levels, improved 
oxygenation parameters and a trend towards a shorter hospital stay, whereas another 
well-powered trial by Friesecke et al. [38] found no benefits of FO infusion in critically ill 
patients. Friesecke et al., however, initiated the lipid infusion after the initial inflammatory 
process was terminated, while Barbosa and coworkers started the infusions earlier 
on at a point where patients had a higher risk of mortality and higher IL-6 levels. This 
again supports the hypothesis that the timing of FO supplementation initiation is of key 
importance. 
The mechanisms underlying any effects of FO supplementation have as yet not been 
elucidated. Although we found clear modulations of plasma phospholipid and PBMC fatty 
acid composition, no effects of FO infusion on leukocyte functions or (anti)oxidant balance 
were observed except for higher vitamin E levels after both lipid emulsion infusions. The 
latter was expected since both emulsions are enriched with vitamin E. In contrast to 
our results, Mayer et al. [36] showed decrements of LPS-induced TNF-α, IL-1, IL-6 and 
IL-8 production by monocytes after FO infusion, whereas SO tended to decrease TNF-α 
production. In our investigation, effects on LPS-induced PGE
2
 production appeared not 
different between groups. This is in contrast with a study of Rees et al. who observed 
a decreased LPS-induced PGE
2
 production after oral FO supplementation to healthy 
volunteers [39]. Guarini et al. [29] showed that although EPA and DHA proportions in 
neutrophils increased after 2 weeks of oral FO supplementation to healthy volunteers, 
neutrophil functions were not affected. The absence of a hyperinflammatory state, which 
is usually present after surgery or trauma or in patients with sepsis, is the most probable 
explanation for the lack of effect on immune function of FO in these healthy subjects. 
In conclusion, the parenteral lipid infusion protocol used in this study induces a prolonged 
modulation of plasma and cell membrane phospholipid compositions and seems a feasible 
tool to study parenteral lipid effects in a wide range of clinical situations. 
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sUMMaRY aND DIsCUssIoN
As outlined in chapter 1, this thesis focuses on complications related to the use of 
(total) parenteral nutrition (TPN) in the home setting (Home Parenteral Nutrition). 
Overall, these complications mainly comprise (1) problems related to the presence of a 
central venous access device and (2) infections related to impaired immune functions 
that have previously been attributed to the lipid component of TPN formulations. The 
use of a central venous catheter (CVC), such as a subcutaneously tunneled catheter or 
subcutaneous port, has been shown to be an independent risk factor for the occurrence 
of several types of infections. In decreasing order of frequency these include bloodstream 
infections, infections of the catheter exit site and infections of the subcutaneous tunnel 
tract. Of these, especially catheter-related bloodstream infections can be life-threatening 
and put a serious strain on both the patients quality of life as well as hospitals’ resources. 
In addition, there is evidence to suggest that, apart from catheter-related problems, also 
nutritional components, mainly lipids, affect the human immune defense system and may 
therefore contribute to the high infection rate observed in TPN patients. The investigations 
in this thesis therefore aimed to cover both these aspects. First, the feasibility of surgically 
created arteriovenous fistulae (AVFs) as an alternative vascular access for CVCs in patients 
using long-term HPN was evaluated. Second, the immune modulating properties of both 
novel as well as more traditionally used lipid emulsions were studied in detail. 
a R T e R I oV e N o U s F I s T U l a e a s  Va s C U l a R aC C e s s
From the start of our home parenteral nutrition (HPN) program on, in the early 1970’s, 
our centre has used surgically created AVFs on a regular basis, whereas worldwide mainly 
CVCs (mostly subcutaneously tunneled catheters and less frequently subcutaneous ports) 
are used to obtain vascular access. In chapter 2, a patient is presented who has been 
using HPN for more than 37 years at this moment with an excellent quality of life. After 
repeated serious CVC-related complications in the early ‘70s, she has eventually continued 
HPN uneventfully by means of an AVF. Based on this patient and on our general idea 
that complication rates might be lower during AVF than during CVC use, we performed 
a comprehensive retrospective analysis of all our data on survival and complications 
of CVCs and AVFs, which is described in chapter 3. We included 127 consecutive long-
term HPN patients, in whom 716 CVCs and 120 AVFs were created. Of the 120 AVFs, 63% 
became functional (6 failed during creation, 39 failed during maturation, mainly due to 
occlusions). After exclusion of accesses with missing data, 623 CVCs (343 catheter years) 
and 62 AVFs (194 access years) were analyzed. It was shown that in this long-term HPN 
population the occlusion incidence rate was slightly higher in AVFs compared with certain 
types of CVCs. The incidence rate of the most important HPN related complication, i.e. 
blood stream infections, however, was extremely low in AVFs compared with all types 
of CVCs. These results suggest that AVFs are safe and valuable alternatives for CVCs in 
patients in whom (life-)long-term dependency on HPN can be expected. In this respect, 
it is important to realize that multiple catheter (re)placements may result in vascular 
damaging, which compromises the possibilities to obtain central venous access and might 
in the end necessitate small bowel transplantation. 
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Within the limitations of any retrospective study, the presented data in this thesis suggest 
that AVFs can provide a (very) long-term vascular access in HPN patients. Although this 
remains to be proven, the success rate of AVFs might possibly even further be increased 
by only using autologeous grafts and in case AVFs are considered at an earlier stage in 
HPN treatment, i.e. prior to multiple CVC insertions that compromise the options for 
successful AVF creation.
I M M U N e M o D U l aT I o N BY  Pa R e N T e R a l  l I P I D s
As mentioned in chapter 1, results on the immune modulating effects of parenteral 
lipids have so far been very disparate, most probably as a result of widely varying clinical 
conditions, medication use and experimental settings. In this thesis the immune modulating 
properties of structurally different, novel as well as more commonly used parenteral lipid 
emulsions in both the in vitro and the in vivo/ex vivo setting were evaluated. To rule out 
underlying diseases that invariably influence immune function, the investigations were 
performed in a more homogeneous population of healthy subjects.
In vitro studies 
Previous in vitro studies performed at our department have already shown that the 
function of the human immune system indeed can be modulated by parenteral lipid 
emulsions. In this respect, the structure and more specifically the carbon-chain length 
of the fatty acids in the triglycerides appeared to be of key importance. It seemed that 
medium-chain triglyceride (MCT) containing lipid emulsions, in contrast to pure long-chain 
triglyceride (LCT) containing emulsions or ‘structured lipids’ (SL) activate neutrophils and 
induce leukocyte function impairment. MCTs were shown to increase the production of 
reactive oxygen species, sensitize neutrophils for stimulus-induced intracellular calcium 
signaling and increase the expression of relevant cell membrane activation markers on 
leucocytes. Also, MCT’s impair leukocyte migration and the capacity of neuthrophils to 
kill Candida albicans. 
These previous studies were mainly performed on leukocytes that were isolated from whole 
blood and next incubated with lipids. Isolation procedures, however, are likely to introduce 
functional changes, especially pre-activation, or ‘priming’. In chapter 4 we describe a 
study where we performed a phenotypic analysis of the expression of membrane surface 
activation markers (CD11b, CD66b, CD62L) on neutrophils and monocytes incubated with 
structurally different lipids in whole blood of healthy volunteers, i.e. without previous 
cell isolation. In addition to the more commonly used emulsions based on pure LCT or 
mixed LCT/MCT, emulsions based on olive- (containing long chain triglycerides with mono 
unsaturated fatty acids(LCT-MUFA)) and fish oil (containing very long chain triglycerides 
(VLCT)) were included in this analysis. In accordance with the previous observations in 
isolated neutrophils, cell membrane markers changed in a way that was compatible with 
cell activation (increased CD11b and CD66b expression and decreased CD62L expression) 
after exposure of whole blood neutrophils and monocytes to MCT-containing emulsions. 
In clear contrast with the effects of LCT/MCT, LCT and VLCT decreased the expression of 
CD11b and CD66b on neutrophils, with increased expression of CD62L, while LCT-MUFA 
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and SL only increased CD62L. The observation that other emulsions containing pure LCTs, 
SL, LCT-MUFA or VLCT did no activate leukocytes indicates that these effects are MCT-
specific and not due to lipid per se or caused by other emulsion components. 
In chapter 5, phagocyte function, represented by the capacity of human neutrophils to 
eliminate Streptococcus pneumoniae, in the presence of different parenteral lipids was 
assessed. It was demonstrated that all parenteral lipid emulsions that were investigated 
(pure MCTs, LCT/MCTs, pure LCTs, SL, LCT-MUFA and VLCT) negatively affect the bacterial 
elimination capacity of neutrophils and that this effect is dependent on the triglyceride 
structure of the lipid emulsion. By far the strongest effect was observed after incubation 
with emulsions containing MCTs, such as pure MCT’s or a mixture of LCT/MCTs. In 
accordance with our previous work in this field, the neutrophil modulating effect of LCT/
MCT was lipid-dose dependent within a (clinically relevant) concentration range of 1-10 
mmol/L.
The concomitant in vitro effect on cell activation and cell function impairment by MCTs 
might be caused by a lipid-induced exhaustion of the neutrophil cellular metabolism 
due to a lipid-induced, continuous, and therefore probably inadequate, cell activation. 
As outlined in chapter 1, the use of pure LCTs, which contain high amounts of n-6 
PUFAs, is believed not to be optimal and might even be harmful based on the idea that 
incorporation into cell membranes and subsequent intracellular metabolism of n-6 PUFAs 
leads to a predominantly pro-inflammatory immune response in line with the actions of 
the involved eicosanoids that are mainly derived from arachidonic acid. It has to be kept 
in mind here that MCTs were initially added to LCT emulsions in order to decrease the 
amount of pro-inflammatory n-6 PUFAs (mainly linoleic acid) that was considered to be 
detrimental. In this respect, it is remarkable that LCT/MCT seems to be the most potent 
leukocyte activator in all of our in vitro studies. The observed upregulation of CD11b and 
CD66b expression occurred within 15 minutes after the exposure of leukocytes to MCTs, 
suggesting that mechanisms other than lipid membrane incorporation also play a role 
here. Since it was recently shown that the (previously) orphan Pertussis Toxin(PT)-sensitive 
G-protein coupled receptor (GPCR), GPR84, has medium-chain fatty acids as its ligand, in 
chapter 6, the involvement of such a PT-sensitive GPCR in the MCT-induced neutrophil 
activation in vitro was investigated. Pre-incubation of neutrophils of healthy volunteers 
with PT did however not inhibit the activation of neutrophils by MCTs indicating that 
the cellular activation by MCTs is not mediated by a PT-sensitive GPCR. MCTs have been 
shown to mimic the effects of activators of protein kinase C (PKC). Alternative pathways 
including PT-insensitive receptors or downstream activation mechanisms of PKCs might 
therefore be involved in the in vitro MCT effects on neutrophil activation. 
In / ex vivo studies 
Inspired by the consistent MCT effects in all investigated aspects of neutrophil activation 
and function in vitro, a randomized placebo-controlled crossover study in human healthy 
volunteers exploring the effects of intravenous administration of a LCT/MCT based 
emulsion versus a pure LCT based emulsion on leukocyte function was performed 
(chapter 7). Sparse data from literature indicated that LCT/MCT infusion, in contrast to in 
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vitro exposition, did not affect human leukocyte functions. Based on our in vitro finding 
that neutrophil exposition to MCTs results in increased adhesion molecule expression on 
neutrophil cellular membranes, it was hypothesized that in the in vivo setting activated 
neutrophils might be ‘sequestrated’ due to capillary adhesion and extravascular migration, 
and thus might disappear from the venous blood pool. As a consequence, evaluation of 
lipid-induced neutrophil modulation in leukocytes obtained from peripheral blood might 
result in false negative findings due to blood sampling error. The occurrence of leukocyte 
sequestration was evaluated by in vivo monitoring of the distribution of autologous Tc-
99m-HMPAO-labeled leukocytes during saline or lipid infusions. It was shown that there 
are no indications for significant modulation of neutrophil functions and -activation 
during short-term infusion of LCT and LCT/MCT emulsions in human healthy volunteers. 
Furthermore, the clearance of radio-labeled leukocytes from pulmonary, hepatic and 
splenic circulations was not delayed during any infusion. This observation makes it 
unlikely that the observed discrepancies between results of in vitro versus in vivo study 
designs is explained by lipid-induced leukocyte activation and subsequent sequestration. 
Other explanations to be considered in the design of future studies include the possibility 
that, in vivo, the plasma concentrations of MCT are too low to exert the neutrophil 
activating effects that were observed in vitro due to rapid MCT clearance from the plasma. 
Furthermore, in vivo the plasma may contain components that inhibit or neutralize any 
immune modulating effects of MCT. 
In the past two decades, lipid emulsions based on fish oil (FO) have been developed. 
The high amount of n-3 PUFAs in FO has been shown beneficial effects in the onset and 
treatment of cardiovascular disease and cancer cachexia. Several studies have shown a 
clinical benefit of the inclusion of FO in parenteral nutrition in different clinical settings 
such as septic and gastrointestinal surgical patients (chapter 1). The mechanisms behind 
these biological effects of FO have not become completely clear so far. To this end, we 
designed an infusion protocol in which parenteral lipid emulsions were administered 
during 1 h (0.2 g/Kg BW) to healthy volunteers on three consecutive days. After a wash out 
period of three weeks the infusion was repeated with the other lipid emulsion or saline 
(randomized cross-over design). This repeated but brief infusion of pure FO (containing 
very long chain triglycerides, VLCT) and soybean oil (LCT) emulsions produces a long-term 
modulation of n-3 and n-6 PUFA proportions in plasma phospholipids and peripheral 
blood mononuclear cells that reflects the composition of the lipid formulation, and, most 
importantly, does so in a safe and well-tolerated manner (chapter 8). No effects of VLCT 
or LCT infusion on leukocyte functions or (anti-)oxidant balance were observed except 
for higher vitamin E levels after both lipid emulsion infusions, which was expected since 
both emulsions contain vitamin E. The absence of a hyperinflammatory state, which is 
usually present after surgery or trauma or in patients with sepsis and might be diminished 
by n-3 PUFAs, is the most probable explanation for the lack of effect on immune function 
of FO in these healthy subjects. The results of both these in vivo studies underscore 
that the observed lipid effects depend on the experimental setting, thus precluding any 
generalizations. Nevertheless, the infusion protocol presented in chapter 8 provides a 
feasible tool to study the effect of intravenous lipids on cell functions in various clinical 
situations with an imbalanced immune system. 
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CoNClUsIoNs
The studies presented in this thesis reveal that AVFs are a safe and well tolerated alternative 
to CVCs for long-term parenteral nutrition administration and that AVFs dramatically 
reduce the occurrence of blood stream infections. The timing of AVF creation, i.e. prior to 
vascular damage by repeated CVC insertion, in our opinion is of key importance.
With regard to the effects of parenteral lipids on the human immune system it appears that 
various parenteral lipid formulations distinctly affect the functions of human leukocytes 
in vitro depending on their triglyceride structure. MCT containing emulsions are by far the 
most potent in this respect. The MCT effects on neutrophil activation are not mediated by 
a pertussis toxin sensitive G-protein coupled receptor. Intravenous administration of MCTs 
to healthy humans does not mimic the effects that are observed in vitro. The absence of 
(measurable) neutrophil activation in vivo can not be attributed to lipid-induced leukocyte 
activation and subsequent cellular sequestration leading to blood sample error. These 
conflicting results underscore the need for a cautious interpretation of any observations 
made in vitro. The contradiction between clinical benefits of FO infusion in patients with a 
compromised immune system and the seemingly absent modulation of immune function 
in healthy subjects presented here emphasizes the need for well-powered clinical studies 
in clearly defined patient populations. In the future, further unraveling of the mechanisms 
behind the biological effects of parenteral lipids should result in the development of 
patient-tailored nutrition regimens. The lipid infusion protocol presented in chapter 8 of 
this thesis seems a feasible tool to be used in such studies.
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saMeNVaTTINg eN DIsCUssIe
Zoals uiteengezet in Hoofdstuk 1, gaat dit proefschrift over complicaties gerelateerd aan 
het gebruik van totaal parenterale voeding (TPV) in de thuissituatie (thuis TPV). Het betreft 
dan voornamelijk (1) problemen die gerelateerd zijn aan de aanwezigheid van een toegang 
tot de centraal veneuze bloedbaan en (2) infecties gerelateerd aan een verminderde functie 
van het afweersysteem, die eerder werden toegeschreven aan de lipidencomponent van 
TPV. Het gebruik van een centraal veneuze catheter (CVC, zoals een subcutaan getunnelde 
katheter of een katheter met een subcutane poort) blijkt een onafhankelijke risicofactor 
te zijn voor het ontstaan van verschillende kathetergerelateerde infecties. In aflopende 
frequentie betreft dit bloedbaaninfecties, infecties van de katheterinsteekopening en 
infecties van de subcutane katheter ‘tunnel’. Hiervan zijn vooral de bloedbaaninfecties 
levensbedreigend. Deze hebben dan ook een grote impact op de kwaliteit van leven 
van de patiënt en op de benodigde medische zorg en daaraan gerelateerde kosten. Ook 
zijn er aanwijzingen dat bestanddelen van de parenterale voeding, en dan vooral vetten, 
een negatief effect hebben op het menselijke afweersysteem en daardoor mogelijk 
bijdragen aan het hoge infectierisico bij TPV patiënten. De onderzoeken in dit proefschrift 
zijn daarom op deze twee aspecten gericht. Ten eerste werd de geschiktheid van een 
arterioveneuze fistel of ‘shunt’ als alternatief voor de CVC bij patiënten die langdurig thuis-
TPV gebruiken onderzocht. Ten tweede werden de immuunmodulerende eigenschappen 
van zowel nieuwere als ook meer klassieke vetemulsies nader onderzocht.
s H U N T s a l s  Va s C U l a I R e  T o eg a N g
Vanaf het begin van de behandeling met thuis TPV door het UMCN in de vroege 70er-jaren 
werden er regelmatig shunts als vasculaire toegang aangelegd. Wereldwijd worden er echter 
met name CVC’s (vooral subcutaan getunnelde katheters en in mindere mate subcutane 
poorten) gebruikt. In hoofdstuk 2 wordt een patiënte beschreven die al meer dan 37 jaar 
thuis-TPV gebruikt en een opvallend goede kwaliteit van leven heeft. Na herhaaldelijke 
ernstige CVC-gerelateerde complicaties begin jaren ’70, heeft ze uiteindelijk het gebruik 
van thuis-TPV zonder problemen kunnen voortzetten middels een shunt. Naar aanleiding 
van deze patiënt en gebaseerd op onze algemene indruk dat complicatie-aantallen lager 
zijn met een shunt dan met een CVC hebben we een uitgebreide retrospectieve analyse 
van ons TPV-cohort verricht. We hebben de complicaties van shunts en CVC’s tegen elkaar 
afgezet en de resultaten staan beschreven in hoofdstuk 3. Er werden 127 opeenvolgende 
patiënten geïncludeerd die langdurig thuis-TPV gebruikten. Bij hen werden 716 CVC’s 
en 120 shunts aangelegd. Van deze 120 shunts, kon uiteindelijk 63% gebruikt worden (6 
mislukten tijdens de aanleg, 39 ‘rijpten’ niet goed, dit was vooral te wijten aan occlusies). 
Na exclusie van de veneuze toegangen met ontbrekende gegevens, werden 623 CVC’s 
(343 katheterjaren) en 62 shunts (194 shuntjaren) onderzocht. We vonden dat in deze 
‘langdurig thuis-TPV populatie’ de incidentie van occlusies gering hoger was met shunts 
in vergelijking met CVC’s. De incidentie van de belangrijkste thuis-TPV-gerelateerde 
complicatie, de bloedbaaninfectie, was echter zeer laag tijdens het gebruik van een 
shunt in vergelijking met alle onderzochte typen CVC’s. Deze resultaten wijzen erop dat 
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shunts een veilig en waardevol alternatief zijn voor CVC’s bij patiënten bij wie (levens-) 
lange afhankelijkheid van thuis-TPV verwacht kan worden. Daarbij is ook van belang dat 
men zich realiseert dat veelvuldige katheter (her)plaatsing kan resulteren in vaatschade 
waardoor de toegangsmogelijkheden tot het veneuze vaatbed sterk beperkt kunnen 
worden. Dit kan uiteindelijk leiden tot een indicatie voor dunne darmtransplantatie.
Ondanks de beperkingen van een retrospectief onderzoek, wijzen onze resultaten erop 
dat shunts als zeer duurzame veneuze toegang kunnen dienen bij thuis-TPV patiënten. 
Daarbij is onze verwachting dat het succespercentage van shunts nog verder verhoogd 
kan worden als slechts autologe (lichaamseigen) ‘grafts’ gebruikt worden. Bovendien 
adviseren wij dat de aanleg van een shunt vroeg in het thuis-TPV traject overwogen 
wordt, voordat herhaaldelijke CVC-plaatsingen vaatschade hebben aangericht die de 
mogelijkheden van shuntaanleg beperken.
I M M U U N M o D U l aT I e  D o o R Pa R e N T e R a l e  V e T T e N
Zoals beschreven in hoofdstuk 1, zijn de gegevens uit de literatuur betreffende de 
immuunmodulerende effecten van parenterale vetten tot dusverre erg tegenstrijdig. Dit 
is waarschijnlijk voornamelijk te wijten aan de grote heterogeniteit aan klinische situaties, 
medicatiegebruik en experimentele opzetten van de verschillende onderzoeken. In dit 
proefschrift, werden de immuunmodulerende eigenschappen van zowel nieuwere als 
meer traditionele parenterale vetemulsies in vitro en ook in vivo/ex vivo onderzocht. Om 
het effect van een onderliggende aandoening uit te sluiten werden de onderzoeken in 
een meer homogene populatie van gezonde vrijwilligers uitgevoerd.
In vitro onderzoeken
Eerder in vitro-onderzoek op onze afdeling toonde aan dat de functie van het menselijke 
afweersysteem gemoduleerd kan worden door blootstelling aan parenterale vetemulsies. 
Hierbij is de structuur, en dan voornamelijk de koolstofketenlengte van de vetzuren in 
het triglyceridemolekuul, grotendeels bepalend. Gebleken is dat middellange-keten 
triglyceriden (medium chain triglycerides; MCT’s) bevattende emulsies, in tegenstelling 
tot lange-keten triglyceriden (long chain triglycerides; LCT’s) bevattende emulsies of 
‘structured lipids’ (SL), neutrofielen activeren en de functie van leukocyten verminderen. 
MCT’s verhogen de productie van zuurstofradicalen, de gevoeligheid van neutrofielen 
voor stimulus-geïnduceerde intracellulaire calcium-signalering en de expressie van 
relevante activatiemarkers op leukocyten. Daarnaast remmen MCT’s de migratie van 
leukocyten alsmede de capaciteit van neutrofielen om Candida albicans te doden. 
In deze eerdere onderzoeken werden leukocyten geïsoleerd uit volbloed gebruikt die 
vervolgens geïncubeerd werden met de vetten. Isolatieprocedures kunnen echter 
resulteren in functionele veranderingen zoals bijvoorbeeld pre-activatie of ‘priming’. 
In hoofdstuk 4 beschrijven we een fenotypische analyse van membraanoppervlakte-
activatiemarkers (CD11b, CD66b, CD62L) in neutrofielen en monocyten uit volbloed van 
gezonde vrijwilligers. Deze cellen werden blootgesteld aan een reeks van structureel 
verschillende vetten. Naast de klassieke vetemulsies op basis van pure LCT’s of een 
mengsel van LCT/MCT, werden ook emulsies op basis van olijfolie (welke enkelvoudig 
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onverzadigde vetten bevatten (LCT-MUFA)) en visolie (welke zeer lange keten triglyceriden 
bevatten (very long chain triglycerides; VLCT’s)) in deze studie gebruikt. Net als in de 
eerdere onderzoeken met geïsoleerde leukocyten, waren er tekenen van celactivatie 
met verhoogde expressie van CC11b en CD66b en verlaagde expressie van CD62L. In 
tegenstelling tot de LCT/MCT effecten, resulteerde blootstelling aan LCT of VLCT in een 
verlaagde CD11b en CD66b expressie en juist een verhoogde expressie van CD62L. LCT-
MUFA en SL verlaagden alleen de CD62L expressie maar veranderden de expressie van 
CC11b en CD66b niet. De observatie dat andere emulsies, die pure LCT’s, SL, LCT-MUFA 
of VLCT bevatten, geen leukocytenactivatie induceren wijst er op dat deze effecten MCT-
specifiek zijn en niet veroorzaakt worden door de aanwezigheid van vetten op zich of door 
andere emulsiecomponenten. 
In hoofdstuk 5, werd de capaciteit van humane neutrofielen om Streptococcus pneumoniae 
te elimineren in de aanwezigheid van verschillende parenterale vetten bepaald. Deze 
studie toonde aan dat alle onderzochte vetemulsies (pure MCT’s, LCT/MCT’s, pure LCT’s, 
SL, LCT-MUFA en VLCT) de potentie van neutrofielen om bacteriën te elimineren verlagen. 
Dit effect bleek afhankelijk van de triglyceridestructuur van de vetemulsie. Het effect was 
veruit het grootste na incubatie met MCT-bevattende emulsies, zoals pure MCT’s of een 
mengsel van LCT/MCT’s. Conform eerdere onderzoeken, bleek dit neutrofiel-modulerende 
effect van LCT/MCT’s afhankelijk van de gebruikte vetconcentratie. Wij hebben een 
klinisch relevante concentratierange van 1-10 mmol/L getest. Het stimulerend effect op 
celactivatie maar daarbij remmend effect op de celfunctie wordt mogelijk veroorzaakt 
door een MCT-geïnduceerde continue en daardoor mogelijk inadequate celactivatie 
welke leidt tot uitputting van het cellulaire metabolisme van de neutrofiel. 
Zoals beschreven in hoofdstuk 1, wordt het gebruik van LCT-emulsies, die grote 
hoeveelheden n-6 meervoudig onverzadigde vetzuren (polyunsaturated fatty acids; 
PUFA’s) bevatten, als suboptimaal beschouwd. Dit idee is gebaseerd op het principe dat 
inbouw van n-6 PUFA’s in celmembranen en de daaropvolgende intracellulaire afbraak 
resulteert in een pro-inflammatoire immunologische respons overeenkomend met 
de effecten van de betrokken eicosanoïden die met name uit arachidonzuur gevormd 
worden. Zoals eerder aangestipt werden de MCT’s oorspronkelijk aan LCT-emulsies 
toegevoegd om de hoeveelheid pro-inflammatoire n-6 PUFA’s (vooral linolzuur) (die als 
potentieel schadelijk beschouwd werden) te verminderen. In dit kader is het opvallend 
dat LCT/MCT in al onze in vitro onderzoeken de meest potente leukocytenactivator blijkt 
te zijn. De geobserveerde toename van CD11b en CD66b expressie trad reeds binnen 
15 minuten na blootstelling van de leukocyten aan MCT’s op. Dit wijst erop dat andere 
mechanismen dan vetzuurincorporatie in de celmembranen hierbij een rol spelen. Omdat 
het recent is aangetoond dat een pertussis toxine (PT)-gevoelige G-eiwit gekoppelde 
receptor (GPCR), de GPR84, middellangeketenvetzuren als ligand heeft, hebben we in 
hoofdstuk 6 de betrokkenheid van een PT-gevoelige GPCR in de MCT-afhankelijke in vitro 
neutrofielactivatie onderzocht. Pre-incubatie van neutrofielen van gezonde vrijwilligers 
met PT resulteerde echter niet in remming van de neutrofielactivatie door MCT’s. Dit 
wijst er op dat de cellulaire activatie door MCT’s niet gemedieerd wordt door een PT-
gevoelige GPCR. MCT’s blijken de effecten van proteïne kinase C (PKC) activatoren 
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na te bootsen. Alternatieve werkingsmechanismen via PT-ongevoelige receptoren of 
celactivatiemechanismen ‘downstream’ van PKC zijn derhalve mogelijk betrokken bij de 
in vitro MCT-afhankelijke effecten op neutrofielactivatie.
In / ex vivo onderzoeken
Geïnspireerd door de consistente MCT-effecten in alle door ons onderzochte aspecten 
van neutrofielfuncties en -activatie in vitro, hebben de stap naar het menselijke model 
gemaakt. In een gerandomiseerde placebogecontroleerde cross-over studie hebben we 
de effecten van intraveneuze toediening van een LCT/MCT-emulsie versus een pure LCT-
emulsie op leukocyten functies van gezonde vrijwilligers onderzocht (hoofdstuk 7). Er 
was literatuur voorhanden die erop wees dat LCT/MCT-infusie, in tegenstelling tot in vitro 
blootstelling, geen effect had op humane leukocytenfuncties. Gebaseerd op onze in vitro 
bevinding dat blootstelling van neutrofielen aan MCTs resulteert in verhoogde expressie 
van adhesiemoleculen op de celmembraan van neutrofielen, onderzochten wij de 
hypothese dat in vivo de geactiveerde leukocyten door adhesie aan de capillaire vaatwand 
en daaropvolgende extravasculaire migratie uit de circulerende bloodpool verdwijnen 
(‘sequestratie’) en daardoor ontbreken in de bloedmonsters die middels venapunctie 
bij de gezonde vrijwilligers genomen worden. Het meten van leukocytenactivatie in 
deze bloedmonsters zal hierdoor tot vals negatieve resultaten leiden. Het optreden van 
leukocytensequestratie werd bepaald door in vivo meting van de verdeling van autologe 
met Tc-99m-HMPAO gelabelde leukocyten tijdens intraveneuze infusie van fysiologisch 
zout of vetemulsies. Er bleken geen aanwijzingen te zijn voor significante veranderingen 
van neutrofielfuncties of –activatie tijdens kortdurende intraveneuze infusie van LCT en 
LCT/MCT-emulsies in gezonde vrijwilligers. Ook bleek de klaring van radioactief-gelabelde 
leukocyten uit de longen, lever en milt onafhankelijk te zijn van de verschillende soorten 
vetinfusies. Het is dus onwaarschijnlijk dat de gevonden verschillen tussen in vivo en 
in vitro resultaten verklaard worden door leukocytenactivatie en daaropvolgende 
leukocytensequestratie. Een andere verklaring is de mogelijkheid dat in vivo de MCT’s 
heel snel uit het plasma verdwijnen waardoor de MCT-concentratie in het plasma te laag 
wordt om de neutrofielactiverende effecten te bewerkstelligen die in vitro gezien werden. 
Aan de andere kant is het ook goed denkbaar dat het plasma bepaalde bestanddelen 
bevat die de immuunmodulerende effecten van MCT’s remmen of neutraliseren. 
In de laatste 20 jaar zijn er vetemulsies op basis van visolie ontwikkeld. Visolie is rijk aan 
n-3 PUFAs en dit blijkt gunstig te zijn voor het voorkómen van hart- en vaatziekten en 
voor cachectische kankerpatiënten. Een reeks aan onderzoeken heeft duidelijk gemaakt 
dat de toevoeging van visolie aan parenterale voeding bij patiënten die een grote operatie 
hebben gehad of die een sepsis hebben, over het algemeen gunstig is (hoofdstuk 1). Tot 
op heden is het hoe en waarom visolie zo gunstig is onopgehelderd. Wij ontwikkelden 
daarom een infusieprotocol waarbij parenterale vetemulsies gedurende 1 uur (0.2 g/
Kg lichaamsgewicht) op drie opeenvolgende dagen intraveneus werden toegediend 
aan gezonde vrijwilligers. Na een interval van drie weken werd de infusie herhaald met 
de andere vetemulsie of fysiologisch zout (gerandomiseerde cross-over studie-opzet). 
Deze herhaaldelijke kortdurende infusie van een visolie-emulsie (VLCT) en een soja-olie 
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emulsie (LCT) resulteert in een langdurige modulatie van de n-3 en n-6 PUFA verhouding 
van plasmafosfolipiden en perifeer bloed mononucleaire cellen, welke de samenstelling 
van de vetemulsies weerspiegelt. Deze kortdurende infusie bleek veilig te zijn en werd 
goed verdragen (hoofdstuk 8). Er werd geen effect van VLCT- of LCT-infusie op de 
functies van de leukocyten of het (anti-)oxidantenevenwicht gezien. Wel werd door de 
vetemulsies de vitamine E concentraties verhoogd, niet geheel onlogisch omdat vitamine 
E een bestanddeel is van beide vetemulsies. De afwezigheid van een ‘hyperinflammatoire 
status’, zoals die meestal aanwezig is na een operatie of in patiënten met sepsis en 
die afgezwakt kan worden door n-3 PUFA’s, is de meest plausibele verklaring voor de 
afwezigheid van immuunmodulerende effecten van visolie in deze gezonde vrijwilligers. 
De resultaten van deze beide in vivo onderzoeken benadrukken dat de gevonden effecten 
afhankelijk zijn van de experimentele opzet waardoor deze niet gegeneraliseerd kunnen 
worden. Het infusieprotocol dat in hoofdstuk 8 beschreven wordt, is echter een geschikt 
model om de effecten van parenterale vetemulsies op celfuncties te bestuderen. 
CoNClUsIes
De onderzoeken zoals beschreven in dit proefschrift laten zien dat shunts veilige en goed 
verdraagbare alternatieven zijn voor CVC’s voor patiënten die langdurige parenterale voeding 
moeten (gaan) gebruiken. Het gebruik van een shunt verlaagt het aantal bloedbaaninfecties 
drastisch. Naar onze mening is het erg belangrijk om de shunt tijdig aan te leggen, dat 
wil zeggen voordat er vaatschade door herhaaldelijke CVC plaatsingen zijn opgetreden. 
Met betrekking tot de effecten van parenterale vetten op het afweersysteem hebben we 
aangetoond dat diverse parenterale vetemulsies op een verschillende manier de humane 
leukocytenfuncties beïnvloeden in vitro. Deze effecten zijn afhankelijk van de structuur 
van de triglyceriden, maar MCT bevattende emulsies zijn het meest potent. De effecten 
van MCT’s op neutrofielen blijken niet gemedieerd te worden door een pertussis toxine 
gevoelige G-eiwit gekoppelde receptor. Intraveneuze toediening van MCT’s bij gezonde 
vrijwilligers geeft andere effecten dan dat wij in vitro vonden. Uit onderzoek met gelabelde 
leukocyten is gebleken dat vetinfusie er niet voor zorgt dat geactiveerde leukocyten uit de 
bloedbaan verdwijnen. Dit is dus niet de verklaring voor het feit dat we in vitro wel, maar 
bij infusie van vet in gezonde vrijwilligers geen effect zagen. Deze tegenstrijdige resultaten 
benadrukken dat resultaten uit in vitro onderzoeken niet zomaar geëxtrapoleerd kunnen 
worden naar de situatie in de mens. Het verschil tussen de effecten van visolie bij gezonde 
vrijwilligers en patiënten met een gecompromiteerd immuunsysteem maakt duidelijk 
dat in toekomstig onderzoek selectie van populatie erg belangrijk is. Het is daarbij van 
belang om er achter te komen wat het mechanisme is van de gunstige effecten van visolie. 
Gewapend met deze informatie hopen we dan uiteindelijk met een op de individuele 
patiënt toegesneden voedingsadvies te komen. Het infusieprotocol dat gepresenteerd 
werd in hoofdstuk 8 van dit proefschrift kan daarbij een leidraad zijn. 
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AVF: arteriovenous fistula
BSI: blood stream infection 
CI: confidence interval
CVC: central venous catheter
DAG: diacylglycerol
DHA: docosahexaenoic acid 
DPA: docosapentaenoic acid
EPA: eicosapentanoic acid 
FA: fatty acid
fMLP: N-formyl methionyl-leucyl-phenylalanine
FO: fish oil
HBSS: Hank’s balanced salt solution
HPN: Home parenteral nutrition
LCFA: long chain fatty acid
LCT: long chain triglyceride
MCFA: medium chain fatty acid
MCT: medium chain triglyceride
MUFA: mono-unsaturated fatty acid
OO: olive oil
PAC: Port a Cath
PLC: phospholipase C
PMA: phorbol 12-myristate 13-acetate
PT: pertussis toxin
PUFA: polyunsaturated fatty acid
ROS: reactive oxygen species
SL: structured lipids
STZ: serum-treated zymosan
SO: soybean oil
TPN: Total parenteral nutrition
VLCT: very long chain triglyceride
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Dr. Wanten, mijn copromotor. Beste Geert, toen ik solliciteerde voor de opleiding tot 
MDL-arts vroeg de voormalig opleider, Prof. dr. Jansen, me ook eens met een aantal 
mensen te praten over de onderzoeksprojecten die op de afdeling liepen. Toen ik met jou 
over het TPV-project gesproken had ging ik meteen met een goed gevoel de deur uit. Het 
onderwerp sprak me aan en er was meteen een klik; allebei (medisch) bioloog en arts en… 
allebei noord-Limburger! Als ‘emul(Geert)’ en ‘Micel’ hebben we heel wat vragen rondom 
de effecten van vetten ‘opgelost’!! Je droge humor en relativeringsvermogen hebben 
menig beer op de weg van mijn promotie-onderzoek verjaagd! Je was erg betrokken maar 
liet me vooral ook mijn eigen koers varen. Geert, geweldig bedankt! 
Prof. dr. Drenth, mijn promotor. Beste Joost, toen het onderzoek al vrijwel af was, ben je 
pas mijn promotor geworden. Toch heb je altijd bijzonder veel interesse getoond in de 
voortgang van mijn onderzoek en in mij als persoon. Ik heb dit altijd erg op prijs gesteld, 
dank je wel hiervoor!
Beste Hennie, mijn rechter (en vaak ook linker) hand. In alle experimenten heb je mij 
enorm geholpen….miljoenen bacteriën heb je geteld, liters supernatant afgepipetteerd 
(ook in het weekend!) en kilometers voor me gelopen (naar het LKI en de researchtoren 
en terug, en nog een keer heen…en terug…), niks was je teveel! Super bedankt voor alles 
wat je voor me gedaan hebt en voor dat je mijn paranimf wilt zijn.
Wilbert, Rene, Wim, Annie en Albert, op de eerste dag van mijn onderzoekstijd hebben 
jullie me ingewijd in de wereld van het ‘rikken’. Er ging geen pauze voorbij zonder een 
kaartje te leggen. Ook als we druk aan het schrijven waren werden we opgetrommeld… 
Wilbert belde dan: ‘de hoogste tijd!’. Bedankt voor alle gezelligheid in de net iets te kleine 
koffiekamer en voor alle leuke en leerzame momenten op het lab!
Esmé, Loes en Marloes, mijn kamergenootjes. Wat een gezellige tijd hebben we gehad. 
Samen lachen, samen huilen, samen ‘kappoeshienoeen’, samen planten (vergeten) 
water (te) geven (sorry Esmé..), en samen mandarijnenpartjes tellen. Bedankt voor de 
vakinhoudelijke discussies, de gezelligheid, de steun in moeilijke tijden maar vooral ook 
voor het feit dat jùllie wèl altijd wisten waar Ìk mee bezig was! Esmé, in het bijzonder 
bedankt voor het lay-outen van mijn proefschrift en voor dat je mijn paranimf wilt zijn.
Evelyn Olthof, vol enthousiasme heb je het TPV-stokje van me over genomen. Ik kijk uit 
naar je resultaten.
Hilbert, Melissa, Manoe, Bjorn en alle andere promovendi op de afdeling MDL, dank voor 
de steun en gezelligheid!
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Mayke, Anneke, Joantine, en Anne, erg leuk dat jullie allemaal als student mee geholpen 
hebben aan de onderzoeken van dit proefschrift. Bedankt voor jullie inzet en enthousiasme!
Martijn, Leo, Serena, Mieke, Lieke, Corinne en alle andere collega’s uit ‘de kelder’ en later 
uit de ‘buitenhoek’. Het was een stukje lopen, maar dat had je ook wat; altijd een warm 
welkom en een kopje thee! Leo, jij in het bijzonder verdient een BEDANKT in hoofdletters; 
onmisbaar was je hulp bij het database-onderzoek! Martijn, heel erg bedankt voor al je 
statistische adviezen en heldere blik op het onderzoek. Eindelijk weet ik nu wanneer ik de 
‘macaroni-correctie’ moet toepassen!
TPV-verpleegkundigen uit Nijmegen, door de goed geordende lijsten van de TPV-patiënten 
werd het database onderzoek toch een tikje makkelijker. Renate en Anne, bedankt voor 
het ‘ophalen’ van onze prijs in Chicago.
Alle proefpersonen van de in vivo studies, super bedankt dat jullie telkens trouw terug 
kwamen en dat jullie steeds zo mooi op tijd waren!!
Karin en Astrid, verpleegkundigen van de ‘functie-afdeling MDL’, de proefpersonen waren 
altijd welkom op jullie afdeling tijdens de infusies. Bedankt voor het ‘oppassen’!
Dames van het secretariaat MDL, altijd leuk om bij jullie even binnen te lopen voor iets 
nuttigs of zomaar voor een kletspraatje. Dank jullie wel voor jullie behulpzaamheid.
Magda, Liesbeth, Trees, en de andere buurtjes van de interne geneeskunde, heel erg 
bedankt voor alle hulp bij de ELISA’s en gas-chromatografie en voor de gezelligheid toen 
we nog met z’n allen bij elkaar op de onderverdieping zaten. 
Marij, Eugenie, Rob, Frank en alle anderen van de afdeling hematologie. Dank voor al jullie 
onmisbare hulp bij de FACS.
Dr. Willems, beste Peter, en Sjenet van de afdeling biochemie, dank jullie wel voor jullie 
gastvrijheid en hulp bij de calciummetingen. Peter, ik heb er van genoten om met je te 
brainstormen over alle hobbels en bobbels in de calcium-curven! 
Prof. dr. Hermans, beste Peter, en Elles van het LKI, bedankt voor de enorme gastvrijheid 
bij de pneumococcen-eliminatie experimenten. Altijd zorgden jullie ervoor dat er een 
flowkast beschikbaar was en onze experimenten (en dat waren er veel!!) door konden 
gaan! 
Getty Huisman-de Waal, wat hebben wij samen veel lijninfecties geteld en statussen 
gesjouwd. Dit resulteerde in vele gezamelijke ESPEN bezoekjes en twee mooie publicaties. 
Ik heb erg van je gezelschap genoten (vooral ook tijdens de vlucht van Praag naar huis!). 
Prof. Calder, dear Philip, and Paul Noakes, Annette West and Charlotte Rombouts (Institute 
of Human Nutrition, School of Medicine, University of Southampton), thank you so much 
for the intense cooperation during the last in vivo study of this thesis, for the warm 
welcome while visiting your department and for the extremely quick (midnight!) reply’s 
while finishing the manuscript.
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Ton Feuth, statisticus, meer dan verbaasd was ik toen bleek dat er een statisticus bestond 
waarvan ik begreep wat hij bedoelde en andersom! Het heeft wat voeten in aarde gehad 
maar uiteindelijk hebben we samen een fantastische klus geklaard en een zeer mooie 
publicatie voor elkaar gekregen! 
Prof. dr. Oyen, beste Wim, en dr. de Geus-Oei, beste Lioe-Fee, tijdens een van de studies 
van dit promotieonderzoek ontstond de interesse voor de nucleaire geneeskunde en die 
is niet meer over gegaan! Bedankt voor de opleidingsplek en voor de mogelijkheden die 
jullie me gaven om het onderzoek tijdens de opleiding tot een goed einde te brengen. 
Jullie blijvende belangstelling voor de vordering van het manuscript heeft mij enorm 
gestimuleerd om door te zetten! Ook de overige collega’s van de afdeling Nucleaire 
Geneeskunde, dank jullie wel voor het maken van de leukocytenscans maar ook voor 
de interesse in mijn onderzoek en de gezelligheid daarna. In het bijzonder wil ik al mijn 
collega-AIOS bedanken voor hun flexibiliteit wanneer ik er soms toch even tussen uit 
moest glippen om nog gauw iets te regelen!
Prof. dr. Stalenhoef, Prof. dr. Hermans en dr. van Bodegraven, leden van de 
beoordelingscommissie, bedankt voor het groene licht!
Beste vrienden uit Horst, Lottum, Venraij, Helmond, Hedel, Nijmegen, Wamel, Zoelen, 
Soest, Utrecht, Zeist, Naarden en Rotterdam, van jullie heb ik er nooit teveel, maar wel 
teveel om bij naam op te noemen (…ik zou het mezelf namelijk nooit vergeven als ik toch 
iemand vergeet!!). Allemaal reuze bedankt voor jullie interesse, medeleven, maar vooral 
voor alle gezelligheid in de afgelopen jaren. Door jullie bleef mij accu opgeladen! Op 10 
februari maken we er weer een feestje van!
Lieve Dionne en Per, mijn zus en schoonbroer, twee totaal verschillende levens maar toch 
zo’n ontzettend goede vrienden! Grote zus, dank je wel dat je er altijd voor me bent. 
Lieve pap, de dag voordat ik met zwangerschapsverlof ging, zou ik nog een presentatie 
geven op de UEGW in Parijs. Vliegen mocht niet meer en alleen met de auto of trein was 
volgens jou ook geen optie. Jij zou je dochter wel ‘even’ brengen! Uiteindelijk gingen we 
gezellig met z’n viertjes; jij, mam, Dennis en ik. Wat ben ik blij dat we dat gedaan hebben, 
het was namelijk de laatste keer dat ik je zag. Lieve, lieve pap, ook nu had ik je er zo graag 
bij gehad. Je bent de allerliefste, tot later.
Lieve mam, altijd stonden jij en pap voor me klaar en toonden interesse in wat ik deed. Ik 
was vrij om mijn eigen keuzes te maken, jullie vertrouwden er op dat het goed zou komen. 
Ook nu je er alleen voor staat, ben je er altijd voor ons. Als jij bij ons bent is het altijd 
gezellig! Je luistert altijd trouw naar mijn eindeloze verhalen over mijn werk, de kinderen 
en vooral ook de combinatie van deze twee. Het is niet te beschrijven hoe trots ik op je 
ben! 
Lieve schoonfamilie, al bijna mijn halve leven hoor ik er bij jullie helemaal bij! Dank jullie 
wel voor jullie belangstelling in wat ik doe, voor alle hulp in ‘huize Rikken’ en voor alle 
gezellige momenten samen. 
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Jorn en Sam, lieve kleine bengels, als ik bij thuiskomst jullie ondeugende pretoogjes zie en 
oneindige kletspraatjes hoor, krimpen de ogenschijnlijke bergen van een promotie-traject 
tot niet meer dan kleine hobbels. Door jullie kan ik de hele wereld aan! 
Allerliefste Dennis, mijn grootste maatje. De afgelopen jaren waren tropenjaren; huis 
bouwen, nieuwe zaak, Jorn en Sam geboren, specialiseren en promoveren. Wat heeft dit 
‘ons’ sterk gemaakt! Dank je wel voor alle ruimte die je me geeft om mijn ambities waar 
te maken, eigenlijk verdien jij het om gedeelde eerste auteur te zijn van al mijn artikelen! 
Vanaf nu is er weer meer tijd voor jou en ik beloof dat ik ‘s avonds ook weer eens de 
catering zal verzorgen!! 
November 2011
Michelle 
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Michelle Versleijen werd op 9 maart 1976 geboren in Horst. Zij was de tweede dochter van Ger en Ans 
Versleijen. Samen met haar oudere zus, Dionne, 
en haar ouders heeft zij een hele plezierige en 
zorgeloze jeugd gehad in Horst. In 1994 behaalde 
zij haar Gymnasiumdiploma aan het Boschveld 
College te Venray. Aansluitend studeerde zij 
Medische Biologie aan de Universiteit Utrecht 
alwaar zij in 1999 haar doctoraaldiploma behaalde. 
Van 1999 tot 2004 studeerde zij Geneeskunde 
aan de Universiteit Maastricht. Beide studies 
werden Cum Laude afgerond. Eind 2004 werd zij 
aangenomen voor de opleiding tot maag-, darm- 
en leverarts in het Universitair Medisch Centrum 
Nijmegen (UMCN). Hiervoor startte zij met de 
vooropleiding Interne Geneeskunde in het Jeroen 
Bosch Ziekenhuis te ’s-Hertogenbosch. Deze 
werd vanaf januari 2006 onderbroken voor het huidige promotieonderzoek. Tijdens dit 
onderzoek kwam zij in aanraking met de Nucleaire Geneeskunde en wekte dit vakgebied 
een bijzondere interesse bij haar op. Eind 2008 besloot zij van specialisatie te wisselen 
en startte zij met de opleiding tot Nucleair Geneeskundige in het UMCN, welke zij eind 
2012 zal afronden. Zij woont samen met Dennis Rikken en samen hebben ze een zoon 
(Jorn) en dochter (Sam).
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